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ABSTRACT 
Histone H1 phosphorylation is thought to be involved in multiple cellular processes 
including chromatin condensation and transcriptional regulation. Recent studies revealed 
changes in the expression and genomic distributions of H1 variants during cell 
differentiation which appear to contribute to phenotypic differences between cell types, 
but the functional significance of phosphorylation at specific sites in individual H1 
variants and their dynamic regulation in this process has not been investigated. Here we 
show that the global levels of phosphorylation of H1.5-Ser18 (pS18-H1.5), H1.2/H1.5-
Ser173 (pS173-H1.2/5) and H1.4-Ser187 (pS187-H1.4) are regulated differentially 
during pluripotent cell differentiation. Enrichment of pS187-H1.4, but not pS18-H1.5, 
near the transcription start sites (TSSs) of pluripotency factor genes is diminished after 
differentiation. Selective inhibition of CDK7 and CDK9, or siRNA depletion of CDK9 
rapidly diminishes both the global levels and the enrichment of pS187-H1.4 at 
housekeeping genes. Moreover, inhibiting transcription with actinomycin D induces the 
accumulation of pS187-H1.4 at promoters and gene bodies. Notably, the levels of pS187-
H1.4 enrichment after actinomycin D treatment or cell differentiation reflect the extent of 
CDK9 recruitment at the same loci. Remarkably, the global levels of H1.5-S18 and 
H1.2/H1.5-S173 phosphorylation are not affected by these transcription inhibitor 
treatments, and selective inhibition of CDK2 does not affect global phosphorylation of 
H1.4-S187 or H1.5-S18. Although Erk phosphorylates S187-H1.4 in vitro, our data with 
Erk inhibitor treatments and EGF stimulation suggest that Erk does not phosphorylate 
S187-H1.4 in vivo. Studies of cells expressing H1.4 mutants that mimic constitutive 
dephosphorylation and phosphorylation at one or two interphase sites reveal that 
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interphase phosphorylation of H1.4 affects transcription in a gene-specific manner. Taken 
together, our data provide strong evidence that H1 variant phosphorylations are 
dynamically regulated in a site-specific and gene-specific fashion during pluripotent cell 
differentiation, and that the enrichment of pS187-H1.4 at genes is positively related to 
their transcription. H1.4-S187 is likely to be a direct target of CDK9 during interphase in 
vivo while other H1 variant phosphorylations appear to be mediated by distinct kinases.  
  
iv 
 
ACKNOWLEDGEMENTS 
First, I would like to express my gratitude to my advisor, Dr. Craig Mizzen, for his 
constant support and guidance throughout my graduate career. I really appreciate this 
opportunity to pursue an interesting, and yet challenging project in Dr. Mizzen’s lab for 
my graduate research and I could not have completed this thesis without his mentorship. 
Next, I would like to thank my committee members, Dr. Lisa Stubbs, Dr. Benita 
Katzenellenbogen and Dr. Andrew Belmont, for their invaluable advice, suggestions and 
help throughout my graduate studies. I would also like to thank the Department of Cell 
and Developmental Biology and Dr. Jie Chen for their support and encouragement in my 
final year. 
I would also like to thank Ankita Saha and past members of the Mizzen lab for their 
support, help and critical discussion, especially Dr. Yupeng Zheng and Dr. Kuei-Yang 
Hsiao for helping me enter the field of academic research. 
Finally, I would like to dedicate this work to my beloved family, especially my wife Yi 
He. I could not have accomplished it without their love, support and encouragement 
throughout my graduate studies.   
 
  
v 
 
TABLE OF CONTENTS 
 
CHAPTER 1: INTRODUCTION ........................................................................................1 
1.1    Histone H1 and Chromatin Structure ......................................................................1 
1.2    H1 Variants in Eukaryotic Cells ..............................................................................2 
1.3    H1 Structure and Chromatin Binding ......................................................................5 
1.4    Post-Translational Modifications of H1 ..................................................................8 
1.5    H1 Phosphorylation During the Cell Cycle ...........................................................10 
1.6    Functions of H1 Phosphorylation ..........................................................................14 
1.7    Regulation of H1 Phosphorylation ........................................................................26 
1.8    References .............................................................................................................31 
 
CHAPTER 2: DYNAMICS OF H1 PHOSPHORYLATION DURING       
PLURIPOTENT CELL DIFFERENTIATION ..........................................40 
2.1    Introduction ...........................................................................................................40 
2.2    Profiling H1 Variant Expression and Phosphorylation During Cell 
Differentiation .......................................................................................................43 
2.3    Generation and Validation of Antibodies Against Phosphorylated H1                  
and H1 Variants .....................................................................................................45 
2.4    Changes in the Global Levels of Site-Specific Phosphorylation and                     
H1 Variant Expression During Cell Differentiation ..............................................46 
2.5    Changes in H1 Phosphorylation After Differentiation Are Not Simply Due To        
Changes in Cell Cycle Distribution .......................................................................49 
2.6    pS187-H1.4, but Not pS18-H1.5, Is Associated With the Transcription of        
Pluripotency Genes ................................................................................................51 
2.7    Bromodomain Inhibition Affects pS187-H1.4 Association at the              
Promoters of Pluripotency Genes ..........................................................................53 
2.8    Depletion of Individual H1 Variants Does Not Affect the Transcription                    
of Pluripotency Genes ...........................................................................................55 
2.9    Conclusions and Discussion ..................................................................................57 
2.10  Material and Methods ............................................................................................59 
2.11  Figures and Tables ................................................................................................64 
2.12  References .............................................................................................................74 
 
CHAPTER 3: IDENTIFICATION OF KINASES RESPONSIBLE FOR    
INTERPHASE H1 PHOSPHORYLATION ..............................................78 
3.1    Introduction ...........................................................................................................78 
vi 
 
3.2    Inhibition of CDK2 or CDK9 Has Different Effects on Global        
Phosphorylation at S187-H1.4 or S18-H1.5 ..........................................................79 
3.3    Inhibiting CDK7 or CDK9 Rapidly Diminishes Both Global                               
and Gene-Specific Levels of pS187-H1.4 .............................................................81 
3.4    siRNA Depletion of CDK9 Reduces Both Global and Gene-Specific                      
Levels of pS187-H1.4 ............................................................................................83 
3.5    Phosphorylation at S187-H1.4 Is Not Dependent on RNAP II Progression .........85 
3.6    pS187-H1.4 Is Co-Enriched with CDK9 at Specific Gene Loci ...........................87 
3.7    Erk Family Kinases Are Not Likely to Phosphorylate S187-H1.4 in vivo............89 
3.8    Systematic Characterization of Site-Specific H1 Phosphorylations After                   
CDK Inhibitor Treatment ......................................................................................91 
3.9    Conclusions and Discussion ..................................................................................95 
3.10  Material and Methods ............................................................................................99 
3.11  Figures and Tables ..............................................................................................102 
3.12  References ...........................................................................................................117 
 
CHAPTER 4: INVESTIGATING THE FUNCTIONAL SIGNIFICANCE OF 
INTERPHASE H1 PHOSPHORYLATION ON TRANSCRIPTION .....121 
4.1    Introduction .........................................................................................................121 
4.2    Studies of Gene-Specific Transcription in Stable HeLa S3 Cell Lines     
Expressing FLAG-tagged H1.4 Phosphorylation Site Mutants ..........................122 
4.3    Studies of Gene-Specific Transcription in HEK 293 Cells Transfected With 
FLAG-H1.4 Constructs With Phosphorylation Site Mutations ...........................126 
4.4    Efforts to Study the Effects of H1 Phosphorylation on Transcription in            
TKO Mouse ES Cells ..........................................................................................130 
4.5    Material and Methods ..........................................................................................131  
4.6    Figures and Tables ..............................................................................................135 
4.7    References ...........................................................................................................141 
 
APPENDIX  ..................................................................................................................142 
A.1   Validation of the Specificity of pS187-H1.4 Antiserum in ChIP ........................142 
A.2   Evidence for the Regulation of pS187-H1.4 at rDNA Promoter ........................143 
A.3   Evidence for the Role of Histone Chaperones in H1 Variant Expression            
and Distribution ...................................................................................................146 
A.4   Preliminary Analyses of Nucleosomal Arrays Reconstituted With in vivo       
Phosphorylated H1s .............................................................................................148 
A.5   Figures .................................................................................................................150 
A.6   References ...........................................................................................................154
1 
 
CHAPTER 1 
INTRODUCTION 
1.1 Histone H1 and Chromatin Structure 
In eukaryotic cells, DNA is wrapped around histones to form nucleosomes, the 
fundamental repeat of eukaryotic chromatin. The nucleosome is composed of a core 
particle made with DNA and a histone octamer, consisting of two copies of each of the 
four histones, H2A, H2B, H3 and H4, and linker DNA with variable lengths that connects 
the core particles. In the nucleosome core particle, about 146 bp of DNA is wrapped in 
1.7 left-handed superhelical turns around a histone octamer. The fifth histone, termed H1 
or linker histone, is associated with the linker DNA and seals two rounds of DNA at its 
entry/exit site on the surface of the nucleosome core [1, 2]. Binding of H1 at the outer 
surface of nucleosome core particle interacts with ~20 base pairs of DNA in addition to 
the 146 bp of nucleosome core DNA, thus resulting in a micrococcal nuclease-resistant 
particle with 166 bp of DNA, the core histone octamer and one H1 molecule, termed 
chromatosome [3]. 
Linker histones are involved in both the nucleosome structure and the formation of higher 
order chromatin structures. Using electron microscopy, Thoma et al. [4] discovered that 
chromatin with histone H1 folded up from a filament of nucleosomes into 30 nm fiber 
with increasing ionic strength. Although similar folding was also observed for chromatin 
without H1, the structure formed by H1-depleted chromatin was not as condensed and not 
as regularly oriented as in the presence of H1. Sedimentation analyses of H1-depleted 
native chromatin [5] or reconstituted nucleosome arrays [6] folded in the presence or 
absence of linker histones further confirmed the role of H1 in stabilizing higher order 
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chromatin folding. Chromatins reconstituted with different domains of H1 did not 
compact as strongly as those reconstituted with full length H1, indicating that each 
domain of H1 contributes to its ability to stabilize higher order chromatin folding [5]. 
Later study of native and truncated H1.0 assembled onto reconstituted nucleosomal 
arrays showed that the ability of H1.0 to alter linker DNA conformation and stabilize 
condensed chromatin structures is localized to two specific C-terminal subdomains [7]. In 
summary, the above in vitro studies indicate that linker histones stabilize the formation of 
higher order chromatin structure in a salt-dependent manner. However, it remains unclear 
how H1 interacts with nucleosomal and linker DNA and facilitates chromatin folding in 
vivo. More recent studies on the mechanisms of H1 binding in vivo will be discussed later 
in this chapter. 
1.2 H1 Variants in Eukaryotic Cells 
Multiple non-allelic amino acid sequence variants of H1 encoded by single copy genes 
are co-expressed in most higher eukaryotes. For example, Caenorhabditis elegans has 
eight, Xenopus laevis has ﬁve, chicken (Gallus gallus) has seven, while both mouse (Mus 
musculus) and human (Homo sapiens) have eleven H1 variants [2, 8].  Among the 11 H1 
variants in the human genome, seven are somatic subtypes (H1.0, H1.1, H1.2, H1.3, 
H1.4, H1.5 and H1.X), that are differentially expressed in a wide variety of cells and 
tissues; while the others are exclusively expressed in germ-line cells, with three testis-
specific variants (H1t, H1T2 and HILS1) and one oocyte specific variant (H1oo) [2, 8]. 
Among the seven somatic H1 variants in the human genome, H1.1-H1.5 are replication-
dependent variants that are expressed predominantly during S-phase and whose amino 
acid sequences are more conserved to each other compared to the remaining variants [9]. 
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The genes that encode H1.1-H1.5 are clustered in a region of chromosome 6 together 
with core histone genes, but the expression level of each variant is individually regulated 
[9]. In contrast, the amino acid sequences of the replication-independent variants, H1.0 
and H1.X, are more divergent, and the genes that encode H1.0 and H1.X are located on 
chromosome 3 and 22 respectively [10, 11]. H1.2 to H1.5 and H1.X are ubiquitously 
expressed, but the expression level of each variant varies in different cells and tissues. 
H1.1 expression is restricted to certain tissues and cell types (liver, kidney, lung, 
lymphocytes from thymus and spleen, neurons and germ cells), and H1.0 seems to 
accumulate in terminally differentiated cells [9]. The four germ-line specific H1 variants 
are most divergent in amino acid sequences among the 11 human H1 subtypes. They 
replace somatic H1s during spermatogenesis or oogenesis where chromatin undergoes 
extensive structural transitions. The oocyte-specific H1 will retain in early embryo until 
zygotic genome is activated [12]. 
Genome-wide analyses revealed that histone variants have distinct distribution patterns 
over the genome. However, due to the lack of ChIP-grade antibodies against specific H1 
variants, the direct mapping of the distribution of each endogenous H1 variant has not 
been possible. Therefore, most of the work to study genomic distribution of H1 variants 
presented so far employed expression of epitope-tagged or Dam-fused H1 variants. ChIP-
seq analysis of N-terminal tagged (with Myc or FLAG) H1.2 and H1.3 variants in knock-
in mouse ESCs showed depletion of these variants from GC- and gene-rich regions, and 
from active promoters. Comparison of unique peaks for H1.2 and H1.3 revealed that 
H1.3 was more related to GC-rich sequences and LINES, whereas H1.2 was more closely 
associated with AT-rich sequences, Giemsa positive regions and satellite DNA [13]. 
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Another group used the DamID technique to measure the distribution of human H1.1 to 
H1.5 in IMR90 fibroblasts. The results showed that H1.2 to H1.5 were similarly 
distributed and were depleted from CpG-dense regions and active regulatory regions. 
Interestingly, H1.1 showed a distinct binding profile from all other variants (H1.2 to 
H1.5), suggesting a special role for this variant in chromatin function in those cells [14]. 
The distribution of seven somatic H1 variants (H1.2-H1.5, H1.0 and H1.X) has also been 
studied in T47D human breast cancer cells using variant-specific antibodies (against H1.2 
or H1.X) together with HA-tagged H1 variants. By comparing the results from ChIP-seq 
and ChIP-chip experiments, it has been shown that the distribution of H1.2 differed from 
that of other H1 variants and the results obtained from endogenous H1.2 ChIP and HA-
tagged H1.2 are comparable. H1.2 was best correlated with low gene expression, low GC 
content and lamin-associated domains. Although all H1 variants seemed to be less 
associated with active promoters, H1.2 was also depleted around transcription start sites 
of repressed genes [15]. Analyses of the genomic distribution of endogenous H1.5 
revealed distinct differences between human ESC and differentiated cell lines. In 
differentiated cells, but not hESCs, H1.5 is enriched at gene family clusters, especially 
genes that encode membrane and membrane-related proteins. Depletion of H1.5 in 
differentiated cells resulted in a loss of repressive chromatin markers, increased 
chromatin accessibility and deregulation of gene expression, suggesting a specific role of 
H1.5 in the repression of defined gene families in differentiated cells. The difference in 
genomic distribution among H1 variants seems to be correlated with their functional 
distinction in regulating gene expression and chromatin organization. Post-translational 
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modifications, especially different capacities of interphase phosphorylation, might 
contribute to this functional divergence among H1 variants [16]. 
1.3 H1 Structure and Chromatin Binding 
Protease digestion and nuclear magnetic resonance (NMR) analysis of calf thymus H1 
revealed that under physiological conditions, linker histones contain three distinct 
domains: a short N-terminal domain (NTD), a central globular domain (GD) and a long 
C-terminal domain (CTD) [17]. The classical tripartite structure is conserved in all 
metazoan H1s despite their divergence in amino acid sequences. However, some 
protozoans such as Tetrahymena thermophila, have H1s that are similar to metazoan H1s 
in size, solubility and amino acid composition, but lack the central globular domain [18, 
19]. On the other hand, the H1-like protein, Hho1p, in Saccharomyces cerevisiae has an 
extra globular domain in addition to the three-domain structure [20].  
The central globular domain (GD) of H1 has about 80 amino acids and is highly 
conserved among different species [21].  X-ray crystallographic and NMR analyses of the 
GD of chicken erythrocyte H1 and H5 showed that it contains a helix-turn-helix (HTH), 
also known as winged helix fold, which consists of three α-helices and a C-terminal β-
hairpin. Chromatin reconstitution with intact or fragments of H1 showed that the GD is 
necessary for generating the 168 bp chromatosome during micrococcal nuclease digestion 
of native chromatin and is sufficient for specific binding to nucleosome in vitro [5]. 
Extensive effort has been applied to understanding the binding site of GD and its location 
in the chromatosome, and two distinct overall modes of H1 binding to nucleosome have 
been proposed using different biochemical and structural analyses: the symmetric mode 
in which the GD binds nucleosomal DNA at the particle dyad and interacts with similar 
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amounts (approx. 10 bp) of both linker DNAs entering and exiting the particle, forming a 
stem structure [5, 22, 23], or an asymmetric mode in which the GD binds nucleosomal 
DNA in the vicinity of the dyad axis and interacts with 10 or 20 bp of one linker DNA 
[24-30]. The two different modes of binding are likely to differ in their impact on higher 
order chromatin folding by controlling the trajectory of linker DNA, which is supported 
by evidence that the sedimentation coefficient of the nucleosome array containing the GD 
of H5, which binds on dyad, was substantially higher than the one containing the GD of 
Drosophila H1, which binds off dyad [23]. It has been suggested that the preference for 
on-dyad versus off-dyad binding may be determined by the distribution of positively 
charged residues at a limited number of positions within the GD [23]. However, 
additional factors appear to be involved since even though the positive residues thought 
to be key for symmetric binding of GH5 and GH1.0 are conserved in human H1.1 – H1.5, 
current evidence indicates that the GD of human H1.4 and mouse H1.2 bind in an 
asymmetric fashion [28, 31], whereas that of mouse H1.5 appears to bind symmetrically 
[22]. Thus, differences in chromatin binding mode of the somatic H1 variants (H1.1-
H1.5) might be affected by the heterogeneity of local chromatin environment. It is likely 
that the GD of H1.1-H1.5 could bind on the dyad in open chromatin, but might be forced 
to bind off the dyad in condensed nucleosome array in most in vitro assays [23, 32].  
In contrast to the globular domain, both NTD and CTD of H1 are predominantly 
unstructured in aqueous solution, but behave like intrinsically disordered proteins in that 
their interaction with DNA is coupled with folding into conventional secondary structures 
[33-37]. The NTD is the shortest domain of H1 and its role in chromatin is not well 
understood. It has been shown that the NTD is not necessary for the formation of higher-
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order chromatin structures, but its deletion appears to reduce the affinity of H1 to the 
chromatin [38]. FRAP analyses with chimeric H1s, where the NTD of H1.0 and H1.2 was 
swapped, revealed that differences in NTD structure between H1 variants contribute to 
their differential binding properties [39]. The CTD of H1 has approximately 100 or more 
amino acids and is highly variable among variants and among species. Among the five 
somatic H1 variants in human cells, H1.1 and H1.2 have the shortest CTD, while H1.3, 
H1.4 and H1.5 have increasingly longer CTD. The five H1 variants can be classified into 
three binding groups according to their recovery time in FRAP analyses: H1.1 and H1.2 
which showed the weakest binding, H1.3 with moderate binding, and H1.4 and H1.5 with 
the strongest binding, indicating that the length of CTD have a major influence on H1 
binding affinities [40]. Interestingly, although H1.0 has a shorter CTD compared to H1.1, 
the binding affinity of H1.0 is similar to that of H1.3. Since H1.0 has more sequence 
variation compared to H1.1-H1.5, the higher lysine content or difference in the 
distribution and density of DNA binding motifs might contribute to its increased binding 
affinity. A domain swapping analysis in which the CTD of H1.1 had been swapped with 
that of H1.4 showed that the H1.1-H1.4 hybrid containing the NTD and GD of H1.1 
fused to the CTD of H1.4 had similar binding affinity to intact H1.4 [40]. Complete or 
partial deletion of CTD significantly reduced the recovery time of H1 in FRAP studies, 
and single amino acid substitution at one or two S/T-P-X-K site mimicked the effect of 
partial deletion [41]. The above studies suggest that the C-terminal domain is the primary 
determinant of H1 binding to chromatin in vivo. Post-translational modifications, 
especially phosphorylations, at specific S/T-P-X-K CDK consensus sequences in NTD or 
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CTD also contribute to the chromatin binding affinities of H1 variants. This will be 
discussed in more details later in this chapter.  
1.4 Post-Translational Modifications of H1 
Histone H1 can be post-translationally modified. Early studies of 32P-labeled H1 from 
Physarum polycephalum or mammalian cells showed that H1 can be phosphorylated at 
different serine or threonine sites [42-44]. Sequence analysis of H1 variants revealed that 
multiple S/T-P-X-Z motifs (X = any reside, Z= a basic residue) preferred by cyclin 
dependent kinases (CDKs) are distributed over the N- or C-terminal domain of H1 in 
addition to other serine or threonine that is not contained in CDK motifs. Modern mass 
spectrometry (MS) has enabled the precise identification of phosphorylation sites in H1 
variants.  Garcia et al. [45] identified 14 phosphorylation sites at S/T-P-X-Z CDK 
consensus motif plus 5 phosphorylation sites at non-CDK sites from H1.1-H1.5 and H1.X 
from asynchronous HeLa cells. Wiśniewski et al. [46] analyzed H1s prepared from 
several human cell lines and different mouse tissues and found phosphorylation at both 
CDK and non-CDK consensus motifs. Sarg et al. [47] and Zheng et al. [48] used HPLC 
to separate phosphorylated forms of H1 variants followed by MS and identified 
phosphorylation sites of human H1 variants that are phosphorylated during different 
stages of cell cycle. The cell cycle distribution and functional significance of H1 
phosphorylations will be discussed later in this chapter. 
In addition to phosphorylation, other post-translational modifications (PTMs), including 
methylation, acetylation, ubiquitination, formylation, and etc., have also been identified 
in H1 by advanced mass spectrometric approaches [49, 50]. The function and regulation 
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of some of these modifications have been described, but the rest of them remain totally 
unstudied.  
Garcia et al. [45] found that, in HeLa cells, K26 and S27 of H1.4 are simultaneously 
methylated and phosphorylated, respectively. More recent studies revealed that histone 
methyltransferase G9a can methylate H1.4 at K26. This methylation at K26 can be 
demethylated by members of JMJD2 subfamily of demethylases [51]. Methylated 
H1.4K26 can recruit HP1, which promotes the formation of heterochromatin and gene 
silencing. The recruitment of HP1 to methylated H1.4K26 can be reverted by 
phosphorylation at the adjacent S27 residue [52]. The functional interplay between K26 
methylation and S27 phosphorylation of H1.4 was further demonstrated using antibodies 
against single or double modifications at K26/S27 [53]. G9a and its interaction partner 
Glp1 can also phosphorylate H1.2 at K187. However, in contrast to H1.4K26 
methylation, methylation at H1.2K187 does not seem to recruit HP1 and cannot be 
reversed by JMJD2 demethylases [54], indicating functional difference between site-
specific H1 methylations. 
The most abundant lysine acetylation was detected at the N-terminal end of H1 variants, 
which is the result of cotranslational cleavage of methionine, followed by acetylation of 
the second residue of the N-terminal tail [49]. Later mass spectrometry analyses 
identified additional lysine acetylations of H1, most of which contained in the globular 
domain [45, 46]; however, the functional significance of most H1 acetylations is not well 
documented. Using a specific antibody raised against acetylated K34 of H1.4, 
Kamieniarz et al. [55] showed that H1.4K34 acetylation is mediated by GCN5 and is 
enriched at the promoters of actively transcribed genes. H1.4K34 acetylation is thought to 
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stimulate transcription by recruiting components of transcriptional machinery and by 
increasing the mobility of H1 on chromatin [55]. 
1.5 H1 Phosphorylation During the Cell Cycle 
Phosphorylation is the most extensively studied post-translational modification of H1. 
Early studies of isotopic-labeled H1s in several model organisms showed that H1 is 
progressively phosphorylated at multiple sites during cell cycle progression [56]. The 
first evidence of cell-cycle dependent H1 phosphorylation was from the study of a slime 
mold, Physarum polycephalum. The naturally synchronous mitotic cycle of Physarum 
polycephalum makes it a perfect model to study cell cycle dependent activities. Analyses 
of 32P-orthophosphate labeled H1s from different stages of cell cycle revealed that 
Physarum H1 is progressively phosphorylated through S phase and early G2, peaks 
during late G2/M, and then drops to basal level after mitosis [42, 57]. Later studies of 
32P-labeled synchronized cultures of Chinese hamster ovary (CHO) cells obtained similar 
results in which phosphorylated H1 was initially detected in late G1 phase, followed by 
progressively increasing levels during S phase and G2 phase before peaking transiently 
during mitosis [43, 44]. Interphase phosphorylation occurred predominantly on serines of 
the C-terminal fragment generated by N-bromosuccinimide (NBS) cleavage at a single 
tyrosine within the GD. Threonine phosphorylation at both N and C-terminal NBS 
fragments in addition to serine phosphorylation was found during mitosis [44]. These 
findings provided initial evidence that different sites might be involved in interphase and 
mitotic phosphorylation of H1. Analyses of synchronized HeLa S3 cells also confirmed 
the progressive phosphorylation of H1 during the cell cycle and provided new evidence 
that H1 variants within a single cell type possessed different capacities of interphase and 
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mitotic phosphorylation [58, 59]. Subsequently, Talasz et al. [60] employed reverse phase 
HPLC (RP-HPLC) to separate H1 variants from synchronized mouse 3T3 cells and rat 
C6 glioma cells followed by acid urea polyacrylamide gel to analyze their 
phosphorylation status to confirm that individual H1 variants acquire different levels of 
phosphorylation during interphase and mitosis, and these variant-specific differences are 
conserved between mouse and rat. A more recent analysis using RP-HPLC fractionation 
of H1 variants from T-lymphoblastoid cells and activated T cells sorted for different cell 
cycle stages followed by high-performance capillary electrophoresis (HPCE) to separate 
different phosphorylated forms showed that interphase phosphorylation of H1 becomes 
largely established in late G1 or early S phase and that the malignant cells have more 
extensive H1.5 phosphorylation compared to its normal counterpart [61].  
Although multiple lines of evidence implied that H1 variants are progressively 
phosphorylated during cell cycle progression and different sites might be involved in 
interphase and mitotic phosphorylation, none of the above studies have identified any 
site-specific phosphorylation of H1 that are exclusive during interphase or mitosis. More 
recently, mass spectrometry (MS) has been employed to precisely identify 
phosphorylation sites of H1 prepared from asynchronous or synchronized cells. Sarg et 
al. [47] used reverse-phase HPLC followed by hydrophilic interaction liquid 
chromatography (HILIC) to separate different phosphorylated forms of H1.5 from 
CCRF-CEM cells and analyzed the phosphorylation sites via mass spectrometry. They 
found that H1.5 prepared from asynchronous cells can be mono- (1p), di- (2p), or tri-
phosphorylated (3p). Mono-phosphorylated H1.5 can be further divided into two groups, 
the majority of which is phosphorylated at S18 while the rest is phosphorylated at S173. 
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The di-phosphorylated H1.5 is phosphorylated at both S18 and S173 sites, and the tri-
phosphorylated form has an additional phosphate on S189. In contrast, H1.5 that is either 
tetra- (4p) or penta-phosphorylated (5p) was detected in samples prepared from 
mitotically enriched cells, suggesting that additional sites are involved in mitotic H1 
phosphorylation. Mass spectrometry on digested peptides of H1.5-4p or 5p fractions from 
HILIC revealed that H1.5-4p contains all three phosphorylation in H1.5-3p with 
additional phosphorylation at Thr138 or Thr155 and H1.5-5p contains an additional N-
terminal phosphorylation at Thr11 compared to H1.5-4p [47]. The findings of interphase 
versus mitotic phosphorylation sites of H1.5 were further confirmed by immunostaining 
with antisera against pS18, pS173 or pT11 of H1.5. Talasz et al. [62] found that the 
staining of pS18 or pS173 of H1.5 can be detected all over the nucleus in cells at any 
stage of the cell cycle while pT11-H1.5 can only be detected in mitotic cells. In addition 
to the analysis of H1.5, Sarg et al. [47] also identified S173 of H1.2, S172 and S187 of 
H1.4 and S189 of H1.3 as interphase sites of the corresponding H1 variants. 
Immunostaining with antibody against pT146 of H1.4 showed that this phosphorylation 
at Thr-containing CDK site was detectable exclusively in mitotic cells.  
Using hydrophobic interactions chromatography (HIC) followed by top-down mass 
spectrometry (TDMS), our lab identified phosphorylation sites of H1.2 and H1.4 
prepared from HeLa S3 cells. HIC of crude H1 from asynchronous or mid-S phase cells 
showed that H1.4 can be either mono- or di-phosphorylated during interphase while H1.2 
can only be mono-phosphorylated. Further analyses of the fractions of H1.2-1p, H1.4-1p 
and H1.4-2p prepared from mid-S phase HIC samples revealed that H1.2-1p is 
exclusively phosphorylated at S173 site, H1.4-1p is localized exclusively at S187 site and 
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H1.4-2p is phosphorylated at both S172 and S187 sites [48]. Our findings confirmed that 
S173 and S172 + S187 are the interphase sites of H1.2 and H1.4, respectively. 
Furthermore, the hierarchical phosphorylation of H1.4 during interphase is reminiscent of 
previous reports that H1.5 is also hierarchically phosphorylated during interphase [47, 
48], indicating that hierarchical phosphorylation might be a common feature of H1 
variants with more than one interphase sites. In addition, Zheng et al. [48] analyzed H1s 
prepared from mitotically arrested HeLa S3 cells and found that H1.4-6p and H1.2-4p are 
the most abundant forms of H1 during mitosis. MS analysis revealed that H1.4-6p 
includes two interphase sites (S172 + S187) with additional phosphorylation at T18, S27, 
T146 and T154, and H1.2-4p contains one interphase site (S173) plus additional 
phosphorylation at T31, T146 and T154 [48]. Taken together, both Lindner’s and our 
group found that the S-P-X-Z CDK motifs of H1s, known as interphase sites, can be 
phosphorylated during interphase and mitosis, while T-P-X-Z CDK motifs and non-CDK 
motifs can be phosphorylated exclusively during mitosis, thus are called mitotic sites. 
However, no direct evidence was presented in these reports to support the idea that the 
Ser or Thr residue in each CDK motif determines its cell cycle specificity. Remarkably, a 
later study by Raghuram et al. [63] provided additional evidence that S-P-X-Z motif is 
preferentially phosphorylated during interphase by studying phosphorylation of H1.1, 
which only has two S/T-P-X-Z motifs (T152 and S183) in the CTD. In this study, they 
used Phostag gel to compare the phosphorylation status of a series of H1.1 mutants in 
which T152 and/or S183 was mutated to serine, threonine or alanine respectively, and 
found that wild-type or T152A mutant of H1.1 can be mono-phosphorylated, whereas 
S183A mutant cannot be phosphorylated, suggesting that S183 is the predominant 
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phosphorylation sites of H1 during interphase. Interestingly, T152S mutant of H1.1 can 
be either mono- or di-phosphorylated, suggesting that T to S substitution at T-P-X-Z 
motifs can convert mitotic sites to interphase sites. Moreover, no phosphorylation can be 
detected on S183T mutant, and the phosphorylation at 152 or 183 site of H1.1 CTD is 
independent of each other [63]. Taken together, current evidence indicates that Ser-
containing CDK sites are the predominant, if not exclusive, sites of H1 that can be 
phosphorylated during interphase. 
1.6 Functions of H1 Phosphorylation 
1.6.1 Effects of H1 phosphorylation on CTD conformation 
The NTD and CTD of H1 behave like intrinsically disordered protein in aqueous solution 
with coupled binding and folding upon interaction with DNA. Recent biophysical studies 
have provided strong evidence that phosphorylation induces conformational change of 
H1 which affects its DNA binding [32, 64]. Roque et al. [65] compared how 
phosphorylation affected the conformation and DNA binding properties of the CTDs of 
mouse H1.0 and H1.4. Full phosphorylation at all three of the S/TPXZ sites present in 
these domains by CDK2/Cyclin A in vitro did not significantly alter their conformation in 
solutions without DNA, but reduced the extent of α-helical structure and increased the 
content of β structure in the DNA-bound forms compared to the corresponding 
nonphosphorylated samples. Interestingly, the secondary structures of the DNA-bound 
H1.0 and H1.4 CTDs differed somewhat from one another for both nonphosphorylated 
and fully phosphorylated samples, indicating that the differences in amino acid sequences 
between H1 variants are functionally significant in determining their secondary structure 
upon binding to DNA. Using T to A substitutions to mimic dephosphorylation of H1.0 
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CTD at individual or different pairs of S/TPXZ sites, the authors also obtained evidence 
of site-specific effects of phosphorylation on the DNA-bound CTD conformation. 
Surprisingly, full phosphorylation diminished the affinity of the H1.0 CTD for DNA only 
slightly compared to the nonphosphorylated form [65]. The above findings suggest that 
conformational changes of DNA-bound H1 induced by phosphorylation of CTD might be 
more important in altering binding dynamics of H1 on chromatin than changes of net 
charge at sites of phosphorylation, in contrast to evidence obtained from Tetrahymena, 
where net charge at clustered phosphorylation sites determines the effect of H1 on 
transcription [66].  
A later study found that, in the presence of neutral detergents and anionic SDS, the CTD 
of H1.0 folded with proportions of secondary structure motifs similar to those observed in 
DNA-bound H1s [67], suggesting that hydrophobic interactions, instead of charge 
compensation, might play a more significant role in determining the conformation of H1 
CTD upon DNA binding.  Phosphorylation of CTD in vitro by CDK2/Cyclin A to 
different extent led to a decrease in the α-helical content and an increase in that of the β-
structure in the presence of detergent, which is similar to the effect of phosphorylation 
observed for DNA-bound CTD [65, 67], confirming that phosphorylation changes the 
conformational trends of CTD. 
More recently, Lopez et al. achieved partial phosphorylation of native linker histone 
variants from nuclease-solubilized chicken erythrocyte chromatin fragments with 
CDK2/Cyclin A [68]. Infrared (IR) difference spectroscopy studies showed a gradual 
increase of β-structure, with a decrease in α-helix/turns, with increasing H1 
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phosphorylation. These changes of CTD conformation were shown to be associated with 
relaxed chromatin folding and impaired chromatin aggregation [68].  
Moreover, the study of Pin1, a proline isomerase which is recruited to chromatin and 
promotes the dephosphorylation of H1 at specific sites, provided further evidence that the 
phosphorylation status of H1 affects CTD conformation [63]. Fluorescence resonance 
energy transfer (FRET) analyses revealed that Cy3 and Cy5 fluorophores attached to 
either end of the CTD of H1 were brought closer together to produce enhanced FRET 
upon binding to the nucleosome than in solution, indicating conformational change of 
CTD upon chromatin binding [63, 69]. In vitro phosphorylation of fluorophore-labeled 
H1 CTD with CDK2/Cyclin A prior to reconstitution with nucleosome resulted in even 
greater FRET compared to unphosphorylated H1, indicating that phosphorylation 
promotes the conformational change of CTD which brings the two fluorophores even 
closer together. Interestingly, the enhanced FRET was diminished when stoichiometric 
amount of Pin1 was added to the reconstituted nucleosome with phosphorylated Cy3, 
Cy5-labeled H1, suggesting that Pin1 was able to alter the conformation of CTD upon 
interaction with chromatin-bound H1, possibly by promoting the dephosphorylation of 
H1 CTD through recruitment of PP2Ac [63]. 
1.6.2 Phosphorylation regulates H1 binding to chromatin 
Fluorescence recovery after photobleaching (FRAP) microscopy has been employed 
extensively to study the chromatin binding dynamics of fluorescent protein fusions of H1 
and other nuclear proteins in living cells. Studies of H1.1-GFP expressed in human cells 
[70] and H1.0-GFP or H1c-GFP expressed in mouse cells [71] revealed that H1s are 
significantly more mobile than core histone GFP fusions on chromatin, displaying a 
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residence time of just a few minutes before dissociating and rapidly binding again. 
Treating cells with 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) or 
staurosporine, which inhibits the activity of certain serine/threonine kinases,  significantly 
increased the recovery time of H1.1-GFP after photobleaching, supporting the hypothesis 
that interphase phosphorylation promotes H1 dissociation from chromatin [70]. However, 
since these or other kinase inhibitors might have pleiotropic effects in cells in addition to 
altering the phosphorylation status of H1, mutagenesis of S/T-P-X-Z consensus motifs of 
H1s has been used to obtain more direct evidence of the effect of phosphorylation on H1 
binding dynamics to the chromatin. 
As mentioned before, domain swapping between different H1 variants revealed that CTD 
is the primary determinant of H1 binding dynamics on chromatin [40]. Distinct numbers 
and positions of interphase phosphorylation sites among H1 variants might contribute to 
their difference in chromatin binding affinities. Glutamic acid substitution to mimic 
constitutive phosphorylation at T152 or S183, the only S/T-P-X-Z motifs on the CTD of 
H1.1, increased the mobility of GFP-H1.1 on chromatin compared to wild type H1.1 [41]. 
In addition, the T152E substitution had greater effect on chromatin binding of H1.1 than 
S183E mutation, and in each case, the reduction in FRAP recovery time is similar to that 
observed for the deletion of residues 152-214 or 183-214 of H1.1 CTD, suggesting that 
phosphorylation at specific S/T-P-X-Z motif might promote conformational change of 
CTD which affects the DNA binding from individual CDK motifs to the C-terminal end 
of H1. This possibility is further supported by the evidence that the FRAP recovery of 
T152E + S183E double mutant showed no significant difference from that of T152E 
single mutant. In addition, T152A + S183A double mutant, which mimics 
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dephosphorylation of H1.1 CTD, showed increased mobility compared to wild type H1.1, 
which further demonstrates that phosphorylation does not affect chromatin binding 
properties of H1 by simple charge repulsion, but through the induction of the 
conformational change of CTD [41]. 
Contreras et al. [72] compared the FRAP recovery of wild type H1.4-GFP and M1-5-GFP 
in which all five S/T-P-X-Z motifs of H1.4, including two interphase sites and three 
mitotic sites, were mutated to A-P-X-Z in order to mimic constitutive dephosphorylation. 
FRAP analysis showed that M1-5-GFP recovered more slowly and to a lesser extent 
compared to wild type H1.4-GFP after photobleaching in both HeLa cells and WI38 
VA13 cells. In contrast, the FRAP recovery of H1.4-GFP and M1-5-GFP was very 
similar in WI38 cells which has much lower CDK2 activity than HeLa and WI38 VA13 
cells. CDK2/Cyclin A and CDK2/Cyclin E were shown to be able to phosphorylate WT 
H1.4-GFP but not M1-5-GFP in vitro. Thus, these results suggest that phosphorylation by 
CDK2 diminishes H1.4 binding to the chromatin. However, whether all five CDK motifs 
or only a subset of them were affected by CDK2 was not determined [72]. 
Recently, the study of Pin1 revealed more evidence that supports the idea that interphase 
H1 phosphorylation increases the mobility of H1 on chromatin [63]. FRAP analysis of 
GFP-H1.1 and GFP-H1.5 expressed in Pin1 wt or Pin1 -/- cells showed that both GFP-
H1.1 and GFP-H1.5 recovered much faster in Pin -/- cells compared to Pin1 wt cells after 
photobleaching, which is consistent with the finding that Pin -/- cells have higher level of 
global H1 phosphorylation at multiple interphase sites. Comparison of FRAP recovery 
time among wild type GFP-H1.1 and GFP-H1.1 mutants at T152 and/or S183 expressed 
in Pin1 wt or Pin1 -/- cells revealed that S183A, but not T152A, mutation was able to 
19 
 
abolish the enhanced mobility of H1 induced by Pin1 depletion, suggesting that S183 of 
H1.1 is the predominant, if not the only site that can be phosphorylated during   
interphase [63]. 
Chromatin binding of H1 is also affected by the nature of local chromatin environment 
and the direct competition between H1 and other nuclear proteins for binding sites on the 
nucleosome. Misteli et al. [71] found that treating cells with histone deacetylase inhibitor 
Trichostatin A (TSA), which induces hyperacetylation of core histones and a more open 
chromatin structure, enhanced the mobility of both H1.0-GFP and H1c-GFP regardless of 
whether a euchromatin or heterochromatin region was photobleached. FRAP analysis 
revealed the presence of hyperdynamic populations of nuclear architectural proteins, 
including H1.0, H3, H2B and HP1, in pluripotent mouse embryonic stem (ES) cells 
which became less mobile upon differentiation, suggesting that ES cells have a more 
open chromatin structure.  
H1 competes with high mobility group (HMG) proteins for binding sites on the 
nucleosome. All HMGs compete with H1, in a dose dependent fashion, but each HMG 
family has specific effects on the interaction of H1 with chromatin. The interplay 
between H1 and HMGs affects chromatin organization and plays a role in epigenetic 
regulation [73]. FRAP analyses have provided evidence that competition with members 
of the HMGA, HMGB and HMGN families of high mobility group proteins decreases the 
apparent affinity of H1 for chromatin. Competition with H1 by one HMG family member 
was not affected by members of different HMG families, suggesting that the three HMG 
families compete with H1 at different binding sites [74]. Upstream binding factor (UBF), 
a transactivator of RNA polymerase I transcription, also competes with H1 for 
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nucleosome binding. Displacement of H1 by UBF has been suggested to mediate 
transcriptional activation of rDNA [75, 76]. Depletion of UBF results in the accumulation 
of H3K9 trimethylation, HP1 and H1 at rRNA genes. In contrast, the binding of H1.4 and 
pS187-H1.4 was diminished throughout the mouse rRNA gene upon UBF elimination, 
suggesting that the association of H1.4 with rDNA is dependent on UBF [77]. This 
suggests that UBF might compete with individual H1 variants to different extents and 
that H1.4 might be the special H1 variant that is associated with transcriptional 
activation. 
1.6.3 H1 phosphorylation is associated with transcription by RNA polymerases I and II 
It has been a long held notion that histone H1 is a general transcription repressor which 
must be evicted from chromatin before transcription could occur. This idea is mainly 
supported by in vitro transcription assays which showed that RNA synthesis from 
reconstituted chromatin in the presence of H1 was reduced to only 1-4 percent of that 
observed from chromatin without H1. This repression of transcription by H1 can be 
counteracted by the addition of sequence-specific transcription factors and/or basal 
transcription factors which are thought to displace H1 from the chromatin [78, 79]. However, 
the idea of H1 as a general transcription repressor has been challenged by emerging 
evidence that H1 might affect transcription in a gene-specific manner, either facilitating 
or repressing the transcription of individual genes in concert with other chromatin 
context. Gene knockout study showed that loss of H1 does not affect the vegetative 
growth of Tetrahymena thermophila, a ciliated protozoan which contains a single H1 
protein in the macronuclei [80]. Furthermore, depletion of H1 did not result in global 
derepression of transcription but rather affected transcription in a gene-specific fashion 
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[81], which argues against the idea that H1 is a global transcriptional repressor. The first 
line of evidence that H1 phosphorylation might facilitate transcription also comes from 
the studies of T. thermophila. Cells expressing mutants of macronuclear H1 with its five 
clustered S/T residues mutated to alanine (A5) or glutamic acid (E5) to mimic 
constitutive dephosphorylation or phosphorylation, respectively, displayed gene-specific 
rather than global effects on transcription. Interestingly, the effect of E5 strains to 
facilitate gene-specific transcription is similar to that of H1 knockout strains, suggesting 
that phosphorylation of H1 regulates the expression of certain genes by mimicking partial 
removal of H1 [81, 82].  
The mouse mammary tumor virus (MMTV) promoter has been used extensively as a 
model system to study transcriptional regulation by steroid hormone receptors. Histone 
H1 was shown to be bound to MMTV promoter and was displaced upon glucocorticoid 
stimulation which is necessary for the recruitment of NF1 and other transcription factors 
to activate transcription [83]. The MMTV promoter is rapidly activated by glucocorticoid 
via glucocorticoid receptor (GR) induced chromatin remodeling, which becomes 
refractory to the stimulus of glucocorticoid upon prolonged exposure. Lee and Archer 
[84] found that 24 h exposure to dexamethasone led to global dephosphorylation of H1 
together with the inactivation of MMTV promoter which is refractory to hormone 
stimulation. Removal of glucocorticoid from the culture media restored the hormone 
inducibility of MMTV promoter as well as global H1 phosphorylation. This restoration of 
inducibility can be blocked by a kinase inhibitor staurosporine that prevents H1 from 
rephosphorylation.  ChIP analyses with antibody against phosphorylated H1 showed that 
phospho-H1 was depleted from refractory MMTV promoter after prolonged 
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glucocorticoid treatment and re-associated with MMTV promoter after the removal of 
hormone [84]. These results suggest that H1 phosphorylation is positively related to 
glucocorticoid induced MMTV transcription. However, since the antibody against 
phosphorylated H1 used in this study was raised against Tetrahymena macronuclear H1 
[85], whose site-specificity for mammalian H1s has not been identified, it remains 
unclear which site-specific phosphorylation of H1 is involved in this process. 
The Beato lab systematically studied the functional role of H1 and its phosphorylation on 
progesterone activated MMTV transcription [86, 87]. According to their current model, 
the chromatin remodeling complexes NURF and ASCOM are recruited to the MMTV 
promoter by the progesterone receptor (PR) immediately after hormone addition. The 
combined action of ASCOM and the KDM5B methyltransferase increases histone H3K4 
trimethylation, which stabilizes NURF at the promoter. NURF facilitates PR-mediated 
recruitment of CDK2/Cyclin A, which phosphorylates H1 and promotes the dissociation 
of H1 from the promoter in concert with the NURF ATP-dependent remodeling complex 
[88]. The recruitment of CDK2/Cyclin A also activates PARP1, which in turn poly-ADP-
ribosylates H1 leading to its displacement from target sites [89]. This may be a common 
mechanism for gene regulation by progesterone receptor as ChIP analyses revealed that 
H1 is depleted from many PR target genes upon transcriptional activation of PR [88]. 
However, the site-specificity of H1 phosphorylation involved in this process has not yet 
been identified. 
The generation of site-specific antisera against phospho-peptides of H1 has enable the 
study of the effects of site-specific interphase phosphorylations on transcription. 
Immunofluorescence microscopy revealed extensive colocalization of H1.2/H1.5 S173 
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phosphorylation (pS173-H1.2/5) with BrUTP labeling of transcription foci in HeLa and 
HEK 293 cells. In contrast, the staining of S18-H1.5 phosphorylation (pS18-H1.5) 
localized poorly with BrUTP foci, indicating that S18-H1.5 phosphorylation might be 
involved in processes other than transcription [62]. ChIP analyses from our group showed 
that S187-H1.4 phosphorylation (pS187-H1.4) was enriched at the glucocorticoid 
response elements in mouse 3134 cells shortly after dexamethasone treatment. In 
addition, pS187-H1.4 as well as ER-α were co-enriched at estrogen response elements in 
MCF-7 shortly after estradiol stimulation, suggesting that pS187-H1.4 might facilitate 
gene-specific RNA Pol II transcription activated by nuclear hormone receptors [48]. 
Immunofluorescence microscopy also revealed that interphase H1 phosphorylations 
might be involved in the transcription of rDNA by RNA polymerase I (Pol I). Intensive 
punctate staining of pS173-H1.2/5 and pS187-H1.4 was observed in nucleoli of HeLa 
cells which colocalized with fibrillarin. In addition, nucleolar pS187-H1.4 staining also 
colocalized with RNA Pol I, the UBF trans-activator of Pol I and BrUTP labeling of 
nascent 45S pre-rRNA. ChIP analyses revealed that pS187-H1.4 was associated with 
rDNA promoters in asynchronously growing HeLa cells and this association was 
markedly diminished when RNA Pol I transcription was inhibited by actinomycin D [48]. 
As discussed above, depletion of UBF, which impaired Pol I transcription, significantly 
reduced pS187-H1.4 association throughout the mouse rDNA [77]. These findings 
suggest that pS187-H1.4 and pS173-H1.2/5 are associated with the transcription of rDNA 
by RNA polymerase I. 
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1.6.4 Other functions of H1 phosphorylation 
Several lines of evidence indicate that H1 phosphorylation is involved in the process of 
replication. Halmer and Gruss [90] reconstituted SV40 minichromosome with H1s 
extracted from either G0-, S- or M-phase cells that are differentially phosphorylated. 
Using the above reconstituted minichromosomes as a substrate in SV40 in vitro 
replication system, the authors found that minichromosomes reconstituted with S-phase 
H1, which was more extensively phosphorylated than G0-phase H1 but less 
phosphorylated than M-phase H1, showed the highest replication efficiency, indicating 
that replication efficiency is influenced by the phosphorylation status of H1. Alexandrow 
and Hamlin [91] presented evidence that recruitment of Cdc45 during DNA replication 
complex assembly in CHO cells leads to the recruitment of CDK2 and subsequent 
phosphorylation of H1 that promotes chromatin decondensation at replication foci and 
facilitates replication fork progression. Similarly, it has been suggested that 
phosphorylation promotes the loss of H1 from replicating chromatin during S phase and 
that this event plays a critical role in regulating replication origin firing in Physarum 
polycephalum [92]. Immunofluorescence microscopy detected the difference between the 
association of pS173-H1.2/5 and pS18-H1.5 with replicating DNA labeled by EdU. 
Although approximately 50% colocalization was observed for pS173-H1.2/5 and 
replication foci in both HeLa and HEK 293 cells during S-phase, only 5% of pS18-H1.5 
colocalized with EdU staining, indicating that pS18-H1.5 might not be involved in the 
regulation of replication [62]. 
Extra-nuclear functions of H1 phosphorylation have also been reported. Among all H1 
variants, H1.2 seems to be involved in DNA damage response and apoptosis. 
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Biochemical analyses identified H1.2 as a cytochrome c releasing factor in response to X-
ray irradiation. The p53-dependent release of H1.2 to the cytoplasm induced apoptosis by 
promoting the release of cytochrome c from mitochondria in a Bak-dependent manner. 
Depletion of H1.2 enhanced cellular resistance to apoptosis induced by X-ray irradiation 
[93]. In addition, H1.2 was shown to form a protein complex with cytochrome c, APAF-1 
and CASP-9 upon UV irradiation, which triggers the activation of downstream apoptotic 
effectors CASP-3 and CASP-7 [94]. H1.2 has also been shown to be translocated to 
mitochondria and colocalize with Bak following the induction of DNA double strand 
breaks by bleomycin [95]. Phosphorylation of H1.2 might be involved in this signal 
transduction process due to the evidence that phosphorylation at H1.2-T146 is induced by 
DNA damage [96]. H1.2 was found to form a complex with the YB1 and PURα 
transcription factors that significantly repress p53-dependent, p300-mediated chromatin 
transcription [97]. DNA damage induces H1.2 phosphorylation at T146 mediated by 
DNA-PK and acetylation of p53 by p300, which impairs p53 and H1.2 interaction and 
triggers a rapid activation of p53-dependent transcription and apoptosis induction [96]. 
The involvement of other H1 variants in apoptosis has not been well documented. Early 
reports suggested that induction of apoptosis leads to rapid global dephosphorylation of 
H1 variants detected by capillary electrophoresis or autoradiography [98, 99]. However, 
later evidence indicated that dephosphorylation of H1 is not a general feature of early 
apoptosis and that the phosphorylation status of H1 is not related to apoptotic DNA 
fragmentation [100]. Changes in H1 phosphorylation status may be secondary to how 
apoptosis is induced in some reports, since it has been reported that induction by anti-Fas 
caused no significant changes while camptothecin treatment led to rapid H1 
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dephosphorylation [101]. Although conflicting data have been presented regarding 
changes in global H1 phosphorylation during apoptotic induction, the involvement of 
H1.2 and its phosphorylation in the process of DNA damage response and apoptosis was 
well established. 
1.7 Regulation of H1 Phosphorylation 
1.7.1 Identification of kinases for H1 phosphorylation 
As discussed above, phosphorylations of H1 variants at both S/T-P-X-Z CDK consensus 
motifs and non-CDK motifs have been identified by modern mass spectrometry. 
Interphase phosphorylation seems to affect only Ser-containing CDK sites, while T-P-X-
Z sites and non-CDK sites are phosphorylated exclusively during mitosis. Plenty of 
efforts have been applied to identify interphase- or mitotic-specific kinases. However, the 
identification of site-specific kinases for interphase phosphorylation have been 
complicated by the lack of site-specific antisera for all interphase phosphorylation sites of 
each H1 variant and the lack of highly selective inhibitor for each CDK. 
Early biochemical studies showed that four purified CDK/Cyclin complexes were able to 
phosphorylate H1 at all interphase and mitotic sites with no selectivity in vitro [102]. 
However, the fact that different subset of CDK sites are phosphorylated during interphase 
and mitosis suggests that different CDKs might be involved in phosphorylating 
interphase or mitotic sites in vivo. Multiple lines of evidence suggest that CDK2 and 
CDK9 might be responsible for interphase H1 phosphorylation. CDK2 
immunoprecipitated from mouse mammary cells was able to phosphorylate H1 in vitro; 
however, CDK2 immunoprecipitated from cells treated with dexamethasone for 24 h or 
CDK2 inhibitors (CVT-313 or roscovitine) for 24 h or 96 h, respectively, were less 
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efficient in phosphorylating H1 in vitro [103]. Moreover, prolonged treatment of cells 
with dexamethasone (24 h), CVT-313 (24 h) or roscovitine (96 h) significantly reduced 
global H1 phosphorylation as well as the association of phosphorylated H1 at MMTV 
promoter. However, the two CDK inhibitors used in this study are not highly selective 
against CDK2 [104, 105] and prolonged treatment of cells with CVT-313 or roscovitine 
have been shown to arrest cell cycle progression [106]. Therefore, the decrease of H1 
phosphorylation might not be directly attributable to CDK2 inhibition. Furthermore, 
treating cells with roscovitine for 96 h diminished the expression of Cdc2 (CDK1) [103], 
which is important for cell cycle progression through mitosis and is possibly responsible 
for mitotic H1 phosphorylation. Thus, the change of H1 phosphorylation after 96 h of 
roscovitine treatment can be partially attributed to CDK1 depletion. 
Studies from Davie’s group revealed that global phosphorylation level of H1.5 was 
elevated in mouse fibroblast transformed with oncogenes or constitutively active MAPK 
kinase [107, 108]. This elevated H1.5 phosphorylation was attributed to increased CDK2 
activity detected in oncogene-transformed cells, which could be diminished by prolonged 
(24 h) treatment with CDK2 inhibitor olomoucine [109]. However, like roscovitine, 
olomoucine also inhibits CDK1 activity nearly as potently as it inhibits CDK2 [110]. 
Therefore, the decrease of H1 phosphorylation observed after 24 h of olomoucine 
treatment might not be the direct result of CDK2 inhibition. Furthermore, inhibition of 
transcription by actinomycin D or DRB, or inhibiting replication with aphidicolin, 
significantly reduced the global phosphorylation of H1.5, suggesting that this H1 
phosphorylation is positively related to transcription and replication [111]. However, 
since the antisera used in all the above studies to detect H1 phosphorylation were raised 
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against phosphorylated Tetrehymena H1, which has been shown to recognize both 
interphase and mitotic phosphorylations in human and mouse H1 variants [85] 
(unpublished data), it remains unclear whether the changes of H1 phosphorylation 
detected above were attributable to interphase or mitotic phosphorylation or both. 
Additional evidence that supports CDK2 as an interphase H1 kinase came from FRAP 
studies comparing the mobilities of wild type H1.4-GFP and M1-5-GFP (with all five 
S/T-P-X-Z sites of H1.4 mutated to A-P-X-Z). Contreras et al. [72] showed that the 
difference between mobilities of H1.4-GFP and M1-5-GFP was positively related to 
CDK2 activity levels in several different cell lines. Furthermore, overexpressing p21, a 
CDK2 inhibitor protein, significantly reduced the mobilities of H1.4-GFP but not M1-5-
GFP, suggesting a role of CDK2 in phosphorylating H1.4 during interphase. However, as 
mentioned before, this interpretation is challenged by subsequent work that showed only 
two out of five sites mutated in M1-5-GFP were interphase phosphorylation sites of H1.4.  
Recent work from Rana’s lab implicated CDK9 as a possible interphase H1 kinase. 
Immunoprecipitation showed that the positive transcription elongation factor b (P-TEFb), 
a complex of CDK9 and Cyclin T, interacted with H1 in vivo. Comparison of the ability 
of CDK2/Cyclin A and P-TEFb to phosphorylate WT H1.1 or T152A and/or S183A 
mutants of H1.1 in vitro showed that P-TEFb preferentially phosphorylated H1.1 at S183 
whereas CDK2/Cyclin A preferred to phosphorylate H1.1 at T152 [112]. Treatment of 
serum-starved HeLa cells with flavopiridol, a CDK inhibitor that preferentially inhibits 
CDK9, or siRNA to deplete CDK9 for 48 h decreased the global level of phosphorylated 
H1 [112]. In addition, flavopiridol treatment or CDK9 knockdown also abolished 
differentiation-induced H1 phosphorylation in C2C12 cells [113]. Overexpression of WT 
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CDK9 or dominant-negative CDK9 in HeLa cells increased or decreased global H1 
phosphorylation compared to mock-treated cells [112]. Together, these results suggest 
that CDK9 might be responsible for interphase H1 phosphorylation, but the identity of 
phosphorylation sites affected by CDK9 still remains unknown. 
Although no unequivocal data have been presented so far to link certain kinases to the 
phosphorylation of specific interphase sites of H1, recent studies have identified multiple 
kinases that seem to be responsible for mitotic H1 phosphorylation in a site-specific 
manner. Taking advantage of a specific antibody raised against phosphorylated T11 of 
H1.5, Happel et al. [114] found that GSK-3 was able to phosphorylate T11-H1.5, but not 
T146-H1.4 in vitro. In contrast, either CDK1 or CDK5 was able to phosphorylate T146-
H1.4, but not T11-H1.5 in vitro. In addition, the global level of pT11-H1.5 in mitotic 
cells was significantly reduced after incubation with GSK-3 inhibitors, suggesting that 
GSK-3 is responsible for T11-H1.5 in vivo during mitosis. Using similar approach, Chu 
et al. [115] found that protein kinase A (PKA) was able to phosphorylate H1.4 at S36 
both in vivo and in vitro. Hergeth et al. [116] found that Aurora kinases were able to 
phosphorylate S27 of H1.4 both in vivo and in vitro. Furthermore, siRNA depletion of 
Aurora B, but not Aurora A, diminished the global level of pS27-H1.4 in MCF-7 cells, 
indicating that Aurora B is responsible for S27-H1.4 phosphorylation in vivo. 
1.7.2 Identification of H1 phosphatases 
Early biochemical analyses using calf thymus H1 phosphorylated by p34cdc2 or PKA in 
vitro showed that PP2A class phosphatases are the predominant phosphatases in tissue 
and nuclear extracts that could efficiently dephosphorylate H1 phosphorylated by both 
p34cdc2 and PKA, whereas PP1 worked poorly on p34cdc2 phosphorylated H1 [117-119]. 
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In contrast, a later study concluded that PP1 was more likely to be the phosphatase for 
endogenous H1 in mitotic cells based on the ability of various compounds to inhibit 
dephosphorylation of H1 in crude metaphase chromosomes isolated from colchicine-
arrested HeLa cells [120]. Based on these findings, it seems that PP2A preferentially 
dephosphorylates H1 at S/T-P-X-Z CDK motifs during both interphase and mitosis; 
whereas PP1 preferentially dephosphorylates H1 at non-CDK sites during mitosis. 
However, this idea has not been validated by further studies and no information has been 
presented about the site-specificity of phosphatases on H1 until recently. A study by 
Raghuram et al. [63] suggests that recruitment of PP2Ac to interphase phosphorylation 
sites of H1 by the phosphorylation-directed proline isomerase Pin1 is involved in 
regulating the levels of interphase H1 phosphorylation [63]. Global levels of pS173-
H1.2/5 and pS187-H1.4 were found to be markedly higher in asynchronous cultures of 
Pin1 -/- cells compared to wild type cells, even though the total levels of CDK2 and 
PP2Ac activity were comparable, and PP2Ac immunoprecipitated from wild type and 
Pin1 -/- cells dephosphorylated pS187-H1.4 similarly in vitro. Moreover, addition of 
purified Pin1 stimulated the dephosphorylation of pS187-H1.4 in vitro. As discussed 
above, additional experiments described by Raghuram et al. [63] support a model in 
which recruitment of Pin1 and PP2Ac to sites of transcription leads to dephosphorylation 
and changes in CTD conformation via proline isomerization that stabilize H1 binding to 
chromatin.  
The interplay between the activities of kinases and phosphatases determines the half-life 
of H1 phosphorylation at specific chromatin loci, which is important for H1 functions in 
regulating chromatin structure and gene expression. However, essentially nothing is 
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known about the half-life of H1 phosphorylation in interphase cells and whether it 
persists to different extents based on the identities of the sites, the H1 variants, the 
chromatin loci, and the phosphatase(s) involved. Further research needs to be done in 
order to investigate how specific PP2A complex and CDK interacts to regulate the levels, 
distribution, and half-life of interphase H1 phosphorylation in a chromatin context-
specific fashion. 
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CHAPTER 2* 
DYNAMICS OF H1 PHOSPHORYLATION DURING PLURIPOTENT CELL 
DIFFERENTIATION 
2.1 Introduction 
Embryonic stem (ES) cells are pluripotent cells typically derived from the inner cell mass 
of preimplantation blastocysts that have the ability of self-renewal and differentiation into 
cells of all three germ layers: endoderm, mesoderm and ectoderm [1, 2]. Transcription 
factors such as Oct4, Sox2 and Nanog, which are involved in the core transcriptional 
regulatory circuitry, work synergistically to maintain pluripotency and self-renewal of ES 
cells [3]. Once differentiation is initiated, lineage specification occurs by the 
implementation of genome-expression programs that give each cell type a unique 
transcriptional profile. Although the molecular mechanisms for self-renewal, 
maintenance of pluripotency and lineage specification are not well understood, emerging 
evidence suggests that epigenetic mechanisms, including chromatin structure, chromatin 
dynamics and histone modifications, play important roles in this fundamental process. 
Multiple lines of evidence suggest that open chromatin is one of the major characteristics 
of embryonic stem cells featuring less condensed chromatin and higher ratio of 
euchromatin versus heterochromatin compared to differentiated cells [4, 5]. In addition, 
the expression of several ATP-dependent chromatin-remodeling factors is elevated in ES 
cells, and the disruption of their expression results in premature embryonic death prior to 
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implantation, suggesting an active role of chromatin-remodeling complexes in 
maintaining stem cell identity and initiating differentiation [4]. FRAP microscopy 
revealed that major architectural chromatin proteins, including core histones, 
heterochromatin protein HP1 and linker histones, are hyperdynamic and bind loosely to 
the chromatin in ES cells, but not lineage committed cells, and become more tightly 
bound to chromatin upon differentiation [6]. This hyperdynamic property of certain 
chromatin structural proteins might be attributable to post-translational modifications or 
global changes in chromatin structure. In accordance with the idea that ES cells have 
more open chromatin structure than differentiated cells, the global levels of histone 
PTMs, such as H3K9me3 that enriches in heterochromatin, are less abundant in ES cells 
[6]. ChIP-seq analyses showed that the distribution of repressive markers, such as 
H3K9me3 and H3K27me3, was largely expanded in fibroblast compared to human ES 
cell [7]. On the other hand, histone acetylation at H3K9, a general mark of open 
chromatin, has been shown to be reduced after the differentiation of human ES cells [8]. 
A more recent proteomic study revealed that the global abundance of multiply acetylated 
H4 peptides was decreased after the differentiation of mouse ES cell. ChIP-seq studies 
showed that Brd4 and acetylated histone H4 co-enriched at the regulatory elements of 
pluripotency genes in ES cells and lineage-specific genes in embryoid bodies, suggesting 
that H4 acetylation might be involved in the regulation of ESC differentiation [9].   
In addition to core histones, recent studies revealed that the expression of individual H1 
variants and possibly their post-translational modifications also play important roles in 
ES cell maintenance and differentiation. Analyses of the abundance of the mRNAs 
encoding seven somatic H1 variants suggest that they are differentially expressed during 
42 
 
the differentiation of human ES cells (hESCs) in vitro. The protein abundance of H1.0 
was shown to increase in differentiated cells, and depletion of H1.0 in hESC impaired its 
differentiation [10]. H1 triple-knockout (TKO) mouse ES cells (mESCs) depleted of H1c, 
H1d and H1e (H1.2-4) displayed global alterations in chromatin structure and an 
impaired capacity for differentiation compared to wild type mESCs [11, 12]. Comparison 
of the genomic distribution of H1.5 in hESCs versus differentiated cell lines suggests that 
H1.5 becomes enriched at genes encoding membrane-related proteins and specific gene 
family clusters during cellular differentiation. Depletion of H1.5 results in loss of SIRT1 
and H3K9me2 and increased chromatin accessibility, suggesting that H1.5 might play a 
repressive role in maintaining condensed chromatin at defined gene families in 
differentiated cells [13]. Moreover, the expression of H1.X was shown to increase during 
retinoic acid (RA)-induced differentiation of NT2 cells. ChIP-qPCR revealed that H1.X 
was preferentially incorporated to the promoter region of Nanog, indicating that H1.X 
might facilitate transcriptional repression of pluripotency genes during differentiation 
[14]. The above findings support the idea that individual H1 variants might have different 
impact on ES cell differentiation, although the mechanisms involved have not yet been 
defined. Since the most conspicuous difference between H1 variants is the different 
numbers of sites for interphase phosphorylation that vary in their relative location and 
amino acid sequence context, differences in the expression, genomic distribution and 
interphase phosphorylation dynamics may enable individual H1 variants to play distinct 
roles during ES cell differentiation. However, little is known about the dynamics of 
interphase H1 phosphorylation and their functional significance during cellular 
differentiation. In this chapter, we used both antibody dependent and independent 
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approaches to study the dynamics of interphase H1 phosphorylation and their association 
with gene-specific transcription during pluripotent cell differentiation.   
2.2 Profiling H1 Variant Expression and Phosphorylation During Cell 
Differentiation 
Our lab has developed a highly effective chromatography, called hydrophobic interaction 
chromatography (HIC), that can separate H1 variants as well as their different 
phosphorylated forms at the same time. Using this technique, we found that HeLa S3 
cells express mostly H1.2 and H1.4, and H1.2-1p, H1.4-1p and H1.4-2p are abundant 
during interphase [15]. In order to study the dynamics interphase H1 phosphorylation 
during cellular differentiation, we used HIC to investigate the H1 profile of NT2 cells 
differentiated with retinoic acid (RA) in a 7-day period.  
NT2 cell is an embryonal carcinoma (EC) cell line derived from human teratocarcinoma, 
which shares many properties with hESCs and is widely used as a substitute for hESCs 
because it can be grown without feeders, has the ability to recover rapidly from freezing 
and thawing, and can be obtained in large numbers on a routine basis while retaining a 
relatively homogeneous phenotype [16]. Retinoic acid (RA) induces pluripotent NT2 
cells to differentiate along a neural lineage [16, 17]. HIC analyses of crude H1 prepared 
from pluripotent NT2 cells revealed that NT2 cells expressed H1.2, H1.3, H1.4 and H1.5 
predominantly. In addition to peaks representing non-phosphorylated H1 variants, peaks 
for mono- and di-phosphorylated H1.5 (H1.5-1p, -2p), mono-phosphorylated H1.4 (H1.4-
1p) and mono-phosphorylated H1.2 (H1.2-1p) were also detected, while the 
phosphorylation of H1.3 was not readily detectable using this method (Fig. 2.1A). In 
contrast to HeLa S3 cells, which have high levels of phosphorylation on H1.4 and H1.2 
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[15], NT2 cells seemed to have higher levels of phosphorylation on H1.5 compared to 
other H1 variants, whereas H1.2 and H1.4 were phosphorylated to much lesser extents, 
indicating that the phosphorylation levels of individual H1 subtypes vary in different cell 
lines. Following the addition of RA, the level of H1.5 mono-phosphorylation (H1.5-1p) 
appeared to remain stable for the first three days but then decreased markedly between 
days 3 and 7 of RA treatment. Similarly, the level of H1.4 mono-phosphorylation (H1.4-
1p) also decreased during 7 days of RA treatment, but the kinetics differed from those of 
H1.5-1p. Loss of H1.4-1p was apparent after one day of RA treatment and appeared to 
decrease somewhat further over the following 6 days. In contrast, the level of H1.2 
mono-phosphorylation (H1.2-1p) appeared to remain constant throughout the treatment 
interval. Moreover, the levels of non-phosphorylated H1.2 and H1.3 appeared to increase 
after 7 days of RA treatment, which is consistent with previous findings that the 
expression of H1.2 and H1.3 were induced during embryoid body differentiation of 
mESCs [12]. 
The same approach was applied to study the dynamics of H1 phosphorylation during the 
differentiation of mouse ES cell. Pluripotent mESCs were maintained in ES cell media 
with leukemia inhibitory factor (LIF) and differentiation was induced by removal of LIF 
from the media [18, 19]. HIC analyses revealed that some, but not all, of the same 
changes in NT2 cells were observed upon differentiation of mES cells (Fig. 2.1B). In 
particular, the level of H1.5-1p showed a similar marked decrease in differentiated 
mESC. However, in contrast to NT2 cells, H1.4-1p in mESC remained constant or even 
slightly increased after differentiation, suggesting that these interphase phosphorylations 
of H1 are differentially regulated in NT2 or mES cells. Since murine H1.2 and H1.3 co-
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eluted in HIC, it is hard to determine whether the phosphorylation levels of H1.2 or H1.3 
changed during this process.  
In summary, HIC analyses of pluripotent and differentiated NT2 or mESC indicated that 
interphase phosphorylations of H1 variants were dynamically changed during the process 
of differentiation. The decrease of H1.5-1p seemed to be a common feature of pluripotent 
cell differentiation. However, it remained unclear which site-specific phosphorylations 
were involved in this process.  
2.3 Generation and Validation of Antibodies Against Phosphorylated H1 and H1 
Variants  
Previous report showed that S18, S173 and S189 are the predominant interphase sites of 
H1.5. The majority of H1.5-1p affected S18 while the rest affected S173 [20]. Therefore, 
the change of H1.5-1p during pluripotent cell differentiation (Fig. 2.1) might be due to 
changes of pS18 and/or pS173 of H1.5. Our lab has generated an antibody against pS173 
peptide that is identical in H1.2 and H1.5 [15]; thus, we needed to generate an antibody 
against pS18-H1.5.  
pS18-H1.5 antibody was generated by immunizing rabbit with synthetic phosphopeptide 
containing pS18 and flanking sequences of H1.5 (CPVEKpSPAKK) coupled to 
maleimide-activated keyhole limpet hemocyanin. In addition, pan-H1.5 and H1.0 
antibodies were also generated by immunizing rabbit with full length recombinant human 
H1.5 and H1.0. The specificity of these antisera was characterized by immunoblotting. 
Immunoblots with recombinant H1.0-H1.5 revealed that our antisera against H1.0 or 
H1.5 specifically recognized their corresponding H1 variant, with little or no cross-
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reactivity with other H1 variants (Fig. 2.2A). In addition, our H1.0 or H1.5 antibodies 
recognized a single band in crude H1 extracted from WI-38 VA-13 cell as well as whole 
cell lysates of WI-38 VA-13 or HeLa cell, indicating that these antibodies can detect 
endogenous H1.0 or H1.5 (Fig 2.2B). In contrast, our antibody against pS18-H1.5 did not 
detect any signal from recombinant H1.5 and H1.0, but recognized a single band from 
crude H1 preparation of WI-38 VA-13 cell (Fig. 2.2C), suggesting that our pS18-H1.5 
antibody did not cross-react with unmodified H1.5. The pS18-H1.5 antibody detected 
multiple bands from whole cell lysates of HeLa cell. However, only the H1.5 band 
disappeared after competition with pS18-H1.5 peptide, suggesting that other bands are 
due to non-specific binding of the antibody (Fig. 2.2D).  The specificity of pS18-H1.5 
antibody was further tested against HIC-purified fractions of H1.5-2p, H1.5-1p and H1.5-
0p from CCRF-CEM cells. As we expected, both pS18-H1.5 and pS173-H1.5 antisera 
detected the H1.5 band in H1.5-1p and showed a stronger signal for H1.5-2p (Fig. 2.2E), 
which is consistent with previous report that H1.5-1p is comprised of H1.5 
phosphorylated at either S18 or S173, whereas H1.5-2p is phosphorylated at both S18 
and S173 [20]. However, both pS18-H1.5 and pS173-H1.5 antisera showed a weak signal 
for H1.5-0p. This was likely due to the incomplete resolution of H1.5-0p and H1.5-1p by 
HIC, which led to the contamination of H1.5-0p fraction by small amount of 
phosphorylated H1.5 (Fig. 2.2E). 
2.4 Changes in the Global Levels of Site-Specific Phosphorylation and H1 Variant 
Expression During Cell Differentiation 
To investigate the dynamics of H1 phosphorylation during cellular differentiation in a 
site-specific manner, we analyzed NT2 and mESC before and after 7 days of 
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differentiation by immunoblotting with antisera against pS18-H1.5, pS173-H1.2/5, 
pS187-H1.4 as well as their corresponding H1 variants. Control analyses revealed that 
expression of the Oct-4, Sox-2 and Nanog transcription factors all decreased significantly 
in NT2 cells after RA addition, confirming differentiation and the loss of pluripotency in 
cultures during the treatment interval (Fig. 2.3A). Similarly, Oct-4 and Sox-2 expression 
in mESCs dropped markedly within 1 week after LIF was removed (Fig. 2.3B).   
Comparing the expression and phosphorylation of individual H1 variants in NT2 cells on 
days 0 and 7 of RA treatment using our antisera suggested that the global levels of 
phosphorylation at several sites changed that were not attributable to changes in H1 
variant expression. The level of pS18-H1.5 appeared to be apparently less in 
differentiated cells (Fig. 2.3C). However, only slight decrease was detected using antisera 
against pS173-H1.2/5 or pS187-H1.4 in differentiated NT2 cells compared to pluripotent 
ones, suggesting that these sites might be differentially regulated (Fig. 2.3C). The 
decrease of pS18-H1.5, pS173-H1.5 and pS187-H1.4 was consistent with the reduced 
levels of H1.5-1p and H1.4-1p after NT2 differentiation detected by HIC (Fig. 2.1A). In 
addition, pS173-H1.2 in both undifferentiated and differentiated NT2 cells was 
dramatically less abundant than pS173-H1.5, consistent with HIC data that only low level 
of H1.2-1p was detected in NT2 cells (Fig. 2.1A). Blots for total H1.4 and H1.5 
suggested that these changes in site-specific phosphorylation during NT2 cell 
differentiation occur in the absence of significant changes in H1.4 and H1.5 expression. 
However, we found that expression of H1.0 and H1.2 was induced in differentiated NT2 
cells compared to the undifferentiated cells (Fig. 2.3C). The induction of H1.2 expression 
was supported by HIC data that H1.2-0p increased after differentiation of NT2 cell (Fig. 
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2.1A). However, the induction of H1.0 was not detected by HIC because H1.0 co-elutes 
with phosphorylated H1.5, thus the increase of H1.0 after differentiation was masked by 
decrease of H1.5 phosphorylation. Our findings are consistent with previous evidence 
that changes in H1 variant protein levels associated with differentiation in NT2 cells were 
detectable only for H1.0, despite significant changes in the mRNA levels for multiple 
variants in NT2 cells and human ES cells [21]. 
Similar to NT2 cell, mESC also showed a markedly decrease of pS18-H1.5 after 
differentiation (Fig. 2.3C). A more significant decrease of pS173 on both H1.2 and H1.5 
was detected in mESC upon differentiation compared to that in NT2 cells. However, in 
contrast to NT2 cells, the pS187-H1.4 blot showed a slight increase after the 
differentiation of mESC, consistent with the increase of H1.4-1p in differentiated mESC 
observed by HIC (Fig. 2.1B). Moreover, the expression of H1.4 and H1.5 were slightly 
increased upon differentiation of mESC, in addition to the significant induction of H1.0 
expression (Fig. 2.3C). Although the signals obtained for total H1.5 in mESCs were less 
intense than those for NT2 cells, we assume that this reflects weaker binding of mouse 
H1.5 by the antiserum due to species-specific amino acid sequence differences rather 
than a marked difference in abundance. Our findings on the increase of H1.4 and H1.0 
expression upon LIF withdrawal are consistent with previous report that the expression of 
H1.2, H1.3 and H1.4, in addition to H1.0, was found to increase when mESC was 
differentiated to form embryoid bodies [12]. 
Taken together, the above findings from NT2 and mESC suggest that induction of H1.0 
expression and diminished interphase phosphorylation of H1.5 at the S18 and S173 sites 
are common features of pluripotent cell differentiation. These may be accompanied by 
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additional changes in phosphorylation and H1 variant expression depending on the cell 
type and other factors. 
2.5 Changes in H1 Phosphorylation After Differentiation Are Not Simply Due To 
Changes in Cell Cycle Distribution 
Embryonic stem cells exhibit a very unusual cell cycle structure compared to 
differentiated cells, characterized by a short G1 phase and a high proportion of cells in S 
phase [22]. Flow cytometry analyses of propidium iodide stained NT2 cells revealed that 
a large proportion of undifferentiated NT2 cells were in S phase. Upon differentiation, 
increasing percentage of cells in G1 was observed with decreasing amount of cells in S 
phase [23, 24] (Fig. 2.4A). As mentioned above (Chapter 1.5), analyses of 32P-phosphate 
labeled H1s prepared from synchronized cells revealed that H1 phosphorylation 
progressively increases during the interphase before reaching maximum level at mitosis 
[25-30]. However, none of the above studies involved any site specificity, so it remains 
unclear whether the increase of H1 phosphorylation during interphase is due to increased 
phosphorylation level on a fixed number of sites or due to more sites being 
phosphorylated. A more recent chromatographic study of cells sorted for different cell 
cycle stages showed that the majority of interphase phosphorylation of H1 variants were 
established during G1. A clear increase of phosphorylation on all interphase sites of H1.2, 
H1.3, H1.4 and H1.5 was observed during S phase and this pattern is largely preserved in 
G2/M cells with additional hyperphosphorylated forms being identified [31]. Therefore, a 
decrease of cell population in S phase might lead to reduced interphase phosphorylation 
on all H1 variants. If the changes of H1 phosphorylation observed during the 
differentiation of NT2 or mES cells were merely due to reduced cell population in S-
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phase, we would expect to see a uniform dephosphorylation at all interphase sites of H1 
variants. However, our findings that interphase H1 phosphorylations were differentially 
regulated during differentiation in NT2 and mESC, especially that global pS187-H1.4 
level increased after mESC differentiation, strongly argues against this hypothesis.  
To further investigate this issue, we synchronized undifferentiated and differentiated NT2 
cells at G1/S by thymidine block and assessed H1 phosphorylation by HIC. Flow 
cytometry analyses of propidium iodide stained cells showed that both pluripotent and 
differentiated NT2 cells were successfully synchronized at G1/S by thymidine block (Fig. 
2.4A). If the differences of H1 phosphorylation between pluripotent and differentiated 
NT2 cells were attributed only to changes in cell cycle distribution, we would expect to 
see similar patterns of H1 phosphorylation if the cells were synchronized. Interestingly, 
the HIC profile of thymidine blocked NT2 cells before or after differentiation looked 
similar to their asynchronous counterpart (Fig. 2.4B). However, the HIC profile of 
thymidine blocked pluripotent NT2 cells was apparently different from that of thymidine 
blocked NT2 cells after differentiation, with higher levels of phosphorylation on H1.5 
and H1.2 (Fig. 2.4B), suggesting that other mechanisms including transcriptional 
regulation and chromatin organization in addition to cell cycle regulation might be 
involved in mediating H1 phosphorylation during cell differentiation. The variant specific 
dephosphorylation in this process provide further evidence for the functional diversity 
between H1 variants. 
51 
 
2.6 pS187-H1.4, But Not pS18-H1.5, Is Associated With the Transcription of 
Pluripotency Genes  
Given our findings that decrease of the global levels of pS18-H1.5, pS173-H1.2/5 and 
pS187-H1.4 accompanied down regulation of pluripotency factor expression during RA-
induced differentiation of NT2 cells, we wondered whether these changes in site-specific 
H1 phosphorylation might contribute to their transcriptional regulation. Therefore, we 
used ChIP-qPCR to investigate the association of these phosphorylated forms of H1 at 
pluripotency genes and housekeeping genes before and after differentiation of NT2 cells 
(Fig. 2.5). 
pS187-H1.4 was enriched at the transcription start sties (TSSs) of pluripotency gene (Fig. 
2.5A) as well as housekeeping genes (Fig. 2.5B) in pluripotent NT2 cells. Upon 
differentiation, the association of pS187-H1.4 at the TSSs of pluripotency genes dropped 
markedly, whereas no significant changes of pS187-H1.4 at the TSSs of housekeeping 
genes were observed (Fig. 2.5A and B). Although the level of pS187-H1.4 decreased 
globally during NT2 cell differentiation, the findings from ChIP-qPCR indicate that the 
association of pS187-H1.4 was not uniformly diminished throughout the genome, but 
was selectively depleted from the TSSs of pluripotency factor genes. Therefore, the 
above data implied that the enrichment of pS187-H1.4 at the promoter regions of 
pluripotency genes was positively correlated with their transcription, which agrees with 
our report that pS187-H1.4 was enriched at hormone response elements shortly after 
hormone stimulation [15]. Taken together, the findings here and in previous report 
suggest that pS187-H1.4 might play a positive role in RNA polymerase II (Pol II) 
mediated transcription. 
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Similarly, we found that pS173-H1.2/H1.5 association with the TSSs of pluripotency 
genes, but not housekeeping genes, decreased slightly after differentiation, although the 
changes were not statistically significant due to variations between biological repeats 
(Fig. 2.5A). Since the pS173 antibody detects S173 phosphorylation on both H1.2 and 
H1.5, we are unable to discern whether the decrease at pluripotency gene TSSs in 
differentiated NT2 cells is due to changes in the association of both pS173-H1.2 and 
pS173-H1.5 or the selective loss of one form over the other. However, since the global 
level of pS173-H1.2 appears to be remarkably lower than that of pS173-H1.5 in both 
pluripotent and differentiated NT2 cells (Figs. 2.1A and 2.3C), it is possible that the 
decrease in ChIP signal reflects selective depletion of pS173-H1.5 from pluripotency 
gene promoters in differentiated cells. 
In contrast, the level of pS18-H1.5 was not significantly changed at any of the promoters 
assessed (Fig. 2.5A and B). Since the global level of pS18-H1.5 decreased notably during 
NT2 cell differentiation (Figs. 2.1A and 2.3C), our data support the possibility that pS18-
H1.5 is not directly correlated with transcription, which is consistent with evidence from 
immunofluorescence microscopy that pS18-H1.5 does not co-localize with Br-UTP 
labeling of nascent transcripts [32]. Thus, the higher level of pS18-H1.5 in pluripotent 
NT2 cells might be associated with higher population of cells in S-phase (Fig. 2.4A) and 
more open and dynamic chromatin in pluripotent cells [4, 6]. 
Taken together, the results shown in Figure 2.5 suggest that interphase phosphorylation at 
S187 of H1.4 and possibly at S173-H1.2/5, associated with gene promoters is positively 
correlated with transcription whereas dephosphorylation or depletion of these forms 
correlates with transcriptional repression. In addition to facilitating transcription of 
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pluripotency factor genes, the higher levels of pS187-H1.4 and pS173-H1.2/H1.5 we 
found in pluripotent NT2 cells might also be associated with the more global 
transcriptional activity found in ES cells [33]. Our results also suggest that the impact of 
interphase phosphorylation at the H1.5-S18 NTD site on transcription may differ, in 
general, from that of the two CTD sites investigated, H1.2/H1.5-S173 and H1.4-S187. 
2.7 Bromodomain Inhibition Affects pS187-H1.4 Association at the Promoters of 
Pluripotency Genes 
In Chapter 2.6, we showed that pS187-H1.4 association is positively related to the 
transcription of pluripotency genes in NT2 cells. Therefore, we are curious how pS187-
H1.4 is regulated during the differentiation of pluripotent cells. Recent studies showed 
that BRD4 occupied the super-enhancer and promoter region of pluripotency genes and 
inhibition of BRD4 recruitment in ESC induced differentiation along neuroectodermal 
lineage [9, 34]. So we treated NT2 cells with a bromodomain inhibitor, JQ1, which 
prevents the recruitment of BRD4 to acetylated histone tails [35], and assessed pS187-
H1.4 level at gene promoters by ChIP-qPCR (Fig. 2.6). 
Interestingly, 1 h treatment of JQ1 appeared to induce pS187-H1.4 association at both 
pluripotency and housekeeping genes, except for NANOG and RNU11 (Fig. 2.6A). In 
contrast, 8 h JQ1 treatment resulted in markedly decrease of pS187-H1.4 level at 
promoters of POU5F1 and NANOG, whereas the pS187-H1.4 level at ACTB and 
ACTG1 promoters still remained elevated compared to mock-treated cells (Fig. 2.6B). 
The bi-phasic reaction of pS187-H1.4 level at pluripotent gene promoters to JQ1 
treatment can possibly be explained by the dual function of JQ1, which releases active P-
TEFb from 7SK RNA complex [36] in addition to inhibiting BRD4 recruitment.  
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P-TEFb, a complex of CDK9 and Cyclin T, promotes transcriptional elongation of Pol II 
from poised promoters [37]. In human cells, a large proportion of P-TEFb is kept inactive 
by sequestration in a 7SK snRNA complex together with HEXIM1 and other proteins  
[38, 39]. Some small molecules, including JQ1, can transiently release active P-TEFb 
from 7SK complex, which results in temporary enhancement of CDK9 activity [36]. The 
enhanced CDK9 activity activates the transcription of HEXIM1, which in turn triggers 
the reassembly of 7SK complex. Therefore, the equilibrium between inactive and active 
P-TEFb will be back to normal after 6 h of JQ1 treatment [36]. As discussed in Chapter 
3, CDK9 is likely to phosphorylate H1.4 at S187. Therefore, the increase of pS187-H1.4 
level at gene promoters after 1 h JQ1 treatment is probably due to temporarily enhanced 
CDK9 activity. 
On the other hand, JQ1 is also a bromodomain inhibitor, which prevents the binding of 
BRD4 to acetylated histones. Previous evidence showed that BRD4 interacts with P-
TEFb both in vivo and in vitro, and depletion of BRD4 results in reduced CDK9 
recruitment and transcriptional inhibition [40]. Bromodomain inhibition or BRD4 
depletion in human and mouse ES cells reduced the expression of pluripotency genes but 
not housekeeping genes, suggesting that not all Pol II transcription is dependent on 
BRD4. In addition, ChIP-seq studies revealed that bromodomain inhibition decreased the 
association of BRD4 and CDK9 at super-enhancer regions and promoters of pluripotency 
genes in hESC [34]. Therefore, it is highly likely that 8 h JQ1 treatment inhibited the 
recruitment of CDK9 by BRD4 at the promoters of POU5F1 and NANOG, which 
resulted in reduced pS187-H1.4 level at these loci. However, the level of pS187-H1.4 at 
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some housekeeping genes was not affected by BRD4 inhibition, implying that BRD4 
does not regulate pS187-H1.4 level at all Pol II genes. 
2.8 Depletion of Individual H1 Variants Does Not Affect the Transcription of 
Pluripotency Genes 
We have shown that the global levels of pS187-H1.4 and pS18-H1.5 were reduced in 
differentiated NT2 cells (Fig. 2.3), whereas the association of pS187-H1.4, but not pS18-
H1.5, decreased at the promoters of pluripotency genes after differentiation (Fig. 2.5), 
which suggests that H1.5 and H1.4 might play distinct roles in the differentiation of 
pluripotent cells. Therefore, we used siRNA to knockdown specific H1 variants in 
pluripotent or differentiated NT2 cells and assessed their effect on transcription by      
RT-qPCR. 
One of the siRNAs we used targets a conserved sequence in H1.2 and H1.4; therefore can 
knockdown H1.2 and H1.4 simultaneously. The other siRNA is specific for H1.5. 
Immunoblotting showed that siRNA against H1.2/H1.4 significantly reduced the protein 
levels of H1.2 and H1.4 in NT2 cells, with little effect on H1.5 expression. In contrast, 
H1.5 siRNA markedly knocked down the expression of H1.5. Meanwhile, the level of 
H1.4 was also decreased while the expression of H1.2 was up-regulated (Fig. 2.7A). 
RT-qPCR showed that the expression of pluripotency genes (POU5F1, SOX2 and 
NANOG) were high in undifferentiated NT2 cells, which dropped dramatically after 
differentiation. The expression of housekeeping genes appeared to be regulated 
individually during differentiation of NT2 cells, with ACTG1 up-regulated, GAPDH 
down-regulated and ACTB unchanged. The expression of a neural marker, PAX6, was 
markedly induced after differentiation, suggesting that NT2 cells were differentiated 
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along neural lineage. Interestingly, the mRNA levels of multiple H1 variants (H1.2, H1.4 
and H1.5) were significantly reduced after differentiation, which is consistent with 
previous report that the mRNA expression of H1.2, H1.4 and H1.5 was diminished after 8 
days of RA-induced differentiation of NT2 cells (Fig. 2.7B). However, we have 
demonstrated that the protein levels of H1.4 and H1.5 were not significantly changed 
while that of H1.2 was induced after NT2 differentiation (Chapter 2.4), suggesting that 
the protein levels of H1 variants during differentiation were post-transcriptionally 
regulated. 
RT-qPCR with H1 variant-specific primers confirmed that the siRNAs we used 
significantly reduced the mRNA levels of their corresponding H1 variants. Depleting 
H1.2/H1.4 or H1.5 in pluripotent or differentiated NT2 cells did not change the 
expression of pluripotency genes, indicating that none of the above H1 variants are 
necessary for the maintenance of high level transcription of pluripotency genes in 
undifferentiated NT2 cells or the transcriptional repression of pluripotency genes after 
differentiation (Fig. 2.7B). This is consistent with findings in mESC that knocking out 
individual H1 variants did not result in any significant phenotype [41], suggesting that H1 
variants can compensate for each other to maintain a normal H1 to nucleosome 
stoichiometry. Compound deletion of H1.2, H1.3 and H1.4 in mESC resulted in lethality 
in early embryo development and impaired capability of differentiation, suggesting that 
the stoichiometric H1 to nucleosome ratio is essential for normal ESC differentiation [11, 
12, 42]. Similarly, depleting individual H1 variants seemed to have little effect on the 
transcription of housekeeping genes. However, depletion of H1.2/H1.4 appeared to 
induce the expression of neural-specific genes, NES and PAX6, suggesting that H1.2 or 
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H1.4 might be responsible for repressing the expression of differentiation-associated 
genes. 
Taken together, the above findings suggest that none of the above somatic H1 variants 
(H1.2, H1.4 or H1.5) are essential for the maintenance of pluripotency in NT2 cells. 
Depleting H1 variants individually did not affect transcription globally but might inhibit 
or enhance transcription in a gene-specific manner. In addition, depletion of H1.5 alone 
or H1.2 and H1.4 together might have different effect on gene-specific transcription. An 
earlier study using shRNA to knock down individual H1 variants in T47D breast cancer 
cells revealed that H1 variants might have distinct roles in cell growth and gene 
expression. Depletion of H1.4 appeared to induce cell death in T47D cell, whereas H1.2 
knockdown resulted in a G1-phase arrest and the repression of cell cycle related genes 
[43]. Moreover, depletion of H1.5 in human fibroblast resulted in loss of SIRT1 and 
H3K9me2 binding, increased chromatin accessibility and deregulation of gene-specific 
transcription [13]. In summary, our findings together with previous reports suggest that 
although H1 variants seem to be able to compensate for each other in ESC maintenance 
and differentiation, individual H1 variants appear to play distinct roles in regulating gene-
specific transcription. 
2.9 Conclusions and Discussion 
Dramatic epigenetic changes have been observed after the differentiation of ES cells, 
including expanded occupancy of repressive markers, such as H3K9me3 and H3K27me3 
[7], and the reduction of active histone marks, such as acetylation at H3K9 and multiple 
sites of H4 [8, 9]. However, it remained unclear whether changes in H1 phosphorylation 
were also involved in this process before this study. The data presented here suggest that 
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changes in interphase phosphorylation at specific sites of H1 variants are characteristics 
of pluripotent cell differentiation. 
Global decrease of pS18-H1.5 and pS173-H1.2/5 seems to be a common feature of 
pluripotent cell differentiation (Fig. 2.3C). The association of pS173-H1.2/5 at 
pluripotency genes was slightly decreased after differentiation whereas that of pS18-H1.5 
remained constant (Fig. 2.5), suggesting that pS173-H1.2/5 and pS18-H1.5 might play 
different role in this process. This functional distinction between pS173-H1.2/5 and 
pS18-H1.5 is supported by immunofluorescence microscopy analyses that pS173-H1.2/5, 
but not pS18-H1.5 colocalized with Br-UTP labeling of newly-transcribed RNA [32]. 
However, the functional significance of pS18-H1.5 in cellular differentiation has not yet 
been elucidated. It is likely that the drop of global pS18-H1.5 is associated with the 
spreading of heterochromatin and reduced H1 mobility after ES cell differentiation. 
ChIP-seq analyses for the genome-wide distribution of pS18-H1.5 before and after ES 
cell differentiation might provide further insight into the role of pS18-H1.5 in this 
process. 
The global level of pS187-H1.4 was decreased in NT2 cells but increased in mESC after 
differentiation (Fig. 2.3C), suggesting that this interphase phosphorylation was 
differentially regulated in these cell lines. ChIP-qPCR revealed that pS187-H1.4 
association with pluripotency genes, but not housekeeping genes, was significantly 
reduced after differentiation of NT2 cells (Fig. 2.5), suggesting a positive role of pS187-
H1.4 in transcriptional regulation of pluripotency genes. Although previous studies from 
multiple labs, including our own lab, revealed that H1 phosphorylation is involved in 
transcriptional activation mediated by nuclear hormone receptors [15, 44-47], the data 
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presented here provide the first line of evidence that a site-specific H1 phosphorylation is 
positively associated with Pol II transcription which is not activated by nuclear hormone 
receptors. The enrichment of pS187-H1.4 at the TSSs of actively transcribed gene is in 
line with ChIP-seq data that H1 variants are generally depleted from transcription start 
sites [48, 49], because phosphorylation appears to promote H1 dissociation from 
chromatin according previous FRAP microscopy studies [50-52]. The level of pS187-
H1.4 at pluripotency gene promoters seems to be dependent on BRD4 recruitment (Fig. 
2.6). It is likely that the drop of BRD4 at the enhancers and promoters of pluripotency 
genes after ES cell differentiation results in reduced CDK9 recruitment and less pS187-
H1.4 association, which then causes the transcriptional repression of pluripotency genes. 
The relationship between CDK9 recruitment and S187-H1.4 phosphorylation will be 
elaborated in Chapter 3.  
Taken together, the data presented here suggest that site-specific interphase 
phosphorylations of H1 are dynamically changed during the differentiation of pluripotent 
cells. pS187-H1.4 and possibly pS173-H1.2/5 are associated with transcriptional 
regulation of pluripotency genes whereas pS18-H1.5 might be involved in other cellular 
processes. The distinct distribution patterns of interphase H1 phosphorylations suggest 
that different kinases might be involved in regulating site-specific interphase H1 
phosphorylation. 
2.10 Material and Methods 
Cell culture and differentiation 
NTERA-2/D1 (NT2) human embryonal testicular teratocarcinoma cells and W4/129S6 
mESCs were obtained from Dr. Fei Wang (UIUC). NT2 cells were grown in DMEM + 
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10% FBS and subcultured by scraping. Differentiation was induced by dissociating cells 
with trypsin, followed by seeding at a density of 1x106 cells per T-75 flask or 1.33x104 
cells/cm2 in DMEM, supplemented with 10% FBS and 10 μM all-trans retinoic acid 
(RA). mESCs were maintained in DMEM with high glucose, supplemented with 15% 
FBS (ES-Cult FBS, Stemcell Technologies, 06952), 0.1 mM non-essential amino acids 
(Gibco), 1 mM sodium pyruvate (Gibco), 0.1 mM β-mercaptoethanol (Sigma), 2 mM L-
glutamine (GlutaMAX, Gibco), 1000 U/mL LIF (Nacalai USA, NU0012) and 1X 
penicillin/streptomycin (Gibco) on gelatin-coated plates. The cells were fed with fresh 
medium daily and subcultured in new gelatin-coated plates by trypsinization every other 
day. Differentiation was induced by seeding cells in ES cell medium without LIF. 
Histone preparation and chromatography 
Crude histones were extracted from isolated nuclei with 0.4N H2SO4 as described 
previously [53]. Crude H1 was prepared by 5% perchloric acid fractionation of crude 
histones and recovered by precipitation with 20% (w/v, final concentration) 
trichloroacetic acid (TCA). Hydrophobic interaction chromatography (HIC) was 
performed using a 4.6 mm ID × 100 mm PolyPROPYL A column (PolyLC Inc.) and a 
multistep linear gradient from buffer A (2.5 M (NH4)2SO4 in 50 mM sodium phosphate, 
pH 7.0) to buffer B (1.0 M (NH4)2SO4 in 50 mM sodium phosphate, pH 7.0). Fractions 
were collected by time and proteins were recovered by precipitation with 20% TCA. 
siRNA transfection 
siRNA transfection was performed using Oligofectamine (Invitrogen) according to 
manufacturer’s protocol. Cells were seeded the day before transfection in order to reach 
30-50% confluency at the time of transfection. Transfection reagents and siRNAs were 
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diluted in Opti-MEM (Gibco) before mixed together and incubated for 20 min at room 
temperature. The complexes were then added directly to the cell culture media and the 
cells were harvested after 72 hrs. 
Immunoblotting 
Whole cell lysates or histone extracts were electrophoresed in 15% polyacrylamide gels 
containing SDS, transferred to a PVDF membrane and blocked with 5% milk powder in 
TBS for 1h at room temperature. The blocked membrane was then incubated with 
primary antibody at 4oC overnight, washed with TBST, and incubated with secondary 
antibody conjugated with HRP (Amersham, NA-931 or NA-934) for 1h at room 
temperature, washed with TBST again and developed with chemiluminescence reagents 
(Thermo, SuperSignal West Pico Chemiluminescent Substrate) and images recorded with 
a series of lengthening exposures on X-ray films. Bitmap images were generated from 
selected films using a flatbed scanner and densitometry performed using ImageJ 
<https://imagej.nih.gov/ij/>.   
The pS18-H1.5 antibody was generated by immunizing rabbits with a synthetic 
phosphopeptide (CPVEK-phosphoserine-PAKK) conjugated to maleimide-activated 
keyhole limpet hemocyanin (Thermo Fisher Scientific) using standard procedures. Pan 
antisera to H1.0 and H1.5 were generated by immunizing rabbits with full length 
recombinant human H1.0 or H1.5 as described previously [15]. The antisera to pS187-
H1.4, pS173-H1.2/5 and pan-H1.4 have been described previously [15]. The antibodies 
against other histones and pluripotency markers were obtained from Abcam: H1.2 
(ab4086), histone H3 (ab1791), Oct4 (ab19857), Sox2 (ab97959), Nanog (ab21624). The 
commercial antibody against pS18-H1.5 (61107) was purchased from Active Motif. 
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For peptide competition assays, 10 µg of non-phosphorylated (CPVEKSPAKK) or 
phosphorylated (CPVEKpSPAKK) H1.5-S18 peptides (Genscript) were incubated with 2 
µL of primary antisera in a small volume (500 μL) of PBS for 2 hours at room 
temperature. These mixtures were then further diluted in TBST for use in 
immunoblotting. 
Antibody dilutions for immunoblotting 
pS187-H1.4 (UI-86), 1:1000; pS173-H1.2/5 (UI-83), 1:500; pS18-H1.5, 1:1000; H1.4 
(UI-99), 1:1000; H1.5, 1:2000; H1.2 (ab4086), 1:5000; H1.0, 1:2000; H3 (ab1791), 
1:10000; Oct4 (ab19857), 1:1000; Sox2 (ab97959), 1:1000; Nanog (ab21624), 1:300. 
Cell Synchronization and FACS 
NT2 cells were synchronized at G1/S by culturing in media with 2 mM thymidine for 16 
hrs. The distribution of cell population at different cell cycle phases was assessed by 
Fluorescence-Activated Cell Sorting (FACS) analysis of propidium iodide stained cells 
fixed by 70% ethanol. 
ChIP and qPCR 
Chromatin immunoprecipitation (ChIP) experiments were performed as described 
previously with minor modifications [15]. Cells were cross-linked by adding 
formaldehyde directly to cultures (1% final) and incubating for 8 min at room 
temperature. 125 mM final glycine was added, and cultures were incubated for 10 min at 
room temperature. Cells were then washed twice with cold PBS, scraped, and 
resuspended in ChIP lysis buffer with protease and phosphatase inhibitors. Chromatin 
was sheared to ~1 kb mean length by repeated cycles of sonication in a 4oC water bath 
using a Bioruptor (Diagenode). After centrifuging at 18,000g for 10 min, the supernatants 
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were diluted 10-fold with ChIP dilution buffer.  Aliquots representing 1–2×106 cells in 
1.0 ml final volume were used for each pull down. Samples were incubated with specific 
antibodies (15 μL pS187-H1.4, 30 μL pS173-H1.2/5, 10 μL pS18-H1.5 (Active Motif)) at 
4oC overnight. Immunocomplexes were incubated with 50 μL BSA-blocked protein G 
Dynabeads (Invitrogen) for 4 hrs at 4oC, collected using a magnetic rack, and washed 
sequentially with ChIP wash buffer I, II, III and twice with TE. Beads were eluted twice 
with 200 μL 1% SDS in 0.1 M NaHCO3 at 65oC for 10 min. The combined eluates were 
made 200 mM NaCl (final), incubated at 65°C overnight to reverse cross-links, digested 
with 50 μg/mL RNase A at 37°C for 30 min, and then digested with 50 μg/mL proteinase 
K at 50°C for 1 h. The DNA fragments were then purified by phenol/chloroform 
extraction, recovered by ethanol precipitation using 20 μg glycogen as a carrier, and 
dissolved in 50 μL of deionized water. ChIP products were quantitated by real-time PCR 
using SYBR Green master mix (Applied Biosystems) and the primers listed in Table 2.1. 
RNA extraction and RT-qPCR 
Total RNA was extracted by TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions. The crude RNA was subjected to DNase I digestion at 37oC for 1h and then 
cleaned up using Qiagen RNeasy Mini Kit. cDNA was generated from 100 ng of total 
RNA using SuperScript III First-Strand Synthesis System (Invitrogen). Quantitation of 
gene products was performed by real-time PCR using SYBR Green master mix (Applied 
Biosystems) and the primers listed in Table 2.2. 
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2.11 Figures and Tables 
Figure 2.1 
HIC analyses for H1 variant expression and phosphorylation during the 
differentiation of pluripotent cells. 
(A) Crude H1 from NTERA-2 embryonal carcinoma cells induced to differentiate with 10 
μM retinoic acid for 0, 1, 3 or 7 days was fractionated by hydrophobic interaction 
chromatography (HIC). Eluate absorbance at 214 nm (Y axis) is plotted relative to 
time (X axis) for equivalent portions of each separation. The relative elution positions 
of H1.2, H1.3, H1.4 and H1.5 and the phosphorylation stoichiometry of their major 
interphase forms are indicated above the 0 day trace. H1.0 coelutes as a broad peak 
that overlaps with both phosphorylated and nonphosphorylated H1.5 (data not 
shown). 
(B) Crude H1 from W4/129S6 mouse embryonic stem cells induced to differentiate by 
culturing in LIF-free media for 0, 3 or 7 days was fractionated by hydrophobic 
interaction chromatography (HIC). Eluate absorbance at 214 nm (Y axis) is plotted 
relative to time (X axis) for equivalent portions of each separation. The relative 
elution positions of H1.2, H1.3, H1.4 and H1.5 and the phosphorylation stoichiometry 
of their major interphase forms are indicated above the 0 day trace. 
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Figure 2.2 
 
Generation and validation of highly specific H1 antibodies. 
(A) Recombinant H1 variants were analyzed by immunoblotting with our custom antisera 
for H1.5 and H1.0. Ponceau S staining served as a loading control. 
(B) HeLa and WI-38 VA-13 whole cell lysates (WCL) and PCA-extracted crude H1 
(PCAS) from WI-38 VA-13 cells were analyzed by immunoblotting with our new 
antisera against H1.5 and H1.0. 
(C) PCA-extracted crude H1 from WI-38 VA-13 cells and a mixture of recombinant H1.5 
and H1.0 were analyzed by immunoblotting with our custom antisera against pS18-
H1.5. 
(D) Antisera against pS18-H1.5 was mock-treated (none) or preadsorbed with pS18-H1.5 
antigen peptide (pS18) or the corresponding non-phosphorylated peptide (S18) prior 
to immunoblotting with HeLa whole cell lysate. 
(E) HIC fractions for H1.5-2p, H1.5-1p and H1.5-0p prepared from CCRF-CEM cells 
were analyzed by immunoblotting with our custom antisera against pS18-H1.5 or 
pS173-H1.5. Ponceau S staining served as a loading control. 
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Figure 2.3 
 
 
H1 variant phosphorylation is altered at specific sites after pluripotent cells 
differentiate. 
(A) Retinoic acid-induced differentiation of NT2 cells was assessed by immunoblotting 
whole cell lysates with antibodies specific for the indicated pluripotency factors. 
(B) Differentiation of mouse embryonic stem cells after withdrawal of leukemia 
inhibitory factor (LIF) was assessed by immunoblotting whole cell lysates with 
antibodies specific for the indicated pluripotency factors. 
(C) H1 variant expression and the global levels of their phosphorylation at specific sites 
in NT2 and mouse ES cells before (day 0) and after differentiation (day 7 of RA 
treatment or LIF withdrawal) were assayed by immunoblotting whole cell lysates 
with the indicated antisera. Only custom antisera were used to detect H1 variants and 
phosphorylated forms except for H1.2 (Abcam, ab4086). Signals for histone H3 
demonstrate equivalent loading for the NT2 and mESC samples, respectively. The 
numbers below each panel indicate densitometry for differentiated samples relative to 
the respective undifferentiated sample. The blots shown here are representative of 
three biological repeats. The statistics from three biological repeats for this figure are 
shown in Table 2.3. 
  
67 
 
Figure 2.4 
 
 
Changes in H1 phosphorylation during pluripotent cell differentiation is not merely 
due to changes in cell cycle distribution. 
(A) Propidium iodide stained pluripotent (-RA) or differentiated (+RA for 7 days) NT2 
cells were analyzed by flow cytometry. 
(B) Propidium iodide stained pluripotent (-RA +Thy) or differentiated (+RA +Thy) NT2 
cells that were synchronized by thymidine block for 16 h were analyzed by flow 
cytometry. 
(C) The flow cytometry graphs in (A) and (B) were quantitated to show the percentage of 
cell population in various phases of the cell cycle under different conditions. 
(D) NT2 cells were differentiated and/or synchronized as described in (A) and (B), and 
crude H1 was extracted by 5% perchloric acid and analyzed by HIC. Eluate 
absorbance at 214 nm (Y axis) is plotted relative to time (X axis) for equivalent 
portions of each separation. The relative elution positions of H1.2, H1.3, H1.4 and 
H1.5 are indicated above the -RA trace. 
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Figure 2.5 
 
Changes in the levels of phosphorylated H1 variants at pluripotency gene promoters 
correlate with their reduced expression in differentiated NT2 cells. 
(A) The levels of pS187-H1.4, pS173-H1.2/5 and pS18-H1.5 at the transcription start 
sites of pluripotency genes in NT2 cells before and after 7 days of RA treatment were 
assessed by ChIP-qPCR. Negative control ChIP assays employed non-immune rabbit 
immunoglobulin (rIg) in place of primary antisera.  
(B) The levels of pS187-H1.4, pS173-H1.2/5 and pS18-H1.5 at the transcription start 
sites of housekeeping genes in NT2 cells before and after 7 days of RA treatment 
were assessed by ChIP-qPCR. Negative control ChIP assays employed non-immune 
rabbit immunoglobulin (rIg) in place of primary antisera. Custom antisera were used 
for pS187-H1.4 and pS173-H1.2/5 ChIP. Commercially available antisera (Active 
Motif) was used for pS18-H1.5 ChIP. The data are expressed as the percent relative to 
input DNA (mean ± s.e.m., *: p<0.05, **: p<0.01).  
69 
 
Figure 2.6 
 
 
JQ1 treatment affects pS187-H1.4 association differentially at pluripotency genes 
and housekeeping genes. 
(A) NT2 cells were mock-treated (DMSO) or treated with 10 µM JQ1 (Cayman) for 1 h. 
The levels of pS187-H1.4 at the transcription start sites of pluripotency genes and 
housekeeping genes were assessed by ChIP-qPCR.  
(B) NT2 cells were mock-treated (DMSO) or treated with 10 µM JQ1 for 8 h. The levels 
of pS187-H1.4 at the transcription start sites of pluripotency genes and housekeeping 
genes were assessed by ChIP-qPCR. Negative control ChIP assays employed non-
immune rabbit immunoglobulin (rIg) in place of primary antisera. The data are 
expressed as the percent relative to input DNA. 
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Figure 2.7 
 
 
Depletion of H1 variants does not affect the transcription of pluripotency genes. 
(A) NT2 cells were transfected with siRNA against luciferase, H1.2 and H1.4 or H1.5 
alone for 72 h and the protein levels of H1.2, H1.4 and H1.5 were assessed by 
immunoblotting whole cell lysates. Blot for histone H3 controls for equal loading. 
(B) Undifferentiated (-RA) and differentiated (+RA for 7 days) NT2 cells were 
transfected with siRNA against luciferase, H1.2 and H1.4 or H1.5 alone for 72 h and 
the expression of pluripotency genes, housekeeping genes, neural-specific genes and 
H1 variant genes were assessed by RT-qPCR.  
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Table 2.1 
List of ChIP-qPCR primers 
POU5F1 long forward CTTCGCAAGCCCTCATTT 
POU5F1 long reverse AGGTCCGAGGATCAACCC 
POU5F1 short forward ATGCCATGTTATAGTTTGTG 
POU5F1 short reverse GCTGCTAAGTTCTGGGTTA 
SOX2 forward CGCTAGAAACCCATTTATTCC 
SOX2 reverse CCTAGTCTTAAAGAGGCAGCAA 
NANOG forward TATTATGCAGGCAACTCA 
NANOG reverse AGTATAGAGGAAGAGGAGGA 
ACTB promoter forward GAAAGTTGCCTTTTATGGCTCG 
ACTB promoter reverse TTACCTGGCGGCGGGTGT 
ACTG1 promoter forward CGGCTTTCGGAAAGATCG 
ACTG1 promoter reverse GAGCGGCGGAAGAACAGA 
GAPDH promoter forward TTGGGCTGGGACTGGCTGAG 
GAPDH promoter reverse GGCTGACTGTCGAACAGGAGG 
RNU11 forward ACACGTAGGGCAACTCGA 
RNU11 reverse AAGCACCACTTACTCCAAA 
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Table 2.2 
List of RT-qPCR Primers 
POU5F1 (OCT4) Forward CTTGAATCCCGAATGGAAAGGG 
POU5F1 (OCT4) Reverse GTGTATATCCCAGGGTGATCCTC 
SOX2 Forward GCCGAGTGGAAACTTTTGTCG 
SOX2 Reverse GCAGCGTGTACTTATCCTTCTT 
NANOG Forward CAAAGGCAAACAACCCACTT 
NANOG Reverse TCTGCTGGAGGCTGAGGTAT 
ACTB Forward ATCGTCCACCGCAAATGCTTCTA 
ACTB Reverse AGCCATGCCAATCTCATCTTGTT 
ACTG1 Forward CCCGAGCCGTGTTTCCTT 
ACTG1 Reverse GTCCCAGTTGGTGACGATGC 
GAPDH Forward AAGGAGAGCTCAAGGTCAG 
GAPDH Reverse GAGTAGGGACCTCCTGTTTC 
NES Forward GCAGCACTCTTAACTTACGATC 
NES Reverse CCTACAGCCTCCATTCTTG 
PAX6 Forward GAGTGCCCGTCCATCTTT 
PAX6 Reverse CGCCCATCTGTTGCTTTT 
GFAP Forward GCACGCAGTATGAGGCAATG 
GFAP Reverse CAGGTCGCAGGTCAAGGA 
H1.4 Forward TTACTAAAGCTGTTGCCGCCTCCA 
H1.4 Reverse GCTTGATGCGGCTGTTGTTCTTCT 
H1.2 Forward GCCACTGTAACCAAGAAAGTGGCT 
H1.2 Reverse TCTTAGGCTTGACAACCTTGGGCT 
H1.5 Forward CGAAAAAGGCAACCAAGAGT 
H1.5 Reverse CTTGGCCTTTGCAGCTTTAG 
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Table 2.3 
Statistics for Blots in Figure 2.3C 
 
NT2 mESC 
 
-RA +RA +LIF -LIF 
pS18-H1.5 1.0 0.41 ± 0.16 1.0 0.51 ± 0.11 
pS173-H1.5 1.0 0.70 ± 0.10 1.0 0.51 ± 0.02 
pS173-H1.2 1.0 0.86 ± 0.03 1.0 0.69 ± 0.07 
pS187-H1.4 1.0 0.60 ± 0.17 1.0 0.99 ± 0.07 
H1.5 1.0 1.04 ± 0.06 1.0 0.96 ± 0.25 
H1.4 1.0 0.95 ± 0.08 1.0 1.11 ± 0.05 
H1.2 1.0 1.90 ± 0.26 
  
H1.0 1.0 4.13 ± 0.33 1.0 3.97 ± 1.13 
H3 1.0 1.03 ± 0.03 1.0 1.03 ± 0.03 
  
The blots in Figure 2.3C from three biological repeats were quantitated by densitometry 
as described in Chapter 2.10. The mean ± s.e.m for the densitometry of differentiated 
samples relative to the respective undifferentiated samples in each panel is listed in the 
above table. 
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CHAPTER 3* 
IDENTIFICATION OF KINASES RESPONSIBLE FOR INTERPHASE H1 
PHOSPHORYLATION 
3.1 Introduction 
Interphase phosphorylation of H1 is involved in multiple cellular processes, including 
chromatin organization, transcription and replication [1] (Chapter 1.6). Our current 
findings in NT2 and mouse ES cells (Chapter 2) suggest that interphase H1 
phosphorylation at specific sites are differentially regulated during cell differentiation. 
pS187-H1.4, and possibly pS173-H1.2/5 appear to be involved in transcriptional 
regulation, whereas pS18-H1.5 might participate in other cellular processes. Therefore, it 
is highly likely that different kinases are involved in regulating interphase H1 
phosphorylation at distinct sites. 
As discussed in Chapter 1.5, all interphase H1 phosphorylations identified so far are 
localized exclusively to S-P-X-Z CDK consensus motifs. However, it remains unclear 
which CDK(s) are involved in phosphorylating these sites. Cyclin-dependent kinases 
(CDK) in mammalian cells are a large family of approximately 20 proteins, which can be 
further divided into eight subfamilies. CDKs are involved in multiple cellular processes, 
including cell cycle progression and transcriptional regulation [2]. CDK1, CDK2, CDK4 
and CDK6 are responsible for driving the cells through G1, S, G2 and M phase, whereas 
CDK7, CDK8 and CDK9 are involved in regulating transcriptional initiation and 
                                                          
*: Some material was adapted from the manuscript: 
Site-Specific Regulation of Histone H1 Phosphorylation in Pluripotent Cell Differentiation. 
Ruiqi Liao and Craig A. Mizzen 
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elongation by RNA polymerase II [3, 4]. Previous studies implied that CDK2 and CDK9 
might be responsible for interphase H1 phosphorylation [5-8] (Chapter 1.7). However, 
due to the lack of site-specific antibodies, none of these studies revealed whether CDK2 
or CDK9 can phosphorylate all interphase sites in all H1 variants. In vitro kinase assay 
showed that CDK9 preferentially phosphorylates S183 site of H1.1 whereas CDK2 
preferentially phosphorylates T152 [8]. However, the site-preference of CDK2 and 
CDK9 in vivo still remains to be studied. Here we used our highly specific antibodies 
against site-specific interphase phosphorylation of H1 in combination with kinase 
inhibitor treatment or siRNA knockdown of specific CDKs and revealed that CDK9 is 
likely to phosphorylate S187 of H1.4 in vivo, whereas phosphorylation at S173 of 
H1.2/H1.5 and S18 of H1.5 might be mediated by other kinases. 
3.2 Inhibition of CDK2 or CDK9 Has Different Effects on Global Phosphorylation 
at S187-H1.4 or S18-H1.5 
In order to investigate the effect of CDK2 and CDK9 on site-specific interphase H1 
phosphorylation, we treated NT2 cells with NU6140, a selective inhibitor to CDK2 [9] or 
flavopiridol (FLVP), a selective inhibitor to CDK9 [10, 11] and assessed the global levels 
of pS187-H1.4 and pS18-H1.5 by immunoblotting. Control blots showed that 1 h 
treatment of NU6140 or FLVP successfully reduced the global phosphorylation at T170 
of CDK7 or S2 and S5 of RNAP II CTD (Fig. 3.1B and C), known substrates of CDK2 
and CDK9, respectively [12, 13], suggesting that our preparations of NU 6140 and FLVP 
potently inhibited CDK2 or CDK9 activity.  
Remarkably, the levels of pS18-H1.5 were unaffected during 24 h of NU6140 treatment, 
and were stable during the initial 3 h of FLVP treatment, but a significant decrease was 
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apparent after 8 h of FLVP treatment (Fig. 3.1A). Since the delayed onset of diminished 
pS18-H1.5 may be attributable to the well-documented inhibition of cell cycle 
progression by FLVP [14], our data suggest it is unlikely that either CDK2 or CDK9 is 
involved in regulating interphase phosphorylation at H1.5-S18. However, it remains a 
possibility that the half-life of phosphorylation at S18-H1.5 is longer than that at S187-
H1.4, which might also cause the delayed response of pS18-H1.5 to FLVP treatment. 
Similarly, pS187-H1.4 levels remained unchanged during the first 3 h of NU6140 
treatment, but were increased after 8 and 24 h of treatment, suggesting the likelihood that 
CDK2 also does not directly regulate interphase H1.4-S187 phosphorylation. In contrast, 
FLVP treatments as short as 30 minutes markedly reduced the global levels of pS187-
H1.4, suggesting that CDK9 either mediates phosphorylation at H1.4-S187 or is 
otherwise involved in regulating the global levels of this modification (Fig. 3.1A). 
Our data suggest that CDK2 is not likely to be involved in phosphorylating S187-H1.4 or 
S18-H1.5 during interphase, which seems to be contradicted by previous reports that 
CDK2 is responsible for interphase H1 phosphorylation [5, 6, 15]. One possible 
explanation for this discrepancy is that at least part of the effects after CDK2 inhibition 
observed in previous studies was due to phosphorylation at mitotic sites because the 
antibody used in these studies to detect H1 phosphorylation recognizes phosphorylation 
at both interphase and mitotic sites [16] and three out of five S/T-P-X-Z sites mutated in 
the FRAP analyses are mitotic sites [6]. In addition, the CDK2 inhibitors used in all the 
above studies also inhibit other CDKs, including CDK1, with similar potency [17, 18], 
and prolonged treatment with these inhibitors has been shown to arrest cell cycle 
progression [19]. Therefore, the decrease of H1 phosphorylation observed in these studies 
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might be, at least partially, due to inhibition of the mitotic kinase CDK1 or an indirect 
effect of cell cycle arrest. Our findings that selective inhibition of CDK2 did not decrease 
the global level of pS187-H1.4 or pS18-H1.5 strongly suggest that CDK2 is not 
responsible for interphase phosphorylation at these sites. 
3.3 Inhibiting CDK7 or CDK9 Rapidly Diminishes Both Global and Gene-Specific 
Levels of pS187-H1.4 
Although FLVP inhibits CDK9 preferentially [10], we were concerned that less efficacious 
inhibition of additional kinases by FLVP [11, 20, 21] could reduce pS187-H1.4 levels and 
lead to misidentification of CDK9 as a major kinase for H1.4-S187. We investigated this 
possibility using a recently developed inhibitor, THZ1, that exhibits extraordinarily high 
selectivity for CDK7 due to a novel mechanism of inhibition that involves covalent binding 
to a cysteine residue outside of the kinase domain that is unique to CDK7 [22]. As a subunit 
of both the CDK-activating kinase (CAK) and TFIIH multi-protein complexes, CDK7 is 
involved in regulating cell cycle progression and transcription [2]. TFIIH affects 
transcription via several mechanisms, including phosphorylating the heptapeptide repeats 
of the RNAP II-CTD at Ser5 and Ser7 during initiation and promoter clearance, and 
phosphorylating Thr186 in the T-loop of CDK9 to activate phosphorylation of RNAP II-
CTD heptads at Ser2 and the release of paused RNAP II by the P-TEFb complex [3, 23, 
24]. We reasoned that if H1.4-S187 was a bona fide CDK9 substrate, selective inhibition 
of CDK7 by THZ1 should impair CDK9 (P-TEFb) activation and lead to decreased levels 
of pS187-H1.4. Initial experiments revealed that THZ1 reduced global levels of pS187-
H1.4 in HeLa cells in a dose and time-dependent manner (Fig. 3.2A). We then compared 
the effects of treating HeLa cells for just one hour with 1 µM THZ1 or 1 µM FLVP. Both 
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drugs significantly decreased the phosphorylation of the RNAP II-CTD as evidenced by 
the loss of the phosphorylation-shifted band on immunoblots for total RNAP II and 
decreases in blot signals for phosphorylation at S2 and S5 of the heptad repeats using site-
specific antisera (Fig. 3.2B). Both treatments suppressed global pS187-H1.4 levels 
markedly, with FLVP eliciting a greater reduction than THZ1. However, the reduction of 
global pS187-H1.4 level after THZ1 or FLVP treatment was not as significant as that of 
RNAP II-CTD phosphorylation, which is probably due to the following two reasons. First, 
S187-H1.4 can also be phosphorylated during mitosis. Therefore, the remaining level of 
pS187-H1.4 after THZ1 or FLVP treatment might reflect mitotic phosphorylation at S187-
H1.4, possibly mediated by CDK1 (see Chapter 3.4). Second, the turnover rate of 
phosphorylation at RNAP II-CTD might be higher than that at S187-H1.4, which also 
explains why we observed more significant reduction of RNAP II-CTD phosphorylation 
than pS187-H1.4 after 1 h treatment of THZ1 or FLVP. 
Remarkably, the level of pS18-H1.5 was not affected by either treatment. Both THZ1 and 
FLVP led to slight reductions in the level of pS173-H1.2, but these may have been 
attributable to similar reductions in the expression of H1.2. Both treatments also led to 
increases in the level of pS173-H1.5, but these did not appear to be attributable to increases 
in H1.5 expression. These data provide additional evidence that interphase H1.4-S187 
phosphorylation is regulated differently than that of H1.5-S18, H1.2-S173 and H1.5-S173, 
seemingly due to the involvement of different kinases, but differential rates of phosphoryl 
turnover among sites, or a combination of both factors may also contribute to the 
differences observed.  
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Next, we investigated how CDK7 or CDK9 inhibition affected pS187-H1.4 association 
with specific gene regions. ChIP-qPCR was performed in HeLa cells treated with DMSO, 
1 µM THZ1 or 1 µM FLVP for 1 h. Both THZ1 and FLVP markedly decreased the levels 
of pS187-H1.4 at the promoters and bodies of three housekeeping genes (Fig. 3.2C). 
However, as we found for global pS187-H1.4 levels, the decreases observed for FLVP 
were larger than those for THZ1. Moreover, the effect of THZ1 was more pronounced at 
these promoters compared to the gene bodies, consistent with ChIP-seq data that CDK7 is 
enriched at promoter regions [22]. Given the evidence that CDK9 activity is regulated by 
CDK7 [22, 24], our data support models in which CDK7 indirectly regulates pS187-H1.4 
levels at promoters by controlling CDK9 (P-TEFb) activation whereas CDK9 (P-TEFb) or 
possibly other FLVP-sensitive kinases associated with elongating RNAP II mediate H1.4-
S187 phosphorylation in gene bodies [25]. However, our data do not exclude the possibility 
that H1.4-S187 may also be a bona fide substrate for CDK7. 
3.4 siRNA Depletion of CDK9 Reduces Both Global and Gene-Specific Levels of 
pS187-H1.4 
To further confirm that decreases in the global and gene-specific levels of pS187-H1.4 
upon THZ1 or FLVP treatment are due to inhibition of CDK9, we used siRNA to deplete 
CDK9 in HeLa cells and assessed the global levels of interphase phosphorylations of H1 
variants and the association of pS187-H1.4 with housekeeping genes. In comparison, 
siRNA knockdown for CDK1 in HeLa cells was also performed. Even though the pan-H3 
immunoblot for the repeat shown in Fig. 3.3A suggests that the CDK9-depleted samples 
were slightly overloaded compared to the control samples, the CDK9 immunoblot 
revealed that very little CDK9 remained after 72 h of siRNA treatment, and this was 
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associated with a marked reduction in the global level of pS187-H1.4 (Fig. 3.3A). In 
contrast, the global levels of pS18-H1.5, pS173-H1.2 and pS173-H1.5 increased in 
CDK9-depleted cells, but this may at least be partly attributable to the increased loading 
for these samples compared to the control cells (Fig. 3.3A). These data, together with the 
results from the kinase inhibitor treatments (Figs 3.1 & 3.2), strongly suggest that 
interphase H1.4-S187 phosphorylation depends on the activity of CDK9 whereas other 
kinases mediate interphase phosphorylation of H1.5-S18, H1.2-S173 and H1.5-S173. 
Immunoblot with CDK1 antibody showed that only 5% of endogenous CDK1 was left in 
CDK1-depleted cells after 72 h of siRNA treatment. Interestingly, global phosphorylation 
at all interphase sites assessed, including pS187-H1.4, pS18-H1.5 and pS173-H1.2/5, was 
markedly reduced in CDK1-depleted cells with little or no change in the expression of H1 
variants (Fig. 3.3A), suggesting that CDK1 might mediate H1 phosphorylation at all 
interphase sites. As mentioned in Chapter 1.5, interphase sites of H1 variants are also 
phosphorylated, even to a higher extent, during mitosis. Since CDK1 is mainly activated 
during late G2- and M-phase [2, 26], our data suggest that CDK1 is likely to 
phosphorylate H1 at all interphase sites during mitosis. 
ChIP-qPCR revealed that CDK9 depletion led to striking reductions in the association of 
both CDK9 and pS187-H1.4 with the promoters and bodies of the ACTB and ACTG1 
genes (Fig. 3.3B). However, CDK9 depletion did not affect the binding of CDK9 or 
pS187-H1.4 at the promoter or body of the GAPDH gene significantly. These data 
provide further evidence suggesting that CDK9 phosphorylates H1.4-S187, and that the 
level of pS187-H1.4 at many genes is directly related to the extent of co-enrichment of 
CDK9. Although dramatic reduction of global phosphorylation at S187-H1.4 was 
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observed in CDK1-depleted cells, the association of pS187-H1.4 was not diminished at 
the promoters and bodies of housekeeping genes (Fig. 3.3B). In contrast, significant 
increase of pS187-H1.4 binding upon CDK1 knockdown was detected at both the 
promoter and body of ACTB, the body of ACTG1 and the promoter of GAPDH, some of 
which were accompanied by significant increase of CDK9 association at the same loci 
(Fig. 3.3B). Taken together, these data suggest that CDK1 does not affect the level of 
pS187-H1.4 at specific genes although the global level of pS187-H1.4 is dependent on 
CDK1 activity. Moreover, it appears that H1 phosphorylation at interphase sites is 
differentially regulated during interphase and mitosis. CDK9 is likely to phosphorylate 
S187-H1.4 during interphase whereas CDK1 phosphorylates S187-H1.4, S173-H1.2/5 
and S18-H1.5 during mitosis. However, the kinases that phosphorylate S18-H1.5, S173-
H1.5, or S173-H1.2 during interphase still remain to be identified. 
3.5 Phosphorylation at S187-H1.4 Is Not Dependent on RNAP II Progression  
Our data on global and gene-specific pS187-H1.4 dynamics during NT2 cell 
differentiation (Chapter 2), following short-term inhibition of CDK7 or CDK9 (Chapter 
3.3) and following CDK9 depletion (Chapter 3.4), suggest that H1.4-S187 
phosphorylation by CDK9 could be involved in mechanisms that facilitate transcription 
by promoting initiation, elongation, or both processes. However, the possibility remains 
that enrichment of pS187-H1.4 at active genes is mediated by kinases other than CDK7 
or CDK9 that are associated with progressing RNAP II. To investigate these possibilities 
further, we assessed how inhibiting transcription with drugs that are not kinase inhibitors 
affected the global and gene-specific levels of pS187-H1.4 (Fig. 3.4). Brief (1 hour) 
exposure of HeLa cells to α-amanitin (50 µM), actinomycin D (500 nM) or triptolide 
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(200 nM) elicited small or no changes in the expression of H1.2, H1.4 and H1.5, and the 
global levels of pS18-H1.5, pS173-H1.2, pS173-H1.5 and pS187-H1.4 (Fig. 3.4A). 
Actinomycin D (ActD) induced global RNAP II CTD hyperphosphorylation, consistent 
with prior evidence that ActD and other treatments that promote P-TEFb release from 
7SK snRNP complexes enhance the accumulation of CTD-hyperphosphorylated RNAP II 
[27, 28]. Triptolide (TPL) dramatically reduced the levels of both phosphorylated and 
non-phosphorylated RNAP II, as expected from prior evidence that TPL inhibits the 
helicase activity of TFIIH by covalently binding the XPB subunit and rapidly induces 
proteasome-dependent degradation of the large subunit (RPB1) of RNAPII [29]. Brief α-
amanitin treatment reduced the level of nonphosphorylated RNAP II, but not the 
hyperphosphorylated forms, consistent with prior evidence that α-amanitin induces 
hyperphosphorylation of RNAP II CTD and RPB1 degradation [27, 30].  
Since preferential loss of pS187-H1.4 from genes and regulatory elements in cells treated 
with these inhibitors may not be readily apparent at the global level, we used ChIP-qPCR 
to investigate whether genic levels of pS187-H1.4 are dependent on transcription (Fig. 
3.4B). Remarkably, actinomycin D treatment led to a significant accumulation of pS187-
H1.4 at the promoters and the bodies of ACTG1 and GAPDH genes compared to the 
control sample. α-amanitin increased the level of pS187-H1.4 slightly at all of the gene 
regions assessed compared to control cells, but these differences were statistically 
significant only for the body of the ACTG1 gene. In contrast, TPL caused significant 
decreases in the level of pS187-H1.4 at the GAPDH promoter and the body of the ACTB 
gene, probably due to indirect inhibition of CDK7, which is also a subunit of TFIIH. 
Taken together, the data in Figure 3.4A and 3.4B suggest that the global and genic levels 
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of pS187-H1.4 are not dependent on RNAP II progression, arguing against the possibility 
that kinases other than CDK9 (or possibly CDK7) that are associated with RNAP II 
mediate H1.4-S187 phosphorylation. 
3.6 pS187-H1.4 Is Co-Enriched with CDK9 at Specific Gene Loci  
We showed above that pS187-H1.4 levels at the promoters and bodies of housekeeping 
genes are enhanced in HeLa cells after a short actinomycin D treatment (Fig. 3.4B), 
presumably due to the transient release of active P-TEFb from 7SK complexes by the 
drug [27, 28]. This suggests that the levels of pS187-H1.4 at genomic loci depend on the 
extent of CDK9 recruitment at those same loci. To test this hypothesis, we performed 
ChIP-qPCR on HeLa cells treated with DMSO or actinomycin D for 1 h and assessed the 
levels of CDK9 and pS187-H1.4 at the promoters and bodies of three housekeeping genes 
(Fig. 3.5A). CDK9 binding was significantly enhanced at all of these regions in 
actinomycin D-treated cells compared to DMSO-treated cells, suggesting that active P-
TEFb released from 7SK complexes was recruited to these transcribed genes, although 
the mechanism of CDK9 recruitment was not well characterized. The same was true for 
the association of pS187-H1.4 at the same loci, suggesting a positive relationship 
between CDK9 recruitment and the level of pS187-H1.4 at specific genes. Thus, the 
effects of both CDK9 depletion (Fig. 3.3) and short actinomycin D treatments (Figs. 3.4B 
and 3.5A) support the hypothesis that CDK9 recruited to active genes mediates the 
phosphorylation of H1.4-S187 at these loci. 
This led us to compare the levels of CDK9 and pS187-H1.4 at the TSSs of pluripotency 
genes and housekeeping genes in undifferentiated and RA-differentiated NT2 cells to 
investigate whether the pS187-H1.4 levels at these elements correlated with those of 
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CDK9 in the absence of drug or siRNA treatments (Fig. 3.5B). The levels of both CDK9 
and pS187-H1.4 at the promoters of pluripotency genes in differentiated NT2 cells were 
markedly lower than those in undifferentiated cells, suggesting that the levels of pS187-
H1.4 at these elements depend directly on those of CDK9. The mechanism for CDK9 
recruitment during pluripotent cell differentiation has not been elucidated, but several 
lines of evidence suggest that BRD4 is involved in this process. ChIP-seq analyses 
revealed that the association of acetylated histone H4 as well as BRD4 was reduced at 
pluripotency genes after differentiation [31]. Bromodomain inhibitor treatment resulted in 
diminished BRD4 and CDK9 association at the super-enhancers and promoters of 
pluripotency genes [32], suggesting that CDK9 recruitment at pluripotency genes is 
dependent on BRD4 binding at the same or nearby region. Moreover, our findings in 
Chapter 2.7 that inhibiting BRD4 recruitment by JQ1 led to reduced pS187-H1.4 
association with pluripotency genes but not housekeeping genes further support the 
hypothesis that the level of CDK9 and pS187-H1.4 enrichment at pluripotency genes is 
dependent on BRD4 recruitment. 
However, this simple relationship between CDK9 and pS187-H1.4 enrichment was not 
evident at the housekeeping gene promoters we analyzed. CDK9 binding in differentiated 
cells was increased significantly at the ACTG1 and GAPDH promoters, and to a lesser 
extent at the ACTB promoter, but reductions in the association of pS187-H1.4 that were 
not statistically significant occurred at all three of these sites in differentiated cells. Thus, 
although the data in Fig. 3.5A obtained by treating HeLa cells with actinomycin D 
suggest that the levels of CDK9 binding at housekeeping gene promoters determine the 
levels of pS187-H1.4 at these sites, this is contradicted by the data in Figure 3.5B 
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obtained by treating NT2 cells with RA. One possible explanation for this apparent 
discrepancy is that appreciable amounts of inactive CDK9 (e.g. chromatin–associated 
7SK complexes) are present at housekeeping gene promoters in differentiated NT2 cells 
whereas active P-TEFb predominates due to its release from 7SK complexes in 
actinomycin D-treated cells (see discussion in Chapter 3.9). The data in Fig. 3.5B also 
provide striking evidence for differences in the mechanisms regulating pS187-H1.4 levels 
at the promoters of pluripotency factor and housekeeping genes.  
3.7 Erk Family Kinases Are Not Likely to Phosphorylate S187-H1.4 in vivo 
Our findings above suggest that S187-H1.4 is likely to be a direct target of CDK9 during 
interphase and the levels of pS187-H1.4 at specific genes are dependent on CDK9 
recruitment. However, it remains possible that interphase phosphorylation at S187-H1.4 
can be mediated by kinases other than CDK9. A recent phospho-proteomics study of 
HeLa cells stimulated by EGF detected multiple phospho-peptides of H1.4 that might be 
mediated by Erk [33] and since S187-H1.4 is the only site among all H1 variants which 
contains an Erk substrate consensus sequence (P-X-S/T-P), we investigated the effect of 
Erk on S187-H1.4 phosphorylation using both in vitro and in vivo approaches. 
In vitro studies using recombinant human H1.4 as a substrate showed that H1.4-S187 is 
progressively phosphorylated by Erk with increasing incubation time in the presence of 
ATP (Fig. 3.6A), suggesting that S187 of H1.4 is a preferred target of Erk in vitro. To test 
whether Erk phosphorylates H1.4 in vivo, serum-starved HeLa cells were treated with 
epidermal growth factor (EGF), which activates the MAPK pathway [34], and the global 
level of pS187-H1.4 was assessed by immunoblotting. If S187-H1.4 is a bona fide target 
of Erk in vivo, we would expect to see an increase of pS187-H1.4 upon EGF stimulation. 
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However, immunoblotting data showed that the global level of pS187-H1.4 gradually 
decreased after EGF stimulation in serum-starved HeLa cells (Fig. 3.6B). In addition, 
treating HeLa cells with an Erk-specific inhibitor, FR180204 [35], for 1 h did not change 
the global level of pS187-H1.4 (Fig. 3.6C). Moreover, up to 6 h treatment with two 
different Erk inhibitors, SCH772984 and VX-11e [36, 37], resulted in no change or even 
an increase of global pS187-H1.4 in HeLa cells (Fig. 3.6D). Taken together, the data 
from EGF stimulation and Erk inhibitor treatments argue against the possibility that S187 
of H1.4 is a substrate of Erk in vivo. 
Although EGF stimulation resulted in a decrease of global S187-H1.4 phosphorylation, 
we suspect that induction of pS187-H1.4 levels by Erk activation at specific genes might 
be masked by this global decrease. Therefore, we performed ChIP on serum-starved 
HeLa cells stimulated by EGF for 1 or 4 h and assessed pS187-H1.4 levels at TSSs of 
selected genes by RT-PCR. Four genes (WDR74, HIST2H2BE, RPL37 and PIGL) that 
have strong pS187 peaks at their promoters in HeLa cells (our ChIP-seq data, 
unpublished) and four genes (EMP1, MT1X, IER3, RGS2) that are strongly  induced by 
EGF [38] were selected for PCR analysis (Fig. 3.6E). The data showed that pS187-H1.4 
association at most of these TSSs decreased after 1 h of EGF stimulation and continued 
to decrease after 4 h. RT-PCR data showed that the transcription of EGF-activated genes 
was induced after 1 or 4 h of EGF treatment, whereas that of pS187-H1.4 associated 
genes was not affected (Figure 3.6F). The above data suggest that EGF stimulation 
decreases the level of pS187-H1.4 at specific genes via indirect mechanisms that might 
include inhibition of H1 kinases and/or activation of H1 phosphatases. Moreover, the 
changes of pS187-H1.4 at selected TSSs elicited by EGF do not correlate with the change 
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of transcription of the corresponding genes. In summary, the above findings suggest that 
Erk does not directly mediate interphase phosphorylation at S187 of H1.4 in vivo. 
3.8 Systematic Characterization of Site-Specific H1 Phosphorylations After CDK 
Inhibitor Treatment 
Using short (1 h) treatment of selective inhibitors to CDK9 and CDK7, we found that 
S187-H1.4 phosphorylation is rapidly diminished after CDK9 or CDK7 inhibition. In 
contrast, global level of pS18-H1.5 was not markedly reduced until after 8 h exposure to 
FLVP, suggesting that phosphorylations at S187-H1.4 and S18-H1.5 are differentially 
regulated (Figs. 3.1&3.2). In order to systematically investigate the effect of CDK 
inhibitors on H1 phosphorylation, we assessed the global levels of site-specific H1 
phosphorylation in HeLa cells using immunoblotting during a 24 h time course treatment 
with different kinase inhibitors. 
25 µM roscovitine resulted in a marked decrease of the global levels of pS187-H1.4, 
pS18-H1.5 and pS173-H1.2/5 within 1 h of exposure and the levels of the above 
phosphorylations continued to decrease with increasing time of treatment, which became 
undetectable after 24 h (Fig. 3.7A). Similarly, phosphorylations at TPXZ mitotic sites 
(pT146-H1.4 and pT154-H1.2/4) were also rapidly reduced after roscovitine treatment. 
However, the levels of pT146-H1.4 and pT154-H1.4 appeared to come back after 3 h of 
roscovitine treatment and the level of pT154-H1.4 remained constant between 3 and 24 h 
time points (Fig. 3.7A). Our findings that both interphase and mitotic phosphorylations 
were dramatically reduced after 24 h of roscovitine treatment are consistent with previous 
studies that H1 phosphorylation detected by antibody against phosphorylated 
Tetrahymena H1, which recognizes both interphase and mitotic phosphorylations, was 
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significantly reduced after 96 h treatment of 25 µM roscovitine [5]. The effect of 
roscovitine on H1 phosphorylation is probably due to compound inhibition of both CDK1 
and CDK2, since roscovitine appear to inhibit CDK1 and CDK2 with similar potency 
[18]. In addition, overnight exposure to roscovitine was shown to arrest cells in G1 phase 
[39], which could lead to dramatic decrease of phosphorylation at all interphase and 
mitotic sites of H1. 
Treating HeLa cells with a more specific inhibitor to CDK2, NU6140, resulted in 
different effects on H1 phosphorylations compared to roscovitine (Fig. 3.7B). Global 
levels of pS187-H1.4 and pS18-H1.5 dropped slightly during the first 3 h of NU6140 
treatment, increased at 8 h time point and decreased again after 24 h. Similar trend was 
observed for a mitotic phosphorylation, pT146-H1.4, but the global level of pT146-H1.4 
after short NU6140 treatment was decreased to a greater extent than that of pS187-H1.4 
or pS18-H1.5. In contrast, the global level of pS173-H1.2/5 remained constant during the 
first 8 h of NU6140 treatment and dropped after 24 hrs. Moreover, phosphorylation at 
another mitotic site, pT154-H1.2/4, appeared to be unaltered during the 24 h interval of 
drug treatment, suggesting that phosphorylations at the two TPXZ sites are differentially 
regulated (Fig. 3.7B). Cell cycle analysis revealed that HeLa cells treated with 10 µM 
NU6140 for 24 h have increased G2/M and sub-G1 population [9]. Therefore, the 
changes of H1 phosphorylation after long exposure to NU6140 were likely due to a 
combinatorial effect of cell cycle arrest in G2/M and apoptosis. 
Treatment with a CDK1 selective inhibitor, RO-3306 [40], led to rapid and dramatic 
decrease of pS187-H1.4 and pT146-H1.4. Phosphorylations at pS18-H1.5, pS173-H1.2/5 
and pT154-H1.2/4 were also decreased but to a lesser extent after short RO-3306 
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exposure (Fig. 3.7C). Interestingly, the global levels of all the above phosphorylations 
appeared to come back at 8 and 24 h time point, which is likely due to cell cycle arrest at 
G2/M border after CDK1 inhibition by RO-3306 [40]. The above data, together with our 
data from CDK1 knockdown (Fig. 3.3), suggest that CDK1 is probably responsible for 
mitotic phosphorylation at both SPXZ and TPXZ sites. The increase of site-specific H1 
phosphorylations after cell cycle arrest at G2/M by CDK1 inhibition indicates that other 
kinases active in G2/M phase might substitute CDK1 in phosphorylating H1 during 
mitosis. 
Treating HeLa cells with a broad-spectrum kinase inhibitor, staurosporine [41], did not 
cause global dephosphorylation of H1, but resulted in site-specific effects on H1 
phosphorylations which is comparable to RO-3306 treatment (Fig. 3.7D), suggesting that 
CDK1 might be the major target of staurosporine when used at 50 nM concentration. 
Interestingly, all the above CDK1/CDK2 inhibitors induced bi-phasic changes of 
phosphorylation at one or more S/TPXZ sites. The decrease of H1 phosphorylation after 
short CDK inhibitor treatment is likely due to the direct effect of CDK1/2 inhibition, 
whereas the increase or further decrease of H1 phosphorylation after 8 h of exposure is 
probably due to cell cycle arrest at different phases.  
Treating HeLa cells with inhibitors against CDK9 or CDK7, which are involved in 
RNAP II transcription, elicited different effects on H1 phosphorylation than CDK1/2 
inhibition (Figs. 3.7E-H). As shown before in NT2 cells, FLVP treatment resulted in 
marked reduction of pS187-H1.4 in HeLa cells within 15 min (Fig. 3.7E). In contrast, 
global levels of pS18-H1.5 and pS173-H1.2/5 were not apparently reduced until exposed 
to FLVP for more than 3 h, indicating different dynamics of phosphorylation at the three 
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interphase sites upon CDK9 inhibition (Fig. 3.7E). A newly-developed CDK9-selective 
inhibitor, LDC000067 [20], resulted in similar effects on H1 phosphorylation at 
interphase sites compared to FLVP (Fig. 3.7F), suggesting that the results obtained from 
FLVP treatment is primarily due to CDK9 inhibition. However, FLVP and LDC000067 
caused different effects on the phosphorylation at two mitotic sites (T146-H1.4 and 
T154-H1.2/4), which is probably because these two drugs also inhibit other CDKs, 
including CDK1 and CDK2, with different potency [20]. Inhibiting CDK7 with a 
covalent inhibitor, THZ1 [22], elicited similar changes of site-specific H1 
phosphorylations compared to LDC000067 (Fig 3.7H), which is consistent with our 
hypothesis that CDK7 mediates H1 phosphorylation by activating CDK9 via T-loop 
phosphorylation [3]. In contrast, an inhibitor of RNAP II transcription, DRB, which 
inhibits the activity of CDK9 as well as CDK7 and CDK8 [42], did not cause significant 
changes of H1 phosphorylation within 3 h of treatment. Prolonged exposure (8 or 24 h) to 
DRB significantly reduced the global levels of pS187-H1.4, pS18-H1.5, pS173-H1.2/5 
and pT146-H1.4, possibly via inhibition of CDK9 (Fig 3.7G). The slower reaction of H1 
phosphorylation to DRB treatment is probably caused by the lower affinity of DRB to the 
ATP-binding motif of CDK9 compared to that of FLVP or LDC000067 [20, 42]; thus, a 
higher concentration and longer exposure time is required for DRB to elicit notable 
changes in H1 phosphorylation. The global decreases of interphase phosphorylations 
after prolonged CDK9 or CDK7 inhibition are likely due to cell cycle arrest in G1 [22, 
43]. Moreover, since CDK7 and CDK9 are involved in promoting RNAP II initiation and 
elongation [3, 24], impaired transcription of other kinases, including CDK1, might also 
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contribute to the diminished H1 phosphorylation after prolonged inhibition of CDK7 or 
CDK9. 
3.9 Conclusions and Discussion 
A lingering notion in the chromatin field is that CDKs display little specificity among the 
sites present in individual H1 variants. This view appears to derive from analyses of H1 
phosphorylation by kinases in vitro. For example, four different purified CDKs were 
shown to phosphorylate H1 at all interphase and mitotic sites in vitro [44]. However, as 
noted above, comparison of the sites in individual H1 variants that are phosphorylated 
during mitosis or interphase in synchronized cells suggests that phosphorylation during 
interphase occurs predominantly, if not exclusively, at SPXZ motifs. These same SPXZ 
motifs can be phosphorylated during mitosis, together with TPXZ motifs and non-CDK 
motifs that appear to be phosphorylated exclusively during mitosis [1, 45-47]. These 
findings imply that molecular mechanisms enabling the preferential phosphorylation of 
SPXZ motifs during interphase and the restriction of TPXZ phosphorylation to mitosis 
exist, even though the nature of these mechanisms is unknown. Moreover, the 
mechanism(s) of interphase H1 phosphorylation must also be capable of discriminating 
between different SPXZ sites since phosphorylation of both H1.4 and H1.5 occurs 
hierarchically in vivo [45-47]. 
Several previous reports suggest that CDK2 and CDK9 might be responsible for 
interphase H1 phosphorylation [5-8]. However, none of these studies revealed any site-
specificity or preference of CDK2 or CDK9 against different S/T-P-X-Z motifs in H1 
variants. Here we showed that inhibition of CDK2 with a selective inhibitor, NU6140, 
does not affect the global level of pS18-H1.5 or pS187-H1.4, suggesting that neither of 
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these interphase sites are mediated by CDK2. In contrast, the global phosphorylation at a 
mitotic site, T146-H1.4, is markedly reduced after short NU6140 treatment. Considering 
previous evidence that CDK2 preferentially phosphorylates T152 site of H1.1 in vitro [8] 
and that the mobility of GFP-H1.4, but not GFP-M1-5 (all five S/TPXZ sites in H1.4 
mutated to APXZ, including three TPXZ sites), was positively correlated with the level 
of CDK2 activity [6], our data suggest that CDK2 might preferentially phosphorylate 
TPXZ motifs in vivo. 
In contrast, brief inhibition of CDK9 activity with FLVP markedly reduced the global 
level of pS187-H1.4 but not pS18-H1.5 or pS173-H1.2/5, suggesting that these interphase 
sites are differentially regulated. Inhibiting CDK7 with a highly specific inhibitor, THZ1, 
also dramatically decreased the global level of pS187-H1.4, which further supports the 
idea that CDK9 mediates interphase phosphorylation at S187-H1.4 because CDK7 can 
activate CDK9 by phosphorylating the T-loop at T186 [3]. In addition, brief THZ1 or 
FLVP treatment resulted in significant decrease of pS187-H1.4 association at the 
promoters and bodies of three housekeeping genes, suggesting that CDK9 mediated H1 
phosphorylation is associated with transcription by RNAP II. Moreover, depleting CDK9 
with siRNA led to marked decrease of global pS187-H1.4, but not pS18-H1.5 or pS173-
H1.2/5, as well as the association of pS187-H1.4 at genes where CDK9 association was 
depleted, which further indicates that CDK9 is responsible for S187-H1.4 
phosphorylation. Interestingly, inhibiting RNAP II transcription with non-kinase 
inhibitors (α-amanitin, actinomyicn D, or triptolide) does not lead to significant changes 
of global pS187-H1.4 level, suggesting that phosphorylation at S187-H1.4 is not 
dependent on RNAP II progression. However, brief actinomycin D treatment resulted in 
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elevated pS187-H1.4 levels at the promoters and bodies of selected genes, and this gene-
specific increase of pS187-H1.4 is accompanied by increased CDK9 association at the 
same loci, which is consistent with previous evidence that brief ActD treatment releases 
active P-TEFb from inhibitory 7SK snRNP complexes [27]. Taken together, the findings 
in Chapter 3 suggest that S187-H1.4 is likely to be a direct target of CDK9 during 
interphase and the level of pS187-H1.4 at specific genes is directly related to the extent of 
CDK9 enrichment. Phosphorylation of S187-H1.4 during mitosis is probably mediated by 
CDK1 since CDK1 knockdown and CDK1 inhibition led to dramatic decrease of global 
pS187-H1.4. CDK1 might also mediate mitotic phosphorylation at S18-H1.5 and S173-
H1.2/5. However, the kinases responsible for interphase phosphorylation at S18-H1.5 or 
S173-H1.2/5 remain to be identified. 
Analyses of H1 phosphorylation dynamics during pluripotent cell differentiation (Chapter 
2) revealed that the association of pS187-H1.4 at pluripotency gene promoters was 
significantly reduced after differentiation whereas that of pS18-H1.5 remained unaltered. 
ChIP-qPCR showed that CDK9 association at the promoters of pluripotency genes was 
markedly lower in differentiated NT2 cells, suggesting that the level of pS187-H1.4 at 
these promoters is dependent on CDK9 recruitment. No clear relationship can be 
established between the enrichment of CDK9 and pS187-H1.4 at the promoters of 
housekeeping genes during the differentiation of NT2 cells, suggesting that pS187-H1.4 
is regulated in a gene-specific fashion. Distinct mechanisms might be involved in 
recruiting CDK9 at specific gene regions. BRD4 binding to acetylated histones at the 
enhancers and promoters of pluripotency genes in ES cells can recruit CDK9 and activate 
transcription [31, 32]. Our findings that 8 h JQ1 treatment decreased pS187-H1.4 level at 
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the promoters of pluripotency genes (Chapter 2.7) and that CDK9 enrichment at 
pluripotency genes was diminished after differentiation (Chapter 3.7) suggest that the 
recruitment of CDK9 and pS187-H1.4 at pluripotency genes is dependent on BRD4. In 
contrast, the recruitment of CDK9 and pS187-H1.4 at housekeeping genes seems to be 
independent of BRD4 as JQ1 treatment increased pS187-H1.4 level at their promoters 
(Chapter 2.7). The recruitment of CDK9 to distinct gene regions is further complicated 
by the equilibrium between active P-TEFb and inactive P-TEFb sequestered by 7SK 
snRNP complexes [28, 48]. Recent evidence showed that 7SK snRNP interacts with 
RNAP II and several 7SK snRNP components, including 7SK RNA, HEXIM1 and 
LARP7, are associated with RNAP II transcribed genes [49, 50].  Kruppel-associated 
box-protein 1 (KAP1), which physically interacts with LARP7, was shown to recruit 7SK 
snRNP to the promoter-proximal sites of transcriptionally active genes [51]. In addition, 
7SK snRNP complex appears to be recruited to distal gene enhancer sites in the human 
genome via direct interaction with H4R3me2 by 7SK RNA and the capping enzyme 
MePCE [52]. Therefore, some of the CDK9 ChIP signals detected above might be 
attributed to the recruitment of 7SK snRNP to the promoter regions, which explains why 
we did not see direct correlation between CDK9 recruitment and pS187-H1.4 level at 
housekeeping genes during NT2 cell differentiation. ChIP with antibodies against 7SK 
snRNP components might provide us with further insight into the regulation of pS187-
H1.4 distribution during cell differentiation. 
A variety of mechanisms are involved in releasing P-TEFb from the inhibitory 7SK 
snRNP complex at transcription sites, including post-translational modification of 7SK 
snRNP components and direct interaction with RNA binding protein or transcription 
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regulators [49, 50]. BRD4-dependent recruitment of JMJD6 at distal enhancers, which 
demethylates H4R3me2, was shown to promote the release of active P-TEFb from 7SK 
snRNP and the recruitment of P-TEFb to promoter-proximal sites via gene looping [52]. 
The RNA splicing factor SRSF2 (also known as SC-35), was found to be part of the 7SK 
complex assembled at gene promoters. The binding of SRSF2 to promoter-associated 
nascent RNA triggers the coordinated release of SRSF2 and P-TEFb from the 7SK 
complex, reminiscent of the mechanism used by HIV Tat/TAR to activate the 
transcription of HIV genes [53]. The promoter-bound DEAD-box RNA helicase DDX21 
was found to be recruited to promoters of RNAP II-transcribed genes encoding ribosomal 
proteins and snoRNAs and promote their activation by releasing P-TEFb from the 7SK 
snRNP in a helicase-dependent manner [54]. These different mechanisms for releasing P-
TEFb from 7SK complexes share the common feature that the activation of P-TEFb 
occurs on chromatin where transcription and pre-mRNA processing occurs. No matter 
what mechanisms are involved in releasing active P-TEFb at transcription loci, our 
findings here suggest that the activated P-TEFb then conjointly phosphorylates the CTD 
of RNAP II, DSIF, NELF and H1.4-S187 to facilitate the pause release of RNAP II and 
transcriptional elongation.  
3.10 Material and Methods 
Cell culture 
NT2 cells were cultured and differentiated as described in Chapter 2.10. HeLa cells were 
grown in DMEM+10% FBS and subcultured by trypsinization. Cells were treated with 
flavopiridol (NIH AIDS Reagent Program), NU6140 (Tocris), actinomycin D (Fisher), α-
amanitin (Cayman), triptolide (Tocris), THZ1 (ApexBio), roscovitine, LDC000067 
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(ApexBio), RO-3306 (Tocris), staurosporine or DRB (Cayman) dissolved in DMSO to 
selectively inhibit RNA Pol II or CDK activities as described in the figure legends. 
Immunoblotting 
Whole cell lysates of NT2 or HeLa cells were electrophoresed in 15% polyacrylamide 
gels (6% gel for Pol II blots) containing SDS, transferred to a PVDF membrane and 
blocked with 5% milk powder in TBS for 1h at room temperature. The blocked 
membrane was then incubated with primary antibody at 4oC overnight, washed with 
TBST, and incubated with secondary antibody conjugated with HRP (Amersham, NA-
931 or NA-934) for 1h at room temperature, washed with TBST again and developed 
with chemiluminescence reagents (Thermo, SuperSignal West Pico Chemiluminescent 
Substrate).  
The primary antibodies were used at the following dilutions: 
pS187-H1.4 (UI-86), 1:1000; pS173-H1.2/5 (UI-82), 1:200; pS18-H1.5, 1:1000; pT146-
H1.4 (ab3596), 1:1000; pT154-H1.2/4 (UI-89), 1:1000; H1.4 (UI-100), 1:1000; H1.5, 
1:2000; H1.2 (ab4086), 1:5000; H3 (ab1791), 1:10000; Pol II (sc-899), 1:200; Pol II pS2 
(ab5095), 1:1000; Pol II pS5 (ab5131), 1:1000; CDK9 (sc-13130), 1:200; CDK1 (sc-
8395), 1:200. 
siRNA transfection  
siRNA transfection was performed using Lipofectamine RNAiMAX (Invitrogen) 
according to manufacturer’s protocol. Cells were seeded the day before transfection in 
order to reach 60-80% confluency at the time of transfection. Transfection reagent and 
siRNA were diluted in Opti-MEM (Gibco), mixed, and incubated for 5 min at room 
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temperature. The complexes were then added directly to cell cultures and the cells were 
harvested 72 h later. 
ChIP and qPCR 
Chromatin immunoprecipitation was performed as described in Chapter 2.10 using the 
following antibodies: 15 μL pS187-H1.4, or 20 µL CDK9 (Santa Cruz, sc-484 or sc-
13130). Non-immune rabbit IgG was used in replacement of primary antibodies as a 
negative control. ChIP products were quantitated by real-time PCR using SYBR Green 
master mix (Applied Biosystems) and the primers listed in Table 3.1. 
In vitro kinase assay 
30 µg of reverse-phase HPLC-purified human H1.4 dissolved in 23.8 µL of dH2O was 
mixed with 3 µL of 10X protein kinases reaction buffer (NEB) and 2 µL of Erk2 (NEB, 
P6080S, 100 Units/µL). 1.2 µL of ATP stock (NEB, P0756S, 10 mM) was added to the 
reaction tube whereas 1.2 µL of dH2O was added to the negative control. The reactions 
were incubated at 37oC and 5 µL of samples from each tube were withdrawn at 10, 30, 
60, 90, 120 and 180 min and transferred to a new tube with 100 µL of 20% TCA. Histone 
was recovered by TCA precipitation followed by acetone washes and dissolved in 10 µL 
dH2O. The phosphorylation of H1.4 was assessed by immunoblotting with phospho-
specific antisera. 
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3.11 Figures and Tables 
Figure 3.1 
 
The activity of CDK9, but not CDK2, is required for H1.4-S187 phosphorylation. 
(A) Pluripotent NT2 cells were treated for increasing intervals with 10 µM NU6140 or    
1 µM flavopiridol to preferentially inhibit CDK2 and CDK9, respectively. The global 
abundance of pS18-H1.5 and pS187-H1.4 was assessed by immunoblotting whole 
cell lysates. The blot for histone H3 serves as a loading control. The 0 hour time 
points provide a solvent control (DMSO). Commercial antisera (Active Motif) was 
used to detect pS18-H1.5. The numbers below each panel indicate densitometry for 
each sample relative to the sample at 0 hour time point. 
(B) HeLa cells were treated with DMSO or 10 μM NU6140 for 1 h. The loss of CDK2-
mediated phosphorylation of CDK7-T170 [12] was assessed by immunoblotting 
whole cell lysates with the indicated antisera.  
(C) HeLa cells were treated with DMSO or 1 μM flavopiridol for 1 h. Altered 
phosphorylation in the CTD heptad repeats of RNAP II [13] was assessed by 
immunoblotting whole cell lysates with the indicated antisera. The numbers below 
each panel in (B) and (C) indicate densitometry for the treated samples relative to the 
respective control sample. 
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Figure 3.2 
 
Selective inhibition of CDK7 or CDK9 diminishes pS187-H1.4 levels globally and at 
specific genes.  
(A) HeLa cells were treated with DMSO (solvent control) or increasing amounts of THZ1 
to selectively inhibit CDK7 for 1, 2 or 4 hrs. The global abundance of pS187-H1.4 
and H1.4 was assessed by immunoblotting whole cell lysates. The numbers below 
each panel indicate densitometry for each sample relative to the sample treated with 
DMSO for 1 h. 
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Figure 3.2 (cont.) 
(B) HeLa cells were treated with DMSO (solvent control), 1 μM THZ1 or 1 μM FLVP 
for 1 h to selectively inhibit CDK7 and CDK9, respectively. Immunoblotting of 
whole cell lysates with the indicated antisera was used to monitor the abundance of 
phosphorylated forms of RNAP II and selected H1 variants. The numbers below each 
panel indicate densitometry for the treated samples relative to the control sample. The 
statistics from three biological repeats are shown in Table 3.3. 
(C) HeLa cells were treated as in (B) and the levels of pS187-H1.4 at the promoters or 
gene bodies of housekeeping genes were assessed by ChIP-qPCR. Negative control 
ChIP assays employed non-immune rabbit immunoglobulin (rIg) in place of primary 
antisera. The data are expressed as the percent relative to input DNA (mean ± s.e.m., 
*: p<0.05, **: p<0.01, ***: p<0.001). 
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Figure 3.3 
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Figure 3.3 (cont.) 
siRNA depletion of CDK9 reduced global and gene-specific levels of pS187-H1.4.  
(A) HeLa cells were transfected with siRNA against CDK9 or CDK1 for 72 h. Control 
experiments employed siRNA against luciferase. Immunoblotting of whole cell 
lysates with the indicated antisera was used to assess the global abundance of CDK9 
or CDK1 as well as the abundance and phosphorylation of selected H1 variants. The 
numbers below each panel indicate densitometry for the CDK-depleted sample 
relative to the luciferase siRNA control sample. The statistics from three biological 
repeats of CDK9 siRNA treatment are shown in Table 3.4. 
(B) HeLa cells were transfected with siRNAs against luciferase, CDK1 or CDK9 and the 
levels of CDK9 and pS187-H1.4 at the promoters or gene bodies of housekeeping 
genes were assessed by ChIP-qPCR. Negative control ChIP assays employed non-
immune rabbit immunoglobulin (rIg) in place of primary antisera. The data are 
expressed as the percent relative to input DNA (statistical significance was shown for 
CDK-depleted samples relative to luciferase control. mean ± s.e.m., *: p<0.05, **: 
p<0.01). 
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Figure 3.4 
 
pS187-H1.4 is independent of RNAP II progression.  
(A) HeLa cells were treated with DMSO (solvent control), 50 μM α-amanitin, 500 nM 
actinomycin D (ActD) or 200 nM triptolide (TPL) for 1 h. The abundance and 
phosphorylation of RNAP II and H1.2, H1.4 and H1.5 were analyzed by 
immunoblotting whole cell lysates with the indicated antisera. The numbers below 
each panel indicate densitometry for the treated samples relative to the DMSO control 
sample. The statistics from three biological repeats are shown in Table 3.5. 
108 
 
Figure 3.4 (cont.) 
(B) HeLa cells were treated as in (A) and the levels of pS187-H1.4 at the promoters and 
gene bodies of housekeeping genes were assessed by ChIP-qPCR. Negative control 
ChIP assays employed non-immune rabbit immunoglobulin (rIg) in place of primary 
antisera. The data are expressed as the percent relative to input DNA (mean ± s.e.m., 
*: p<0.05, **: p<0.01, ***: p<0.001). 
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Figure 3.5 
 
CDK9 co-enriches with pS187-H1.4 at specific genes.  
(A) HeLa cells were treated with DMSO (solvent control) or 500 nM actinomycin D 
(ActD) for 1 h. The levels of CDK9 and pS187-H1.4 at the promoters and gene 
bodies of housekeeping genes were assessed by ChIP-qPCR.  
(B) The levels of CDK9 and pS187-H1.4 at the transcription start sites of pluripotency 
factor genes and housekeeping genes in NT2 cells before and after 7 days of RA 
treatment were assessed by ChIP-qPCR. Negative control ChIP assays employed non-
immune rabbit immunoglobulin (rIg) in place of primary antisera. The data are 
expressed as the percent relative to input DNA (mean ± s.e.m., *: p<0.05, **: p<0.01, 
***: p<0.001). 
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Figure 3.6 
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Figure 3.6 (cont.) 
 
Erk does not phosphorylate S187-H1.4 in vivo. 
(A) In vitro Erk kinase assay was performed using recombinant human H1.4 as substrate. 
Samples were collected in 10, 30, 60, 90, 120 and 180 min and analyzed by 
immunoblotting with pS187-H1.4 antibody. Reactions with no ATP served as 
negative control. Crude H1 from WI-38 VA-13 cells served as positive control. 
(B) HeLa cells were serum-starved for 24 h before stimulated with 150 ng/mL EGF for 
different time. The levels of pS187-H1.4 and general H1.4 were monitored by 
immunoblotting whole cell lysates. 
(C) HeLa cells were treated with DMSO or 1 µM Erk inhibitor, FR180204, for 1 h and 
the levels of pS187-H1.4 and general H1.4 were assessed by immunoblotting. 
(D) HeLa cells were treated with DMSO or 1 µM Erk inhibitors (SCH772984, VX-11e) 
for 1, 2, 4 or 6 h and the levels of pS187-H1.4 and general H1.4 were assessed by 
immunoblotting. 
(E) HeLa cells were serum-starved for 24 h before stimulated with 150 ng/mL EGF for 1 
or 4 h and the levels of pS187-H1.4 at selected TSSs were assessed by ChIP-qPCR 
using primers listed in Table 3.1. Negative control ChIP assays employed non-
immune rabbit immunoglobulin (rIg) in place of primary antisera. The data are 
expressed as the percent relative to input DNA. 
(F) HeLa cells were treated as in (E) and total RNAs were prepared. The expression of 
selected genes were analyzed by RT-qPCR using primers listed in Table 3.2. The data 
are expressed as relative amount to -EGF samples.  
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Figure 3.7 
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Figure 3.7 (cont.)
 
Systematic characterization of site-specific H1 phosphorylation after CDK inhibitor 
treatment. 
HeLa cells were treated for increasing intervals up to 24 h with 25 µM roscovitine (A), 
25 µM NU6140 (B), 10 µM RO-3306 (C), 50 nM staurosporine (D), 1 µM flavopiridol 
(E), 10 µM LDC000067 (F), 50 µM DRB (G) or 1 µM THZ1 (H) and the global levels of 
H1 variants and their phosphorylation at specific sites were assessed by immunoblotting 
whole cell lysates with the indicated antisera. 
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Table 3.1 
List of ChIP-qPCR primers 
POU5F1 long forward CTTCGCAAGCCCTCATTT 
POU5F1 long reverse AGGTCCGAGGATCAACCC 
POU5F1 short forward ATGCCATGTTATAGTTTGTG 
POU5F1 short reverse GCTGCTAAGTTCTGGGTTA 
NANOG forward TATTATGCAGGCAACTCA 
NANOG reverse AGTATAGAGGAAGAGGAGGA 
ACTB promoter forward GAAAGTTGCCTTTTATGGCTCG 
ACTB promoter reverse TTACCTGGCGGCGGGTGT 
ACTG1 promoter forward CGGCTTTCGGAAAGATCG 
ACTG1 promoter reverse GAGCGGCGGAAGAACAGA 
GAPDH promoter forward TTGGGCTGGGACTGGCTGAG 
GAPDH promoter reverse GGCTGACTGTCGAACAGGAGG 
ACTB gene body forward CGGGAAATCGTGCGTGAC 
ACTB gene body reverse GGAAGGAAGGCTGGAAGAGTG 
ACTG1 gene body forward CCATCGTCCACCGCAAAT 
ACTG1 gene body reverse TCGAAGGCTTATTCCAGTTTC 
GAPDH gene body forward CTGCTGTAGGCTCATTTGCA 
GAPDH gene body reverse GAGGCTGTTGTCATACTTCTCA 
WDR74 forward CGAGGCGACCGAAGTAAA 
WDR74 reverse GTGGAGTGGACGGAGCAA 
HIST2H2BE forward CCCTAATTTGCATAAGGTGGTT 
HIST2H2BE reverse CGGTTCAGGCATGGTAAGAC 
RPL37 forward CGCATCCTCCTCTTGACC 
RPL37 reverse TCACCATCTCGCTTCTGC 
PIGL forward TAACAGCGGAACCCAACA 
PIGL reverse AGGAGTCCCAAACCCAGA 
EMP1 forward AAGAAACCGCCCATTACA 
EMP1 reverse AAGGGTCCCAGCGACAGA 
MT1X forward CTTGCCTCGAAATGGACC 
MT1X reverse GAAGAAAGCACCTAACGAAATA 
IER3 forward CTGCGGGAGGAGGAGTTA 
IER3 reverse AGCCGAGCGGAGTGTAAGG 
RGS2 forward CGGGAGAACGATAATGC 
RGS2 reverse TCACAGGGTCCGTTTCA 
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Table 3.2 
List of RT-qPCR primers 
WDR74 forward ACAACTGGGAGGATGAGC 
WDR74 reverse TCTTCTTTCTCCGTCTCGT 
HIST2H2BE forward GAATCCGCCTCTTTACCC 
HIST2H2BE reverse AAATGACAGCCGAACTCA 
RPL37 forward CGGTCTTTCTGGTCTCGG 
RPL37 reverse CCACATTTGCCACAGGTC 
PIGL forward TGATTATTGACAACAGGGAT 
PIGL reverse ATCGAAAGTCACCACCAG 
EMP1 forward TCACCACGGCTATTCCTA 
EMP1 reverse TCCCTCCCAGATTCAACG 
MT1X forward TGCATCTGCAAAGGGACG 
MT1X reverse TGTAGCAAACGGGTCAGG 
IER3 forward GACTGGTGGAAGCAGGACA 
IER3 reverse CACAGTAGACAGACGGAGTTGA 
RGS2 forward GACTGTGACCTGCCATAA 
RGS2 reverse AGACCACCTATTCCCTTC 
 
Table 3.3 
Statistics for Blots in Figure 3.2B 
 
DMSO THZ1 FLVP 
p-Pol II 1.0 0.09 ± 0.01 0.08 ± 0.01 
Pol II 1.0 1.32 ± 0.04 1.91 ± 0.10 
Pol II pS2 1.0 0.34 ± 0.09 0.32 ± 0.18 
Pol II pS5 1.0 0.08 ± 0.05 0.07 ± 0.03 
pS187 1.0 0.60 ± 0.07 0.23 ± 0.09 
pS18 1.0 1.07 ± 0.09 1.01 ± 0.05 
pS173-H1.5 1.0 1.00 ± 0.16 1.14 ± 0.17 
pS173-H1.2 1.0 0.90 ± 0.06 0.90 ± 0.07 
H1.4 1.0 0.90 ± 0.02 0.95 ± 0.03 
H1.5 1.0 1.07 ± 0.03 0.94 ± 0.03 
H1.2 1.0 0.87 ± 0.02 0.82 ± 0.06 
 
The blots in Figure 3.2B from three biological repeats were quantitated by densitometry 
as described in Chapter 2.10. The mean ± s.e.m for the densitometry of CDK inhibitor 
treated samples relative to DMSO treated samples in each panel is listed in the above 
table. 
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Table 3.4 
Statistics for Blots in Figure 3.3A 
 
siLuc siCDK9 
CDK9 1.0 0.23 ± 0.04  
pS187 1.0 0.60 ± 0.07 
pS18 1.0 1.40 ± 0.19 
pS173-H1.5 1.0 1.11 ± 0.25 
pS173-H1.2 1.0 1.11 ± 0.08 
H1.4 1.0 1.04 ± 0.03 
H1.5 1.0 0.99 ± 0.06 
H1.2 1.0 1.03 ± 0.12 
H3 1.0 1.1 ± 0.06 
 
The blots in Figure 3.3A from three biological repeats were quantitated by densitometry 
as described in Chapter 2.10. The mean ± s.e.m for the densitometry of CDK9 siRNA 
treated samples relative to luciferase siRNA treated samples in each panel is listed in the 
above table. 
 
Table 3.5 
Statistics for Blots in Figure 3.4A 
 
DMSO α-amanitin ActD TPL 
p-Pol II 1.0 1.25 ± 0.17 1.6 ± 0.18 0.19 ± 0.05 
Pol II 1.0 0.74 ± 0.08 0.25 ± 0.10 0.12 ± 0.02 
pS187 1.0 0.92 ± 0.07 0.97 ± 0.02 0.98 ± 0.07 
pS18 1.0 1.1 ± 0.05 0.99 ± 0.09 1.01 ± 0.07 
pS173-H1.5 1.0 1.06 ± 0.03 1.03 ± 0.03 0.95 ± 0.04 
pS173-H1.2 1.0 1.05 ± 0.03 1.03 ± 0.03 1.04 ± 0.10 
H1.4 1.0 1.07 ± 0.03 1.10 ± 0.06 1.03 ± 0.03 
H1.5 1.0 1.05 ± 0.03 1.05 ± 0.08 1.02 ± 0.06 
H1.2 1.0 1.00 ± 0.05 1.09 ± 0.10 0.96 ± 0.08 
 
The blots in Figure 3.4A from three biological repeats were quantitated by densitometry 
as described in Chapter 2.10. The mean ± s.e.m for the densitometry of Pol II inhibitor 
treated samples relative to DMSO treated samples in each panel is listed in the above 
table. 
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CHAPTER 4 
INVESTIGATING THE FUNCTIONAL SIGNIFICANCE OF INTERPHASE H1 
PHOSPHORYLATION ON TRANSCRIPTION 
4.1 Introduction 
Previous studies in our lab [1] and the data presented here suggest that interphase 
phosphorylation of H1.4 at S187 is associated with transcription by RNA polymerase II. 
Inhibition or siRNA-depletion of CDK9 reduced pS187-H1.4 association with promoters 
and gene bodies, suggesting that CDK9 might mediate S187-H1.4 phosphorylation at 
actively-transcribed genes. However, it still remains unclear whether phosphorylation of 
H1.4 at S187 is a prerequisite for gene expression or a consequence of transcriptional 
activation. Our findings that pS187-H1.4 is independent of RNAP II progression 
(Chapter 3.4) strongly suggest that phosphorylation of S187-H1.4 at specific genes 
happens before the elongation of RNAP II. However, direct evidence for the functional 
significance of site-specific H1 phosphorylation on RNAP II transcription is still lacking. 
A widely-used approach to study the functional significance of a histone modification is 
to abolish this modification by inhibiting or depleting the enzyme that mediate this 
modification in vivo. However, this method is not applicable to studying the function of 
interphase H1 phosphorylation because CDK9, which is likely to phosphorylate S187-
H1.4, is also responsible for phosphorylating RNAP II CTD as well as DSIF and NELF, 
which is required for transcriptional elongation of RNAP II [2]. Thus, the changes of 
RNAP II transcription after CDK9 inhibition cannot be attributed to decreased H1.4-S187 
phosphorylation. In order to study the direct effect of site-specific H1 phosphorylation on 
transcription, we expressed FLAG-tagged H1.4 bearing mutations that mimic constitutive 
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dephosphorylation or phosphorylation at one or two interphase sites in different cellular 
context and assessed gene expression by RT-qPCR. 
4.2 Studies of Gene-Specific Transcription in Stable HeLa S3 Cell Lines Expressing 
FLAG-tagged H1.4 Phosphorylation Site Mutants 
One of the major challenges of studying the effect of H1 mutants on transcription is the 
abundance of endogenous H1 expression. Therefore, it is very difficult to express the 
ectopic H1 mutants at a high enough level to show detectable effects on the background 
of endogenous H1 variants. In order to make the ectopically expressed H1 mutants the 
predominant form of H1 inside the cells, we adopted the following approach by 
generating stable HeLa S3 cell lines that express silencing-resistant H1.4 mutants and 
assessing gene-specific transcription after depleting endogenous H1 variants using 
siRNA. 
Full-length human H1.4 gene was cloned into pcDNA3.1 vector driven by CMV 
promoter and a FLAG (DYKDDDDK) tag was added to the C-terminus of H1.4 gene.  
Silencing resistance mutation was generated by mutating 4 consecutive nucleotides in the 
siRNA recognition sequence which does not change the amino acid sequence. Additional 
mutations were introduced which resulted in alanine (A) or glutamic acid (E) substitution 
at S187 and/or S172 of H1.4 which mimics constitutive dephosphorylation or 
phosphorylation, respectively. Constructs with A or E substitution at S187 or both S187 
and S172 were used to transfect HeLa S3 cells. Transfected cells were subject to 
hygromycin selection for four weeks and colonies were picked by localized trypsinization 
and transferred to 24-well plates. The cells were sequentially transferred to 6-well plates, 
6 cm dishes and 10 cm dishes and then frozen in FBS + 10% DMSO for future use. 
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The expression of FLAG-tagged H1.4 in each clone was assessed by immunoblotting 
with antibodies against FLAG-tag (M2) or general H1.4 (UI-100) and clones which 
expressed FLAG-H1.4 at a closer level to endogenous H1.4 were selected. Unfortunately, 
none of the S187A clones expressed FLAG-H1.4 at a high-enough level which was 
detectable by general H1.4 blot. Therefore, only clones that expressed WT (wild-type), 
2A (S172A+S187A) and 2E (S172E+S187E) mutants of H1.4 were selected for further 
analyses. The stable clone transfected with empty pcDNA 3.1 vector was also included as 
a negative control. 
Immunoblotting with FLAG antibody showed that our WT, 2A and 2E clones expressed 
FLAG-H1.4 at a similar level, whereas untransfected HeLa S3 (S3) cells and cells 
transfected with empty vector (V) did not have any FLAG expression (Fig. 4.1A). 
General H1.4 blot showed an additional band slightly above the endogenous H1.4 band in 
WT, 2A and 2E clones, indicating that our general H1.4 antibody also detects FLAG-
H1.4. The intensity of the FLAG-H1.4 bands compared to that of endogenous H1.4 bands 
suggests that the expression levels of FLAG-H1.4 in these three stable clones are lower 
than that of endogenous H1.4 (Fig. 4.1A). pS187-H1.4 blot only detected FLAG-H1.4 
band in WT clone, but not in 2A or 2E clones where S187 site had been mutated to A or 
E respectively, suggesting that the ectopically expressed WT FLAG-H1.4 was able to be 
phosphorylated (Fig. 4.1A).  
HIC analyses of endogenous H1s showed that HeLa S3 cells express H1.2 and H1.4 
predominantly and H1.5 at a much lower level [1]. Therefore, a mixture of siRNAs 
against H1.2, H1.4 and H1.5 was used to deplete the endogenous H1 variants in the 
above HeLa S3 stable cell lines, which was supposed to allow the silencing-resistant 
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forms of H1.4 to become the predominant linker histone inside the cells. Immunoblotting 
showed that our mixture of siRNAs against H1.2/4/5 was able to efficiently knockdown 
the protein levels of endogenous H1.2, H1.4 and H1.5 in all the stable cell lines (Figure 
4.1B). Strikingly, the expression of H1.5 was undetectable in 2E clones even in luciferase 
siRNA treated cells, suggesting that ectopically expressed H1.4 mutants might affect the 
expression of other H1 variants. However, although our FLAG-tagged H1.4 was 
supposed to be resistant to silencing by siRNA, both M2 and general H1.4 blots showed 
that the levels of FLAG-H1.4 in these stable clones were also decreased after siRNA 
depletion of endogenous H1.2/4/5. One possible explanation is that the H1.4 mRNA 
bearing silencing-resistant mutation can still be targeted and silenced by siRNA against 
endogenous H1.4, but the extent of depletion might be lower compared to endogenous 
ones. However, it is also possible that depletion of endogenous H1s downregulated the 
expression of silencing-resistant FLAG-H1.4 mutants.  
Next, we performed RT-qPCR in the above stable cell lines to investigate how these H1.4 
mutants affected transcription of housekeeping genes. Surprisingly, the mRNA 
expression of ACTB, ACTG1 and GAPDH remained at similar levels in stable cell lines 
expressing empty vector or different H1.4 mutants. Moreover, depleting endogenous 
H1.2/4/5 did not result in significant changes of the expression of three housekeeping 
genes in all four stable cell lines (Fig. 4.2A). The above data seemed to suggest that the 
transcription of these housekeeping genes was not dependent on H1 phosphorylation. 
However, this argument is challenged by the fact that endogenous H1s were still the 
predominant forms of H1 in these stable cell lines even after siRNA depletion of 
125 
 
endogenous H1.2/4/5 (Fig. 4.1B). Therefore, the remaining level of pS187-H1.4 
associated with these genes might still be sufficient to facilitate their transcription. 
In order to test this hypothesis, we performed ChIP-qPCR with antibodies against FLAG-
tag or pS187-H1.4 to study the association of ectopic H1.4 and endogenous H1.4 at the 
promoters of three housekeeping genes in the above stable cell lines. ChIP with M2 
antibody showed that the levels of FLAG-H1.4 at the three gene promoters were similar 
in cell lines expressing WT, 2A or 2E mutants of H1.4 (Fig. 4.2B). Interestingly, the 
levels of pS187-H1.4 in 2A and 2E clones were similar to or even higher than those in 
cells expressing empty vector, suggesting that overexpressing FLAG-H1.4 mutants did 
not suppress the phosphorylation of endogenous H1.4 at housekeeping genes, which is 
consistent with our RT-PCR data that these genes expressed at similar levels in all four 
stable cell lines (Fig. 4.2A). The levels of pS187-H1.4 at housekeeping genes appeared to 
be lower in the cell line expressing wild-type H1.4 (WT) compared to other cell lines 
(Fig. 4.2B). This is probably because FLAG-tagged wild-type H1.4 can also be 
phosphorylated at S187 (Fig. 4.1A) and the level of pS187-H1.4-FLAG at these genes 
might not be readily detected by our ChIP with pS187-H1.4 antisera. Moreover, the 
levels of FLAG-tagged H1.4 at gene promoters seemed to be inversely related to the 
levels of endogenous H1.4 at the same loci as higher levels of pS187-H1.4 were detected 
at ACTB and ACTG1 promoters compared to GAPDH gene, whereas the FLAG signals 
at GAPDH promoter were much higher than those at ACTB or ACTG1 genes (Fig. 
4.2B). Therefore, the ectopic expression of FLAG-H1.4 mutants might have minimal 
effects on the transcription of genes with abundant pS187-H1.4 association. 
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Our data from stable HeLa S3 cells expressing phosphorylation site mutants of H1.4 did 
not demonstrate the correlation between H1 phosphorylation and the transcription of 
housekeeping genes, which is probably due to the high levels of endogenous pS187-H1.4 
and low levels of ectopic H1.4 mutants at these genes. However, these stable cell lines 
might still be useful in studying the effects of H1 phosphorylation on gene-specific 
transcription since previous studies of H1-knockout strain of Tetrahymena thermophila 
[3] and H1 triple-knockout mouse ES cells [4] showed that H1 depletion affects 
transcription in a gene-specific manner. In addition, overexpression of GFP-H1.1 mutants 
in C2C12 cells showed that S183A mutant of H1.1 was able to suppress the induction of 
muscle markers during differentiation [5], suggesting that the transcription of inducible 
genes might be more sensitive to changes in H1 phosphorylation.  Therefore, a genome-
wide study of mRNA expression in the above stable cell lines using microarray or RNA-
sequencing might reveal genes whose transcription is dependent on H1 phosphorylation 
at specific sites. The similar approach can also be applied to other cell systems, such as 
ES cells or MCF-7 cells, to study the effects of H1 phosphorylation on inducible 
transcription during differentiation or hormone stimulation. 
4.3 Studies of Gene-Specific Transcription in HEK 293 Cells Transfected With 
FLAG-H1.4 Constructs With Phosphorylation Site Mutations 
The major problem with the studies in HeLa S3 stable cell lines is that the expression 
levels of FLAG-tagged H1.4 mutants are too low compared to endogenous H1s, which 
makes it hard to show notable effects on the transcription of housekeeping genes. This 
low expression of ectopic H1.4 in stable cell lines is probably due to the silencing of 
CMV promoter that drives the expression of H1.4 mutants during the process of stable 
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cell line generation since previous reports showed that transgenes driven by CMV 
promoter tend to be gradually silenced by epigenetic modifications including DNA 
methylation, histone deacetylation and histone methylation [6-8]. Therefore, we might 
get a higher level of ectopic H1.4 expression by transiently transfecting cells with our 
pcDNA-H1.4-FLAG constructs. We originally expected to transfect NT2 cells with the 
above constructs to study the effects of H1.4 phosphorylation on pluripotency gene 
transcription. However, the expression of FLAG-H1.4 in NT2 cells was too low to be 
detected by general H1.4 antibody (data not shown), which is likely due to low 
transfection efficiency of NT2 cells and the low expression of CMV promoter in 
pluripotent cells. Therefore, we chose to transfect HEK 293 cells with the above H1.4 
mutant constructs, including WT, S187A, S187E, 2A (S172A+S187A) and 2E 
(S172E+S187E) and assessed the expression of genes by RT-qPCR. 
Immunoblotting with M2 and general H1.4 antisera showed that our FLAG-tagged H1.4 
mutants expressed at similar levels in HEK 293 cells 48 h after transfection (Fig. 4.3A). 
The expression levels of FLAG-H1.4 were comparable to those of endogenous H1.4 as 
indicated by the general H1.4 blot, suggesting that higher levels of ectopic H1.4 
expression can be reached by transient transfection in HEK 293 cells. 
Next, we assessed the mRNA levels of 8 genes that have pS187-H1.4 peaks at their 
promoters based on our ChIP-seq data in HeLa cells. RT-qPCR showed that 
overexpressing H1.4 mutants in HEK 293 cells did not markedly change the expression 
of the selected genes (Fig. 4.3B). One interesting pattern is that WT H1.4 seems to 
facilitate transcription whereas S187A and S187E mutants seem to repress transcription, 
but this pattern is not consistent over all eight genes. Since RT-PCR measures the steady-
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state levels of mRNA inside the cells which is affected by both transcription rate and 
mRNA stability. Therefore, the effects of H1.4 mutants on the transcription rate of 
specific genes might be confounded by the compensatory changes of post-transcriptional 
regulation of mRNA stability.  
In order to assess the actual transcription rate of genes in cells transfected with H1.4 
mutants, we adopted the method to measure the heterogeneous nuclear RNA (hnRNA), or 
unspliced mRNA, by RT-qPCR using primers that span the first exon-intron junction of 
each gene, which showed similar changes in transcription rates as detected by nuclear 
run-on assay [9]. This method, which measures the abundance of nascent transcripts of 
specific genes, should reflect the changes in transcription rates more accurately. RT-PCR 
for the unspliced transcripts of EIF3F, INO80B, MTRF1 and PPP1R10 revealed 
interesting effects of H1 phosphorylation on gene-specific transcription (Fig. 4.3C). As 
we expected, S187A mutant of H1.4 significantly repressed the transcription of EIF3F 
compared to WT H1.4. S187E mutant also repressed EIF3F expression, but to a lesser 
extent than S187A. In contrast, S187E mutant markedly reduced the transcription of 
INO80B whereas the effect of S187A was similar to that of WT H1.4. In addition, both 
S187A and S187E suppressed the transcription of PPP1R10 to a similar extent compared 
to WT H1.4. The above data (Fig. 4.3C), together with the data from traditional RT-PCR 
(Fig. 4.3B), suggest that the capacity of dynamic phosphorylation and dephosphorylation 
at S187 might be necessary for H1.4 to facilitate transcription since both S187A and 
S187E appeared to repress transcription of selected genes. Phosphorylation at S172-H1.4 
might have different functions than pS187-H1.4 since 2A and 2E mutants did not show 
more significant effects on transcription than S187A or S187E mutants. However, as 
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mentioned above, the above findings by transient expressing H1.4 mutants in HEK 293 
cells are also complicated by the presence of endogenous H1 variants. The abundance of 
endogenous pS187-H1.4 associated with the above genes might minimize the effect of 
H1.4 mutants on their transcription. Therefore, an ideal model to study the functional 
significance of site-specific H1 phosphorylation is to replace the endogenous H1.4 with 
H1.4 mutants using gene-editing technique, such as CRISPR/Cas9, so that all the H1.4 
present in the cells will be phosphorylation site mutants. However, other H1 variants 
might be able to substitute for wild-type H1.4 in facilitating transcription, which will 
make it more complicated to interpret the data. We could avoid the compensation 
between H1 variants by using model organisms that only express one H1 variant, e.g. 
Drosophila melanogaster and Tetrahymena thermophila. Previous studies in 
Tetrahymena thermophila by replacing the endogenous H1 with mutants that mimics 
dephosphorylation or hyperphosphorylation showed that phosphorylation of five 
clustered sites in Tetrahymena H1 activates or represses gene-specific transcription in a 
manner that is similar to the effects of H1 knockout [10]. The gene-specific effect of H1 
phosphorylation in Tetrahymena was achieved by creating a charge patch which mimics 
partial removal of H1 [11, 12]. However, since the structures and patterns of H1 
phosphorylation in these organisms are so different from mammalian H1s [13], the 
information obtained from these organism might not reflect the functional significance of 
H1 phosphorylation in mammalian cells. 
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4.4 Efforts to Study the Effects of H1 Phosphorylation on Transcription in TKO 
Mouse ES Cells 
Due to the constraint of time, I was not able to perform gene replacement experiments in 
human cell lines, such as HeLa or NT2 cells, to study the effects of H1 phosphorylation 
on transcription. Fortunately, we found another system that might serve as a substitute for 
gene replacement assays in studying the functional significance of site-specific H1 
phosphorylation. Dr. Skoultchi’s lab has generated a triple-knockout (TKO) mouse ES 
cell line in which three endogenous H1s (H1.2, H1.3 and H1.4) were knocked out by 
homologous recombination [14]. Since no endogenous H1.4 is present, we can 
ectopically express wild-type as well as phosphorylation site mutants of H1.4 in TKO 
cells and assess their effects on gene-specific transcription by RT-PCR. 
In order to ectopically express H1.4 mutants in TKO cells, we adopted the sleeping 
beauty transposon system which is supposed to provide high and stable expression of 
transgenes in ES cells [15]. Full-length human H1.4 genes together with the C-terminal 
FLAG-tag was cloned from pcDNA3.1 vector and ligated into pSBbi-GB vector. Site-
directed mutagenic PCR was then performed to introduce alanine or glutamic acid 
substitutions at S187 and S172 of H1.4. pSBbi-GB constructs that encode wild-type, 
S187A, S187E, 2A (S172A+S187A) and 2E (S172E+S187E) mutants of H1.4 were used 
to transfect TKO cells. Empty pSBbi-GB vector was also included as negative control. 
After weeks of selection against blasticidin, TKO cell lines that stably express WT or 
phosphorylation site mutants of human H1.4 will be generated, which will be useful to 
study the functional significance of H1 phosphorylation in several different ways. First, 
we can compare gene-specific transcription in the above cell lines by RT-qPCR or RNA-
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seq. Since no endogenous H1.4 is present in these cell lines, the effects of H1.4 mutants 
on transcription will not be confounded by the effect of endogenous H1.4 
phosphorylation. In addition, we can induce differentiation in the above cell lines and 
assess the effect of site-specific phosphorylation of H1.4 on ES cell differentiation. 
Studies from Fan’s lab showed that TKO cells have impaired capacity of differentiation 
compared to WT mES cells due to reduced H1 stoichiometry [16]. We expect that 
expression of WT human H1.4 will be able to restore the differentiation capacity of TKO 
cells, whereas A or E mutants of H1.4 might enhance or suppress ES cell differentiation. 
Moreover, the C-terminal FLAG-tag of the ectopically expressed H1.4 will allow us to 
study the distribution of H1.4 during cell differentiation or upon kinase inhibitor 
treatments via ChIP since our general H1.4 antibody does not work well in ChIP. 
According to our current model, the recruitment of CDK9 during transcriptional 
activation phosphorylates the CTD of RNAP II, NELF, DSIF as well as S187 of H1.4, 
which allows transcriptional elongation of RNAP II from paused promoters. However, it 
remains unclear whether phosphorylation at S187 facilitates transcription by promoting 
the dissociation of H1.4 from the chromatin. Therefore, the studies of H1.4 distribution in 
the above stable cell lines might provide additional evidence for the mechanism of RNAP 
II pause-release during transcriptional activation. 
4.5 Material and Methods 
HeLa S3 stable cell line generation 
HeLa S3 cells were seeded in 6-well plate and transfected with 2.0 µg plasmid containing 
FLAG-tagged silencing-resistant H1.4 gene in pcDNA3.1 hygro (+) vector and 3 µL 
FuGENE 6 (Promega) according to manufacturer’s protocol. Two days after transfection, 
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the cells were subcultured into 15 cm plate and selected against 300 µg/mL hygromycin 
B. The drug concentration was increased to 450 µg/mL two weeks later. Single colonies 
appeared after three weeks of selection. The colonies were then transferred to 24-well 
plates by localized trypsinization. The cells were sequentially transferred to 6-well plates, 
6 cm dishes and 10 cm dishes and then frozen in FBS + 10% DMSO for future use. The 
expression levels of ectopically expressed H1.4 were assessed by Western Blotting with 
antibodies against FLAG (M2) and general H1.4 (UI-100). 
Transient plasmid transfection 
Cells were seeded in 6-well plates the day before in order to reach 70-90% confluency at 
the time of transfection. 7.5 μL Lipofectamine 3000 (Invitrogen) was diluted in 100 μL 
Opti-MEM (Gibco) and 2 μg of plasmid DNA was diluted in 100 μL Opti-MEM (Gibco) 
with 4 μL P3000 reagent (Invitrogen). The diluted transfection reagents and plasmid 
DNA were then mixed together and incubated at room temperature for 15 min. The 
complexes were then added to the culture media directly and cells were harvested 48 h 
later. 
ChIP, RNA extraction and RT-PCR 
Chromatin immunoprecipitation (ChIP) was performed in HeLa S3 stable cell lines using 
the protocol described in Chapter 2.10. 1 mL aliquots of diluted lysate were incubated 
with 2 μL M2 (mouse monoclonal against FLAG, Sigma-Aldrich, F1804) or 15 μL 
pS187-H1.4 antisera before precipitated with 50 μL BSA-blocked Dynabeads 
(Invitrogen). Recovered DNA from ChIP assays was quantitated by RT-PCR using 
SYBR-green master mix (Applied Biosystems) and the primers listed in Table 4.1. 
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Total RNA was extracted by TRIzol reagent (Invitrogen) according to manufacturer’s 
instructions. The crude RNA was subjected to DNase I digestion at 37oC for 1h and then 
cleaned up using Qiagen RNeasy Mini Kit. cDNA was generated from 100 ng of total 
RNA using SuperScript III First-Strand Synthesis System (Invitrogen). Quantification of 
gene products was performed by real-time PCR using SYBR Green master mix (Applied 
Biosystems) and the primers listed in Tables 4.2 and 4.3. 
H1.4 gene subcloning and mutagenesis 
Wild-type human H1.4 gene with C-terminal FLAG tag was cloned from pcDNA3.1 
vector by PCR with Pfu Turbo DNA polymerase (Agilent) using the primers listed in 
Table 4.4 which added two SfiI sites at both ends of the H1.4 gene. The amplified H1.4 
gene and pSBbi-GB vector (Addgene plasmid # 60520) were then digested with SfiI 
(NEB, R0123S) at 50oC overnight, electrophoresed on an agarose gel and the bands 
corresponding to digested pSBbi-GB vector and H1.4 insert were purified with QIAquick 
Gel Extraction Kit. The concentrations of digested vector and H1.4 insert were then 
quantitated by agarose gel and 5:1 molar ratio of insert and vector were mixed with T4 
DNA ligase (NEB, M0202S) and 1X reaction buffer and incubated at 16oC overnight. 
DH5α competent cells were transformed with the ligation product and spread over LB 
plates with carbenicillin and incubated at 37oC overnight. Plasmids were extracted from 
the colonies appearing on the plate and the sequence of the H1.4 insert was confirmed by 
Sanger sequencing. 
Mutations at S172 and S187 sites of H1.4 were generated by site-directed mutagenic PCR 
using primers listed in Table 4.4. PCR products were subject to DpnI (NEB, R0176S) 
digestion at 37oC overnight before transforming DH5α competent cells. Transformed 
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cells were then spread over LB plates with carbenicillin and incubated at 37oC overnight. 
Plasmids were extracted from the colonies appearing on the plate and the sequences of 
site-specific mutations were confirmed by Sanger sequencing. 
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4.6 Figures and Tables 
Figure 4.1 
 
Silencing resistant H1.4 mutants are expressed in HeLa S3 stable cell lines. 
(A) Stable HeLa S3 cell lines expressing empty vector (V), wild-type (WT), 
S172A+S187A (2A) and S172E+S187E (2E) mutants of H1.4 were selected. The 
expression of FLAG-H1.4 and endogenous H1.4 in normal HeLa S3 cells and the 
above cell lines was assessed by immunoblotting with the indicated antisera. Blot 
with H3 antibody served as a loading control. 
(B) The above HeLa S3 stable cell lines were treated with control siRNA against 
luciferase or a combination of siRNAs against H1.2, H1.4 and H1.5 for 72 h and the 
expression of FLAG-H1.4 as well as endogenous H1 variants was assessed by 
immunoblotting. Blot with H3 antibody served as a loading control. 
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Figure 4.2 
 
Expression of H1.4 mutants does not affect the transcription of housekeeping genes 
in HeLa S3 stable cell lines. 
(A) HeLa S3 stable cell lines were transfected with siRNA against luciferase or H1.2/4/5 
for 72 h and the mRNA levels of ACTB, ACTG1 and GAPDH were assessed by RT-
qPCR.  
(B) The levels of FLAG-tagged H1.4 and pS187-H1.4 at the TSSs of ACTB, ACTG1 and 
GAPDH in HeLa S3 stable cell lines were assessed by ChIP-qPCR. ChIP with non-
immune mouse IgG was employed as negative control. The data are expressed as the 
percent relative to input DNA. 
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Figure 4.3 
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Figure 4.3 (cont.) 
 
Transient expression of H1.4 mutants in HEK 293 cells affects transcription in a 
gene-specific manner. 
(A) HEK 293 cells were transfected with pcDNA3.1 constructs encoding wild-type H1.4 
or H1.4 mutants with A or E substitutions at S187, or at both S172 and S187. The 
expression of ectopic H1.4 was assessed by immunoblotting with antibodies against 
FLAG (M2) and general H1.4 (UI-100). Blot with H3 antibody served as a loading 
control. 
(B) HEK 293 cells were transfected as in (A) and the steady-state mRNA levels of the 
indicated genes were assessed by RT-qPCR with primers listed in Table 4.2. 
(C) HEK 293 cells were transfected as in (A) and the levels of unspliced pre-mRNA of 
the indicated genes were assessed by RT-qPCR with primers listed in Table 4.3. 
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Table 4.1 
List of ChIP-qPCR primers 
ACTB promoter forward GAAAGTTGCCTTTTATGGCTCG 
ACTB promoter reverse TTACCTGGCGGCGGGTGT 
ACTG1 promoter forward CGGCTTTCGGAAAGATCG 
ACTG1 promoter reverse GAGCGGCGGAAGAACAGA 
GAPDH promoter forward TTGGGCTGGGACTGGCTGAG 
GAPDH promoter reverse GGCTGACTGTCGAACAGGAGG 
 
Table 4.2 
List of RT-qPCR primers 
ACTB Forward ATCGTCCACCGCAAATGCTTCTA 
ACTB Reverse AGCCATGCCAATCTCATCTTGTT 
ACTG1 Forward CCCGAGCCGTGTTTCCTT 
ACTG1 Reverse GTCCCAGTTGGTGACGATGC 
GAPDH Forward AAGGAGAGCTCAAGGTCAG 
GAPDH Reverse GAGTAGGGACCTCCTGTTTC 
RNU11 Forward GGCTTCTGTCGTGAGTGG 
RNU11 Reverse AGCTGCCCAAATACCAAA 
EIF3F Forward CTGCCTGGTCCTGCTCTT 
EIF3F Reverse CAGGGTCCCGATAACTCG 
INO80B Forward GGGTCAGGAGGAAGAGGAGG 
INO80B Reverse ACAGGCAGCGGCAGCATAG 
MTRF1 Forward AAGACAAGCGTCAGCAAC 
MTRF1 Reverse CCCTTCCCACCACATAAA 
PPP1R10 Forward AGCCTGCTGAGAAAGATAAG 
PPP1R10 Forward GTGCTGTGGTGCGAAGAG 
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Table 4.3 
List of RT-qPCR primers for unspliced RNA 
hEIF3F +354F GAGACGCAACGAGGGTG 
hEIF3F +504R GGAAAGGACGGTAGGACA 
hINO80B +79F TTCCTCGCAGGACCTCA 
hINO80B +268R AACAGCACCGCCTTTCT 
hMTRF1 +23F TGAAATGTGGCGGGTCT 
hMTRF1 +142R GAGGCAATACAGGAGGC 
hPPP1R10 +174F GATGGCATTTGTGAGTGTT 
hPPP1R10 +304R TGCGGCTTGTTTCTGTT 
 
Table 4.4 
Primers for H1.4 subcloning and mutagenesis 
H1.4 SfiI Forward 
CAAGCTGGCCTCTGAGGCCATGTCC
GAGACTGCGCCTG 
H1.4-FLAG SfiI Reverse 
AAGCTTGGCCTGACAGGCCCTACTT
GTCATCGTCGTCC 
H1.4 S187A Forward 
AAAAAAGGCGCCCAAGGCCCCAGC
GAAGGCCAAAG 
H1.4 S187A Reverse 
CTTTGGCCTTCGCTGGGGCCTTGGG
CGCCTTTTTT 
H1.4 S187E Forward 
CAAAAAAGGCGCCCAAGGAGCCAG
CGAAGGCCAAAG 
H1.4 S187E Reverse 
CTTTGGCCTTCGCTGGCTCCTTGGG
CGCCTTTTTTG 
H1.4 S172A Forward 
GGAGCCAAAAAAGCGAAAGCCCCG
AAAAAGGCGAAAGC 
H1.4 S172A Reverse 
GCTTTCGCCTTTTTCGGGGCTTTCG
CTTTTTTGGCTCC 
H1.4 S172E Forward 
GGAGCCAAAAAAGCGAAAGAGCCG
AAAAAGGCGAAAGC 
H1.4 S172E Reverse 
GCTTTCGCCTTTTTCGGCTCTTTCGC
TTTTTTGGCTCC 
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APPENDIX 
A.1 Validation of the Specificity of pS187-H1.4 Antiserum in ChIP 
The pS187-H1.4 antiserum raised by our lab specifically recognizes the phosphorylation 
at a single site (S187) in both human and mouse H1.4 and has been widely used in 
immunoblotting, immunofluorescence and ChIP assays. The specificity of this antiserum 
was rigorously tested in immunoblotting and immunofluorescence microscopy by peptide 
competition assays in HeLa cells [1], but its specificity in ChIP was not directly assessed. 
Although brief FLVP or THZ1 treatment, which diminished the global level of pS187-
H1.4 in immunoblotting, also significantly reduced the ChIP signal of pS187-H1.4 
antiserum at selected genes (Chapter 3), it remains a possibility that our pS187-H1.4 
antiserum might recognize phosphorylations at other proteins that are also sensitive to 
FLVP or THZ1 in the above ChIP assays. 
In order to validate the specificity of pS187-H1.4 antiserum in ChIP, we performed 
siRNA knockdown of H1.4 in both HeLa and NT2 cells and assessed the levels of pS187-
H1.4 at the TSSs of selected genes. Treating HeLa cells with siRNA against both H1.2 
and H1.4 significantly reduced the global levels of H1.2 and H1.4 as well as the 
phosphorylation at S187-H1.4 (Fig. A.1A). If our pS187-H1.4 antiserum is specific for 
H1.4 in ChIP, we would expect to see a decrease of pS187-H1.4 association at gene 
promoters after H1.4 depletion. As we expected, depletion of H1.2/H1.4 by siRNA 
reduced the levels of pS187-H1.4 at the TSSs of the selected genes (Fig. A.1B), 
suggesting that our pS187-H1.4 specifically recognizes the phosphorylation of H1.4 in 
ChIP assays.  
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Similar to what we observed in HeLa cells, siRNAs against H1.2/H1.4 or H1.4 alone 
reduced the global levels of H1.4 and pS187-H1.4 in NT2 cells (Fig. A.1C). In addition, 
the association of pS187-H1.4 at ACTG1 and GAPDH promoters in NT2 cells was also 
decreased after depletion of H1.2 and H1.4 together or H1.4 alone (Fig. A.1D), 
suggesting that our antiserum against pS187-H1.4 is specific for H1.4 in NT2 cells in 
both immunoblotting and ChIP assays. Moreover, the association of CDK9 at the above 
promoters in NT2 cells remained unaltered or markedly increased after siRNA depletion 
of H1.2/H1.4 or H1.4 alone (Fig. A.1D), suggesting that the decrease of pS187-H1.4 
association at the same loci was due to H1.4 depletion instead of less CDK9 recruitment. 
Taken together, the above data provide direct evidence that our pS187-H1.4 antiserum 
specifically recognizes H1.4 in ChIP assays in both HeLa and NT2 cells; thus can be used 
in the above cell lines to study the genomic distribution of pS187-H1.4. 
A.2 Evidence for the Regulation of pS187-H1.4 at rDNA Promoter 
Our findings in Chapters 2 and 3 showed that the association of pS187-H1.4 at the 
promoters of pluripotency factor genes is positively related to their transcription and that 
the phosphorylation of S187 of H1.4 at RNAP II-transcribed genes is mediated by CDK9. 
Immunofluorescence microscopy studies from our lab showed that pS187-H1.4, as well 
as pS173-H1.2/H1.5, colocalized with stainings of RNA Pol I, the UBF activator of Pol I 
and Br-UTP labelling of nascent 45S ribosomal RNA [1]. In addition, ChIP studies 
revealed that the association of pS187-H1.4 with rDNA promoter was markedly reduced 
after inhibiting RNA Pol I transcription with actinomycin D, suggesting that pS187-H1.4 
is positively correlated with transcription by Pol I [1]. Extensive depletion of UBF, which 
impaired Pol I transcription, significantly suppressed the binding of pS187-H1.4 
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throughout mouse rDNA, which further support the positive role of pS187-H1.4 in Pol I 
transcription [2]. However, the mechanism for the regulation of pS187-H1.4 level at 
rDNA genes still remains elusive. 
Since CDK9, and possibly CDK7, is likely to mediate S187-H1.4 phosphorylation at Pol 
II-transcribed genes (Chapter 3), we wondered whether these kinases also regulate 
pS187-H1.4 level at Pol I-transcribed ribosomal RNA genes. So we treated HeLa cells 
with THZ1 or FLVP, which selectively inhibits CDK7 or CDK9 respectively, for 1 h and 
assessed the levels of pS187-H1.4 at rDNA promoter by ChIP-qPCR. Surprisingly, 
although both THZ1 and FLVP resulted in rapid decrease of global pS187-H1.4 and its 
association at Pol II-transcribed genes, the level of pS187-H1.4 at rDNA promoter was 
differentially affected by these drugs. Similar to what we observed at Pol II genes, 1 h 
THZ1 treatment reduced pS187-H1.4 level at rDNA promoter compared to DMSO 
treated cells (Fig. A.2A). In contrast, 1 h FLVP treatment significantly increased pS187-
H1.4 level at rDNA genes, suggesting that CDK9 might not be involved in mediating 
pS187-H1.4 at Pol I-transcribed genes (Figure A.2A). This is supported by previous 
findings in our lab that FLVP treatment for 3 h did not suppress the transcription of 45S 
pre-rRNA in HeLa cells (unpublished data). The above data showed that CDK7, but not 
CDK9, is involved in regulating pS187-H1.4 level at rDNA promoter, indicating that 
CDK7 might directly phosphorylate S187 of H1.4 at rDNA promoter instead of 
activating CDK9 via T-loop phosphorylation. Previous studies showed that TFIIH, a 
multi-subunit complex comprised of CDK7 and other proteins, is associated with rDNA 
genes and is essential for transcriptional elongation of RNA Pol I [3, 4]. Our findings that 
CDK7 is responsible for S187-H1.4 phosphorylation at rDNA promoter suggest that the 
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phosphorylation of H1.4 by CDK7 might be an important step for the activation of RNA 
Pol I transcription by TFIIH.  
Next, we treated HeLa cells with different inhibitors of RNA Pol I or Pol II transcription 
for 1 h and assessed the level of pS187-H1.4 at rDNA promoter by ChIP-qPCR (Fig. 
A.2B). As we expected, inhibiting RNA Pol II transcription by α-amanitin or triptolide 
did not reduce, but rather enhanced pS187-H1.4 level at rDNA promoter. However, 
treatment with 40 nM ActD, which selectively inhibits Pol I transcription, or 500 nM 
ActD, which inhibits both Pol I and Pol II transcription, also increased the association of 
pS187-H1.4 at rDNA promoter, suggesting that phosphorylation of S187-H1.4 at rDNA 
promoter is not dependent on RNA Pol I progression. The above data seem to be 
contradictory to our previous finding that 3 h ActD treatment decreased pS187-H1.4 level 
at rDNA promoter [1]. However, this decrease of pS187-H1.4 after 3 h ActD treatment 
might be due to secondary effect of Pol I inhibition since 1 h THZ1 treatment is sufficient 
to reduce pS187-H1.4 level at rDNA promoter. Taken together, the data in Fig. A.1A and 
B suggest that CDK7, recruited to rDNA promoter as a component of TFIIH complex, is 
likely to directly phosphorylate H1.4 at S187. The activity of CDK9 is not required to 
maintain pS187-H1.4 level at rDNA promoter, indicating that different mechanisms are 
involved in regulating S187-H1.4 phosphorylation at genes transcribed by RNA 
polymerase I or II. 
ChIP studies in Chapter 2 showed that pS187-H1.4 association with pluripotency factor 
genes was significantly reduced after differentiation, suggesting the positive relationship 
between pS187-H1.4 association and transcription by RNA Pol II. Since pS187-H1.4 is 
also associated with Pol I transcription, we wondered whether the level of pS187-H1.4 at 
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rDNA promoter changed during the differentiation of NT2 cells. ChIP-qPCR showed that 
the level of pS187-H1.4 at rDNA promoter was significantly decreased after RA-induced 
differentiation of NT2 cells (Fig. A.2C), which is consistent with the downregulation of 
rRNA transcription and the dissociation of UBF from rDNA promoter during ES cell 
differentiation [5, 6]. Considering previous evidence that UBF depletion resulted in 
diminished pS187-H1.4 association throughout rRNA genes [2], the data here suggest 
that the dismissal of UBF from rDNA promoter after ES cell differentiation is likely to 
induce downregulation of pS187-H1.4 level at the same loci, probably via less 
recruitment of TFIIH. 
A.3 Evidence for the Role of Histone Chaperones in H1 Variant Expression and 
Distribution 
Histone chaperones are a group of proteins that bind histones and regulate nucleosome 
assembly via different mechanisms [7]. Although the functional significance of multiple 
core histones chaperones have been identified, little is known about how histone 
chaperones regulate H1 deposition and modification. Nuclear Autoantigenic Sperm 
Protein (NASP) is a histone chaperone that interacts with both core and linker histones 
through distinct mechanisms [8]. Two splice variants of NASP, named s-NASP and t-
NASP, are abundantly expressed in cancer, germ, transformed, and embryonic cells, and 
the transcription of both variants appears to be cell-cycle regulated [9]. Depletion of t-
NASP inhibits proliferation and induces apoptosis in prostate cancer cells [10], 
suggesting that this histone chaperone might be important in cell cycle regulation. 
To investigate whether NASP is involved in regulating H1 variant expression, we 
depleted NASP in HeLa cells with siRNA for 48, 72 or 96 h and assessed the expression 
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of H1 variants via immunoblotting (Fig. A.3A). Blot with NASP antibody showed that 
the expression of both t-NASP and s-NASP was markedly reduced after 48 h of siRNA 
treatment whereas moderate reductions of both NASP variants were observed after 72 or 
96 h of siRNA treatment. The protein levels of H1.4 and H1.0 were significantly 
diminished after siRNA knockdown of NASP, which indicates that the interaction with 
NASP might prevent H1 proteins from degradation. However, the expression of H1.5 did 
not seem to be affected by NASP depletion, suggesting that H1.5 might not interact with 
NASP. 
Next, we wondered whether histone chaperones are important for the deposition of H1 
variants at specific gene region. Therefore, we treated HeLa cells with siRNAs against 
prothymosin α (PTα) or NASP and assessed the level of pS187-H1.4 at selected genes. 
Like NASP, PTα is a histone chaperone that directly interacts with histone H1 and 
promotes H1 displacement from chromatin via unknown mechanism [11, 12]. We failed 
to monitor the depletion of PTα by siRNA using standard immunoblotting protocol, and 
we found later in the literature that this highly acidic protein, PTα, is poorly retarded by 
PVDF membrane; thus requires specialized transfer conditions to be immobilized on the 
membrane [13]. Although we were not able to verify the depletion of PTα via 
immunoblotting, our ChIP data showed that siRNA against PTα significantly reduced 
pS187-H1.4 levels at all four genes assessed, whereas NASP depletion decreased pS187-
H1.4 binding at three out of four genes and the extent of reduction at each gene elicited 
by NASP knockdown was not as great as that induced by PTα depletion (Fig. A.3B). The 
above preliminary data suggest that histone chaperones, PTα and NASP, are involved in 
maintaining pS187-H1.4 level at specific genes probably by facilitating H1.4 deposition 
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and/or recruiting specific kinases. The deposition and post-translational modification of 
other H1 variants, including H1.5, might depend on distinct histone chaperones. 
A.4 Preliminary Analyses of Nucleosomal Arrays Reconstituted With in vivo 
Phosphorylated H1s 
Dr. Jeffery Hansen’s lab used chromatin folding experiment and self-association assay to 
analyze the higher order structure of reconstituted 208-12 nucleosomal arrays with or 
without linker histones. Chromatin folding experiment assesses the ability of H1-bound 
nucleosomal arrays to fold into "30 nm" fibers while the self-association assay measures 
the tendency of soluble chromatin fibers to interact and form macroscopic aggregates in 
the presence of increasing concentrations of Mg2+ [14]. Analyses of the reconstituted 
nucleosomal arrays in the above assays revealed that linker histone stabilizes both the 
intermediate and extensively folded states of nucleosomal arrays which resemble the 
structure of native chromatin [14]. Studies of nucleosomal arrays reconstituted with 
sequentially truncated H1.0 showed that the ability of H1.0 to stabilize condensed 
chromatin structures is localized to specific C-terminal subdomains [15]. Further analyses 
of the CTD subdomains revealed that specific amino acid composition plays a 
fundamental role in facilitating chromatin folding by the H1 CTD [16]. Since 
recombinant H1s were used in all the above reconstitution assays, the effects of 
phosphorylation in chromatin folding and higher order structures were not assessed. 
FRAP microscopy studies showed that phosphorylation of H1 at specific sites promotes 
the dissociation of H1 from chromatin [17, 18]. However, direct evidence for the effects 
of H1 phosphorylation on chromatin folding and higher order structures is still lacking. 
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In order to test how H1 phosphorylation affects chromatin folding in vitro, we are going 
to reconstitute nucleosomal arrays with purified fractions of endogenous H1 variants with 
distinct phosphorylation status and analyze the effects of phosphorylation on chromatin 
folding and self-association by ultracentrifugation in collaboration with Dr. Jeffery 
Hansen at Colorado State University. Nonphosphorylated or homogeneously 
phosphorylated H1 variants were purified from crude H1 extracts of HeLa S3 cells using 
hydrophobic interaction chromatography (HIC). H1.4-0p, H1.4-1p, H1.4-2p, H1.2-0p and 
H1.2-1p were purified from asynchronously growing cells while H1.4-6p was purified 
from colchicine-arrested HeLa S3 cells (Fig. A.4A). Proteins were recovered by TCA 
precipitation and resuspended in dH2O. Acid-urea gel electrophoresis, which separates 
histones by net charges [19], showed a single band for each HIC fraction, suggesting that 
these fractions were homogeneously phosphorylated (Fig. A.4B). Reconstitution of our 
purified H1.2-0p and H1.2-1p with recombinant nucleosome arrays was performed by 
our collaborator Dr. Jeffery Hansen. Reconstitutes with H1.2-1p showed a lower 
sedimentation rate at a given r-value (the molar ratio of input H1 relative to nucleosomes) 
when compared to H1.2-0p (Fig. A.4C). This indicates that less H1.2-1p binding occurs 
due to a reduction in affinity of H1.2 for the nucleosome arrays as a consequence of 
phosphorylation. Therefore, further experiments have to be performed in order to find out 
proper r-values for H1.2-0p and H1.2-1p that ensure stoichiometric binding of H1s in 
chromatin folding and self-association assays. Although additional work is necessary to 
determine how site-specific phosphorylation impacts array folding or self-association, the 
data here demonstrate the feasibility of the approach and its utility for comparing how 
distinct levels and sites of H1 phosphorylation affect chromatin structure in vitro.  
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A.5 Figures 
Figure A.1 
 
Validating the specificity of pS187-H1.4 antiserum in ChIP. 
(A) HeLa cells were transfected with control siRNA or siRNA against H1.2/H1.4 for 72 h 
and the global levels of pS187-H1.4, H1.4 and H1.2 were monitored by 
immunoblotting. Blot with CDK7 antibody controls for equal loading. 
(B) HeLa cells were treated as in (A) and the levels of pS187-H1.4 at the TSSs of the 
indicated genes were assessed by ChIP-qPCR. The data are expressed as the percent 
relative to input DNA. 
(C) NT2 cells were transfected with siRNA against luciferase, H1.2 and H1.4 together or 
H1.4 alone for 72 h and the global levels of pS187-H1.4 and H1.4 were assessed by 
immunoblotting. 
(D) NT2 cells were treated as in (C) and the levels of pS187-H1.4 and CDK9 at the TSSs 
of indicated genes were assessed by ChIP-qPCR. The data are expressed as the 
percent relative to input DNA. 
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Figure A.2 
 
Regulation of pS187-H1.4 at rDNA promoter. 
(A) HeLa cells were treated with DMSO, 1 µM THZ1, or 1 µM FLVP for 1 h and the 
level of pS187-H1.4 at rDNA promoter was assessed by ChIP-qPCR. 
(B) HeLa cells were treated with DMSO, 50 µM α-amanitin, 200 nM TPL, 500 nM ActD 
or 40 nM ActD for 1 h and the level of pS187-H1.4 at rDNA promoter was assessed 
by ChIP-qPCR. 
(C) The level of pS187-H1.4 at rDNA promoter in undifferentiated (-RA) or RA-
differentiated NT2 cells for 7 days (+RA) was assessed by ChIP-qPCR. The data in 
(A)-(C) are expressed as the percent relative to input DNA. 
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Figure A.3 
 
Histone H1 chaperones affect pS187-H1.4 deposition. 
(A) HeLa cells were treated with control siRNA (siLuc) or siRNA against NASP 
(siNASP) for 48, 72 or 96 h, and the global levels of H1.4, H1.5 and H1.0 were 
assessed by immunoblotting with specific antisera. Histone H3 blot served as a 
loading control. 
(B) HeLa cells were treated with control siRNA or siRNAs against PTα or NASP for 48 h 
and the levels of pS187-H1.4 at the TSSs of the selected genes were assessed by 
ChIP-qPCR. The data are expressed as the percent relative to input DNA. 
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Figure A.4 
 
Purified H1 variants that are homogenously phosphorylated are used for 
reconstitution assay. 
(A) Hydrophobic interaction chromatography (HIC) of crude H1 prepared from HeLa S3 
cells that were growing asynchronously or arrested in mitosis by 1 μM colchicine.  
(B) Acid-urea gel electrophoresis for H1 fractions purified by HIC. Proteins were 
recovered by TCA precipitation. AEWH= acid extraction of whole histone, PCAS= 
perchloric acid soluble (crude H1). 
(C) The binding of H1.2-0p and 1p to recombinant nucleosomal arrays. 208-12 
nucleosomal arrays were reconstituted with increasing molar ratios (r) of H1.2 prior 
to analytical ultracentrifugation. 
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